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WITNESS SEMINARS:
MEETINGS AND PUBLICATIONS1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine 
Group, associated with the Academic Unit of the Wellcome Institute for the 
History of Medicine, to bring together clinicians, scientists, historians and others 
interested in contemporary medical history. Among a number of other initiatives 
the format of Witness Seminars, used by the Institute of Contemporary British 
History to address issues of recent political history, was adopted, to promote 
interaction between these different groups, to emphasize the potential benefi ts 
of working jointly, and to encourage the creation and deposit of archival sources 
for present and future use. In June 1999 the Governors of the Wellcome Trust 
decided that it would be appropriate for the Academic Unit to enjoy a more 
formal academic affi liation and turned the Unit into the Wellcome Trust Centre 
for the History of Medicine at UCL from 1 October 2000. The Wellcome 
Trust continues to fund the Witness Seminar programme via its support for the 
Wellcome Trust Centre.
The Witness Seminar is a particularly specialized form of oral history, where 
several people associated with a particular set of circumstances or events are 
invited to come together to discuss, debate, and agree or disagree about their 
memories. To date, the History of Twentieth Century Medicine Group has held 
more than 40 such meetings, most of which have been published, as listed on 
pages xi–xix.
Subjects are usually proposed by, or through, members of the Programme 
Committee of the Group, which includes professional historians of medicine, 
practising scientists and clinicians, and once an appropriate topic has been 
agreed, suitable participants are identifi ed and invited. This inevitably leads to 
further contacts, and more suggestions of people to invite. As the organization 
of the meeting progresses, a fl exible outline plan for the meeting is devised, 
usually with assistance from the meeting’s chairman, and some participants are 
invited to ‘start the ball rolling’ on particular themes, by speaking for a short 
period to initiate and stimulate further discussion.
1   The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to Twentieth 
Century Medicine published by the Wellcome Trust and the Wellcome Trust Centre for the History of 
Medicine at UCL.
viii
Each meeting is fully recorded, the tapes are transcribed and the unedited 
transcript is immediately sent to every participant. Each is asked to check his 
or her own contributions and to provide brief biographical details. The editors 
turn the transcript into readable text, and participants’ minor corrections and 
comments are incorporated into that text, while biographical and bibliographical 
details are added as footnotes, as are more substantial comments and additional 
material provided by participants. The fi nal scripts are then sent to every 
contributor, accompanied by forms assigning copyright to the Wellcome Trust.
Copies of all additional correspondence received during the editorial process 
are deposited with the records of each meeting in Archives and Manuscripts, 
Wellcome Library, London. 
As with all our meetings, we hope that even if the precise details of some of the 
technical sections are not clear to the non-specialist, the sense and signifi cance 
of the events will be understandable. Our aim is for the volumes that emerge 
from these meetings to inform those with a general interest in the history of 
modern medicine and medical science; to provide historians with new insights, 
fresh material for study, and further themes for research; and to emphasize to 
the participants that events of the recent past, of their own working lives, are of 
proper and necessary concern to historians.
Members of the Programme Committee of the
History of Twentieth Century Medicine Group, 2005–06
Dr Tilli Tansey – Reader in History of Modern Medical Sciences, Wellcome Trust Centre 
for the History of Medicine at UCL (WTCHM), and Chair
Sir Christopher Booth – WTCHM, former Director, Clinical Research Centre, 
Northwick Park Hospital, London
Dr Robert Bud – Principal Curator of Medicine and Manager of Electronic Content, 
Science Museum, London
Dr Daphne Christie – Senior Research Assistant, WTCHM, and Organizing Secretary
Dr John Ford – Retired General Practitioner, Tonbridge
Professor Mark Jackson – Centre for Medical History, Exeter
Professor Ian McDonald – WTCHM, former Professor of Neurology, Institute of 
Neurology, London
Dr Helga Satzinger – Reader in History of Twentieth Century Biomedicine, WTCHM
Professor Lawrence Weaver – Professor of Child Health, University of Glasgow, and 
Consultant Paediatrician in the Royal Hospital for Sick Children, Glasgow
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INTRODUCTION
Plasma cholesterol as a cause of coronary heart disease (CHD); 
the cholesterol–CHD hypothesis 
During the years following the Second World War, the standardized death 
rate from coronary heart disease (CHD) in men increased sharply in Western 
industrialized countries. When the search for the causes of this increase in CHD 
began, plasma cholesterol was already a prime suspect. It had long been known 
that cholesterol is a major component of advanced atherosclerotic lesions 
in humans and that atherosclerosis could be induced in animals by feeding 
cholesterol (see page 13). Another reason for fi ngering cholesterol was the 
recognition that hypercholesterolaemia due to a mutation in a single gene [the 
familial hypercholesterolaemia (FH) gene] is strongly associated with CHD (see 
pages 29–30). It was hard to argue that in this case CHD was not caused by the 
hypercholesterolaemia.
Case-control studies in the early 1950s showed that in patients with CHD 
the plasma low-density lipoprotein (LDL) cholesterol level was higher than in 
normal controls.2 In the US Framingham prospective study of over 5000 healthy 
men and women followed for more than 30 years, the risk of developing CHD 
was proportional to the plasma total and LDL cholesterol level at entry into the 
study.3 The results of this and other prospective studies were used in the design 
of large-scale clinical trials to test the effect of reducing the plasma cholesterol 
level on CHD incidence. Early trials were disappointing,4 probably because the 
fall in plasma cholesterol levels achieved in the treated groups was too small to 
provide suffi cient statistical power. The most successful of the ‘pre-statin’ trials 
was the 1984 US Lipid Research Clinics’ Coronary Primary Prevention Trial 
(see Table 2, page 76).5 In the treated group the mean fall in plasma cholesterol 
was small, but there was a statistically signifi cant decrease in CHD events. 
Reactions to this result were mixed. Some among the US medical community 
considered that the trial warranted a national campaign to lower cholesterol 
2  Barr et al. (1951).
3  Gordon et al. (1977).
4  Frantz and Moore (1969).
5  Lipid Research Clinics (LRC) Coronary Primary Prevention Trial (1984): 351–64.
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levels in the US population. Others began a campaign to discredit its organizers. 
This ill-tempered controversy continued for many years on both sides of the 
Atlantic, prompting one of the organizers of the trial to recount the history of 
this controversy in a forthcoming book entitled The Cholesterol Wars.6
When statins became available for clinical use (see below), several trials with 
a much better prospect of achieving statistical signifi cance were carried out in 
Scandinavia, Scotland, the US and Australia.7 The results of these trials, reported 
between 1994 and 1998, showed beyond doubt that a reduction in plasma 
cholesterol level signifi cantly reduces CHD incidence in selected populations. 
These results have now been extended by a trial in which Sir Richard Doll 
(1912–2005), one of the architects of the modern clinical trial, played a 
leading role.8 In this trial, involving more than 20 000 UK adults, simvastatin 
signifi cantly reduced the CHD event rate in men and women, including those 
whose LDL cholesterol levels were near the lower limit of the normal range.
The 30 or more steps in the biosynthesis of cholesterol from acetyl-CoA were 
elucidated by several groups, roughly between the early 1950s and the mid-
1970s. The main players were John Cornforth and George Popják (my boss 
at Hammersmith from 1954–62) in Britain; Konrad Bloch and Robert Burns 
Woodward at Harvard; and Feodor Lynen in Munich. Four of the fi ve were 
awarded the Nobel Prize for this work.9 In the opinion of many, Popják should 
have shared the prize, but this was not to be. A key event in the story was the 
fi nding that an essential step in cholesterol synthesis is the formation of units of 
a branched-chain C
5
 compound (isoprenoid units) that give rise to the carbon 
skeleton of cholesterol.10 The breakthrough in the search for the isoprenoid unit 
6  Four extensive excerpts from the forthcoming book by Professor Daniel Steinberg have been published to 
date in the Journal of Lipid Research [Steinberg (2004, 2005a and b, 2006)]. The 1984 trial is discussed in 
Steinberg (2006). 
7  Scandinavian Simvastatin Survival Study (4S) (1994); Shepherd et al. for the West of Scotland Coronary 
Prevention Study Group (1995); Sacks et al. for the Cholesterol and Recurrent Events Trial Investigators 
(1996) ; The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group (1998).
8  Heart Protection Study Collaborative Group (2002).
9  Konrad Bloch and Feodor Lynen shared the Nobel Prize in Physiology or Medicine for 1964 for their 
discoveries concerning the mechanism and regulation of the cholesterol and fatty acid metabolism; and 
Robert Burns Woodward received the Nobel Prize in Chemistry in 1965 for his outstanding achievements 
in the art of organic synthesis; and John Cornforth shared the Nobel Prize in Chemistry for 1975 for his 
work on the stereochemistry of enzyme-catalyzed reactions.
10  Cornforth (1959).
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was the serendipitous discovery of a C
6
 acid (mevalonic acid or MVA) by a group 
of microbiologists searching for growth factors for Lactobacillus acidophilus.11 
When MVA turned out to be an extremely effi cient precursor for cholesterol 
synthesis in vitro, they suggested, correctly, that MVA is decarboxylated to 
give the C
5
 isoprenoid. There followed the discovery by several independent 
groups that MVA is formed in yeast and animal cells by the reduction of 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) by the enzyme 
HMG-CoA reductase.12
In 1957 Gordon Gould, a charming American who was learning to play the 
bassoon, joined Popják’s lab for a year’s sabbatical. He spent his fi rst few months 
writing a couple of chapters for Cook’s book, to the mild annoyance of Popják.13 
But he more than made up for this by showing, with Popják, that when the 
incorporation of 14C-acetate into the cholesterol of a rat’s liver is inhibited 
by feeding cholesterol, there is no change in the rate of incorporation of 
14C-MVA.14 This showed that the rate-limiting step in cholesterol biosynthesis 
lies before MVA. Marvin Siperstein and Violet Fagan then showed that the 
reduction of HMG-CoA to MVA by HMG-CoA reductase is the step that 
determines the rate of synthesis of cholesterol in the liver.15
Popják was medically qualifi ed and had begun his career as a pathologist with an 
interest in atherosclerosis. When I joined his MRC unit at Hammersmith he was 
a card-carrying believer in the cholesterol–CHD hypothesis, but he had turned 
himself into a lipid biochemist hoping, so he told me, that an understanding 
of cholesterol biosynthesis would contribute to the treatment of CHD. The 
feasibility of inhibiting one of the steps in cholesterol synthesis in a clinical 
setting was discussed in Popják’s lab, but as far as I know Popják never explored 
the possibility of inhibiting HMG-CoA reductase. Had Popják thought of asking 
Cornforth to synthesize an analogue of HMG-CoA, they might have discovered 
the fi rst inhibitor of HMG-CoA reductase. In fact, the specifi c inhibition of this 
enzyme was fi rst achieved by a group of Japanese microbiologists.16
11  Wright et al. (1956).
12  Cornforth (1973).
13  Cook (ed.) (1958).
14  Gould and Popják (1957).
15  Siperstein and Fagan (1964).
16  Endo et al. (1976b).
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When Barry Lewis joined my MRC group in 1963 to collaborate in the 
investigation of hyperlipidaemia, we set up a Lipid Clinic at Hammersmith. 
This was the fi rst such clinic in Britain. Our fi rst patient was a 10-year-old Iraqi 
girl with extensive skin xanthomas present since age 4 and a plasma cholesterol 
level of 800–900mg/100ml. Both her parents were hypercholesterolaemic 
and her brother and sister had died from CHD aged 15 and 9. The patient’s 
plasma cholesterol level showed little or no response to corn oil, cholestyramine, 
Atromid, D-thyroxine or neomycin. We therefore decided to try the effect of 
plasmapheresis. In September 1964, on each of four consecutive days, 500ml 
of blood were taken from the patient. The blood was centrifuged and the red 
cells immediately transfused into her. This procedure resulted in a fall in plasma 
cholesterol from 830mg/100ml to 525mg/100ml, but the level returned to 
the baseline value within a few weeks. We did not repeat the procedure. The 
patient died at age 13, after repeated attacks of angina at rest. A post mortem 
was not done. To add to the misfortunes of this family the patient’s father, who 
became the Prime Minister of Iraq, was imprisoned and hanged after the Ba’th 
coup of 1968.
As a member of Popják’s MRC unit at Hammersmith Hospital, I built up a 
small team whose aim was to combine biochemical with clinical lipidology. In 
1962 the MRC and the Postgraduate School agreed to my taking on a clinical 
collaborator and to our having the use of four hospital beds. This was the 
agreement under which Barry Lewis joined me (1963–65). By 1969 our group 
had grown to 11 people. When William Hayes’ MRC Microbial Genetics Unit 
moved from Hammersmith Hospital to Edinburgh I asked the MRC to convert 
my team into a Unit accommodated in the space in the Cyclotron Building left 
by Hayes. This was agreed and in 1969 we became the MRC Lipid Metabolism 
Unit. Our brief included ‘investigation and treatment of patients with disorders 
of plasma lipid metabolism, particularly those leading to ischaemic heart 
disease’. The Unit was closed on my retirement in 1983.
In 1976 a group headed by Endo, working in a laboratory of the Sankyo drug 
company, isolated a compound (compactin, see page 79) from Penicillium 
citrinum.17 They noted that a portion of the compactin molecule bore a striking 
stereochemical resemblance to HMG-CoA. They then showed that compactin 
is a powerful inhibitor of HMG-CoA reductase, and that when given to dogs 
it lowered the plasma cholesterol level. Within a few years of its discovery, 
17  Endo et al. (1976b).
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compactin was shown to lower total and LDL cholesterol levels in heterozygous 
FH patients, without signifi cant clinical or biochemical side-effects. 
Compactin itself never became generally available for clinical use, but in 1980 
Merck Research Laboratories reported the isolation of a more potent inhibitor 
of HMG-CoA reductase from the fungus Aspergillus terreus.18 This compound, 
called lovastatin, was shown to lower the plasma LDL cholesterol level by at 
least 50 per cent in normal humans and FH heterozygotes without side-effects 
when given at a maximum dose rate of 80mg/day (see page 36). Lovastatin is 
now available for prescription use in the US, but not in the UK. Several other 
inhibitory analogues of compactin have now been described and are known as 
statins. The safety and effectiveness of statins opened the way for the defi nitive 
clinical trials discussed above, and raised the possibility of primary prevention 
of CHD in well populations.19
Nick Myant 
Hammersmith Hospital 
18  Alberts et al. (1980). See also Vagelos and Galambos (2004): 132–63.
19  Durrington (2004).
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Sir Christopher Booth:  Ladies and gentlemen, may I warmly welcome you 
today. I am standing in for Tilli Tansey, Convenor of the History of Twentieth 
Century Medicine Group, who would have been here today, but sadly, she has 
a bad attack of the fl u and sends her apologies. 
A Witness Seminar brings together people who have actually been involved in 
a particular historical episode, to talk about the events in their working lives; to 
remember; to discuss and debate. As far as medicine is concerned, we found that 
the technique of a one-to-one interview on videotape was easily fl awed, because 
it depended on the accuracy of the interviewer and how well he or she knew the 
science of the person being interviewed. We believe we get more truthful history 
from a Witness Seminar than we would from single interviews. 
The Group have held more than 40 meetings, some of which are very useful 
historical documents. For example, the meeting on monoclonal antibodies 
included contributions from Dr Georges Köhler and Dr César Milstein.1 That 
document is now of great historic signifi cance, since they are both dead. 
As, of course, this meeting will be a historic document, I hope, for some time 
in the future. I will hand over to Michael Oliver, who has kindly agreed to chair 
this meeting.
Professor Michael Oliver:  It’s very good to see so many familiar faces. Welcome 
to you all. As you realize, we are forcing you back 50 years or so ago to record 
what you were actually thinking about then, where and why. Elspeth Smith 
said to me in a letter, ‘How can you possibly expect us to recall what we were 
thinking about half a century ago, when I can’t remember what I was thinking 
about yesterday?’ 
The purpose of this meeting is to record what we, in the UK, were thinking 
about cholesterol and associated lipids, and their relation to cardiovascular, 
particularly coronary heart disease (CHD), in the last half of the twentieth 
century. 
In the beginning of the 1940s, CHD was regarded as an inevitable result of 
ageing. For example, in the monograph, Vascular Sclerosis, Eli Moschcowitz from 
Boston wrote: ‘Arteriosclerosis [cannot] be prevented, no more than grey hair or 
facial wrinkles’.2 In the UK, Ryle and Russell wrote in 1949: ‘It seems at present 
1  Tansey and Catterall (eds) (1997): 1–34.
2  Moschcowitz (1942): 143.
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remotely unlikely that we shall discover a “cure” for general arteriosclerosis or 
coronary artery disease’.3 Enthusiasm for research into its causes or therapy did 
not arise before the 1950s.
Appreciation of a possible causal link between raised blood cholesterol and heart 
disease had been suggested in the US by Paul Dudley White in the 3rd edition 
(1947) of his textbook Heart Disease:
The cause of atheroma of the coronary arteries as well as that of 
arteriosclerosis in general is unknown… The occasional fi nding of a 
high blood cholesterol content in a fasting case of CHD, especially in the 
young patient under 40, is in favour of a disturbance of fat metabolism, 
at least as one factor.4 
In the UK, there was no mention of cholesterol or lipids in William Evans’ 
infl uential 1948 book, Cardiology.5 Nor of atherosclerosis as a cause of CHD. 
Price’s 1949 textbook on medicine does not mention cholesterol, except in the 
context of gallstones.6 Xanthomata were simply a skin disease and atheroma 
was due to hypertension. So far as I know, the fi rst mention in the UK of any 
relationship between cholesterol and arterial disease was in Paul Wood’s fi rst 
edition of Diseases of the Heart and Circulation in 1950.7 He wrote: 
Lipoid substances accumulate in the intima of the large arteries in a 
patchy irregular fashion, sometimes encroaching on the lumen. The 
lipoid nature of the deposits, their relatively frequent association 
with diabetes and hypercholesterolaemia, suggest some relation to fat 
metabolism…[but] consideration should be given to the possibility that 
raised cholesterol might result from CHD.8 
Meanwhile, in 1949, Jack Gofman, a physicist working in the Donner Laboratory 
in the Berkeley campus of the University of California using an analytical 
ultracentrifuge, recognized that the lipoproteins of human blood are divided 
into two groups – low density lipoproteins and high density lipoproteins – 
3  Ryle and Russell (1949): 389. 
4  White (1947): 479.
5  Evans (1948). 
6  Price (1950).
7  Wood (1950).
8  Wood (1950): 372–4. Emphasis added by Professor Michael Oliver.
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according to their densities (LDL: below 1.05g/ml; HDL: above 1.05g/ml) and 
fl otation rates.9 He labelled the group with 12–20 Svedberg fl otation units [S
f
], 
which we now know as LDL, to be ‘atherosclerogenic’.10
This idea was not immediately taken up in the US and not at all in the UK. A 
month ago [February 2005] I spoke to Jack Gofman, now over 90 years of age, 
and he believes that his views were ignored largely because he was a physicist and 
not part of the orthodox medical scientifi c community. I can remember these 
analyses from the ultracentrifuge being dismissed as irrelevant and artifi cial in 
1952, when I began working on the subject. Anyway, nobody in the UK had 
any money to buy an ultracentrifuge. It did not help when Ancel Keys, who 
submitted Gofman’s data to detailed statistical analysis, claimed in 1951 that 
‘the use of lipoprotein classes as a discriminator between atherosclerosis and 
normal persons is no better than total cholesterol alone’.11
In the early 1950s, three other groups had begun to study lipoproteins: David 
Barr in New York used a low temperature chemical fractionation procedure 
that was laborious and required 25ml of serum;12 Esko Nikkilä in Helsinki 
used fi lter-paper zone electrophoresis;13 and in Edinburgh in 1953 George 
Boyd developed a fi lter-paper zone electrophoresis microtechnique using 0.1ml 
serum.14 Our method was tedious, since it involved elution of cholesterol from 
18 separate 1cm strips of Whatman paper and a run of eight hours. The latter 
was particularly tiresome, since there was no automated switch to stop the 
electrophoresis run, and George and I had to take it in turns to return to the lab 
between 11 pm and 12 midnight.
Ours was the fi rst report in the UK in 1955 of the distribution of cholesterol 
between the α and β lipoproteins in men aged 50 years or under with CHD 
and age-matched controls.15 We found 19 per cent more cholesterol on the β 
fraction and also an absolute decrease in the α fraction in men with CHD. The 
9  Gofman et al. (1949).
10  Gofman et al. (1950, 1952) S
f
 = Svedberg fl otation units, see Glossary, page 146. 
11  Keys (1951).
12  Barr et al. (1951).
13  Nikkilä (1953).
14  Boyd (1954).
15  Oliver and Boyd (1955).
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β/α ratio was in the region of 10 in men with CHD and 2.6 in the controls. 
These are similar to the more familiar ratios of today regarding LDL/HDL 
in hypercholesterolaemic people and were reported at the First International 
Symposium on Atherosclerosis in 1955 [Figure 1].16
Previously, in 1953, we had reported a study of plasma lipids in 200 consecutive 
patients with CHD, and 200 age- and gender-matched controls.17 This was 
the fi rst UK study and at that time was the largest in the world.18 There was 
signifi cant elevation of plasma total cholesterol and the plasma total cholesterol/
phospholipid ratio in the coronary patients at all ages.
When I presented these results in a ten-minute paper at the 1953 Newcastle 
meeting of the British Cardiac Society, there was total silence.19 No one asked 
16  Keys (ed.) (1955).
17  Oliver and Boyd (1953c).
18  For a discussion of the statistical obstacles accompanying large sample sizes, see Ness et al. (eds) (2002): 
77–80.
19  Oliver and Boyd (1953c).
Figure 1: Ancel Keys’ fi rst international symposium on atherosclerosis in Minneapolis–St Paul, 
1955. L to R: Louis Katz, Jack Brock, Michael Oliver, Irvine Page, Paul Dudley White.
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any questions. Paul Wood said that this was ‘irrelevant to cardiology’ and that 
we should proceed to more important communications. Maurice Campbell, 
the President of the Society, commented, ‘Let’s not be too hasty, there might 
just be something in this cholesterol issue’.
The fi rst paper on cholesterol that I published with George Boyd – who died 
from a coronary in 1983 aged only 59 – was earlier. In 1953 we studied changes 
in plasma cholesterol and total phospholipids during the menstrual cycle.20 These 
were derived from daily blood samples taken from 12 young women over fi ve 
weeks with early morning oral temperature measurements to identify ovulation. 
The results showed that the point of lowest plasma cholesterol occurred when 
oestrogen activity was maximal. We regarded this as possibly contributing to the 
rarity of CHD in premenopausal women. This study led us into fi ve years of 
intensive research into the effects of various hormones and endocrine states on 
plasma lipids and lipoproteins.21
At about this time, 1956, John Cornforth at the National Institute for Medical 
Research at Mill Hill, London, and George Popják at the Hammersmith 
Hospital, London, were studying the biosynthesis of cholesterol from acetate.22 
They speculated about the possibility of inhibiting key enzymes to reduce the 
synthesis of 3-hydroxy-3-methylglutarate-CoA (HMG-CoA). It took more than 
20 years before their proposals reached fruition, leading to the development of 
the fi rst statins in the 1980s.23 In 1958, Cook in Dundee published a book on 
the physiology and biochemistry of cholesterol.24 
Now I shall ask Gilbert Thompson to describe the development of interest 
in cholesterol and lipoproteins in the 1960s and onwards – and [Sir John] 
McMichael’s infl uential dismissal of the whole idea.
Professor Gilbert Thompson:  Thank you very much, Michael, for inviting 
me here to say something about my early knowledge of lipidology, which is 
not as lengthy as yours. I was still a medical student when you and Boyd were 
20  Oliver and Boyd (1953a).
21  Boyd and Oliver (1956).
22  Cornforth et al. (1954); Popják (1958). Mill Hill is the location of the Medical Research Council’s 
National Institute for Medical Research in north London.
23  Endo et al. (1977).
24  Cook (ed.) (1958).
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producing the results of your early research. My memories start in 1965 when 
I was working with Chris Booth and we were interested in looking at vitamin 
D metabolism in patients with malabsorption. We set up an absorption test, 
and got hold of some vitamin D to radiolabel. Thanks to advice from Barry 
Lewis, I managed to tritiate the vitamin D rather than everything else in the 
lab and our absorption test went quite well.25 The following year I went to the 
Massachusetts General Hospital in Boston to continue my research. In 1967 
Fredrickson, Levy and Lees produced their fi ve-part paper in the New England 
Journal of Medicine.26 Suddenly everybody in Boston seemed to be thinking and 
talking about cholesterol and lipoproteins, including a couple of very bright 
interns at the Massachusetts General Hospital called Goldstein and Brown.27
I went back to the Hammersmith, where Chris Booth was by now Professor 
of Medicine, because Sir John McMichael had retired, and I continued to do 
some research on vitamin D, although I was getting increasingly interested in 
atherosclerosis and cholesterol. A couple of years later I went to see Graham 
Bull at Northwick Park, to see whether there was any opening for that line of 
research, but he thought it was not a very promising one. In 1972 I managed 
to persuade Chris Booth to give me a year’s leave of absence and I went to 
work with Tony Gotto in Houston, where I fi rst met Anne Soutar, and got 
increasingly involved with apolipoproteins and their metabolism. I came back 
again to the Hammersmith, still trying to do gastroenterology, although I was 
really more interested in lipidology, which, of course, didn’t exist as a specialty 
in those days.
In 1974 John Yudkin’s uncle, a namesake I think, who was Emeritus Professor 
of Nutrition at Queen Elizabeth College, London, wrote an article in The Times 
about the role of sugar in coronary disease.28 I persuaded The Times to let me 
rebut this in an article.29 This led to a BBC debate that was televised at the 
Royal Institution. Don Fredrickson, Peter Taggart and I were up against Yudkin 
25  Thompson et al. (1966).
26  Fredrickson et al. (1967).
27  Goldstein and Brown (1977). Michael Brown and Joseph Goldstein shared the Nobel Prize for Physiology 
or Medicine in 1985 for their discoveries concerning the regulation of cholesterol metabolism. See their 
biographical notes on pages 125 and 127.
28  Yudkin J (1974).
29  Thompson (1974).
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and it created a certain amount of interest.30 One thing led to another, and 
eventually in 1975 I gave up gastroenterology, joined Nick Myant’s Medical 
Research Council (MRC)’s Lipid Metabolism Unit,31 which had been created 
about fi ve years previously and helped him organize a memorable meeting at 
the Hammersmith [see Figure 2]. As most of you know, Nick is probably the 
founding father of lipid research in this country and a man of enormous intellect, 
but great modesty, and many of us owe him a lot.32 He had been McMichael’s 
houseman, which was a bit ironic, seeing as their views differed diametrically.
Before I fi nish I would like to mention one other debate, which took place 
in Rotterdam in 1977 under the aegis of the European Society of Clinical 
Investigation, the motion being ‘that modifi cation of serum lipids by dietary 
and/or other means will infl uence the incidence of, or mortality from, coronary 
heart disease’.33 Shlomo Eisenberg, Lars Carlson and I supported the motion, 
with McMichael, Paul Astrup and Christian Crone against. Crone showed two 
slides: one of a lovely, glossy-coated rat, which he said had been brought up 
on butter; and the other was a miserable, mangey-looking specimen which 
he said had been brought up on polyunsaturated fat. The audience dissolved 
into laughter and that was the end of the debate. Sir John McMichael was 
jubilant about this, not surprisingly, for although he had retired, he was by 
no means inactive. He was sending streams of letters to the Lancet and his 
cup was fi lled to overfl owing when Michael Oliver published the results of the 
WHO trial, which showed that although nonfatal myocardial infarcts (MIs) 
were reduced by clofi brate, deaths from noncardiovascular causes increased.34 
30  The debate, held on 4 September 1974 with Professor Sir George Porter in the chair, was broadcast by 
BBC2 on 30 September 1974 as ‘Controversy: The dietary cause of heart disease is sugar not fat’ and the 
producer was Dominic Flessati. Neither the BBC nor the National Film and Television Archive hold a 
copy of this programme in their collections and The Listener did not publish a summary. We are grateful to 
Professor Thompson for a copy of the announcement of the debate, which will be deposited along with the 
tapes and other records of the meeting in Archives and Manuscripts, Wellcome Library, London.
31  The MRC Lipid Metabolism Unit at Hammersmith Hospital, London, was established in 1969 to 
study lipid metabolism, particularly in relation to the problem of atherosclerosis, and was directed by 
Dr Nick Myant until it was disbanded on his retirement in 1983. See Thomson (1975, 1987): 368. See 
also Introduction.
32  Myant (1990a and b).
33  The European Society for Clinical Investigation’s ‘Controversy in Medicine’ debate was held at the annual 
meeting in Rotterdam on 21 April 1977, chaired by Dr R Hermon Dowling.
34  Principal Investigators (1978, 1984).
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Figure 2: Participants at the Workshop on Familial Hypercholesterolaemia held at the 
Hammersmith Hospital, London, in 1975. 
Key. L to R: 1: R Levy; 2: R Lees; 3: D Steinberg; 4: A Gotto; 5: M Press; 6: N Myant; 
7: G Thompson; 8: A Kharchadurian; 9: M Brown; 10: J Goldstein; 11: G Popják; 12: D Bilheimer; 
13: J Slack; 14: B Lewis; 15: K Mitropoulos; 16: T Miettinen; 17: D Reichl; 18: H Magnani; 
19: S Grundy; 20: J de Gennes; 21: K Hellstrom; 22: G Gibbons.
From Thompson (1999): 32.
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Sir John McMichael came out in the British Medical Journal (BMJ) with an 
article entitled ‘Fats and atheroma: an inquest’, and as far as he was concerned 
that was the end of it.35 He was a great man, I have enormous respect for him, 
but he had a complete blind spot about cholesterol. I am afraid he was totally 
wrong about this, but because of his reputation and infl uence, he completely 
altered the whole climate of cardiology, certainly among senior cardiologists. 
To illustrate this point I want to read a very brief excerpt from a letter that I 
received from a general practitioner: 
Mr Edwards is a 38-year-old man who underwent an extensive coronary 
artery bypass operation in December 1987; his post-operative recovery 
was physically uneventful. However, we were quite concerned about our 
inability to reduce his high cholesterol and triglyceride levels. That was 
in August 1988. His cholesterol was 8.4 to 9.5 and triglyceride 3.3 to 
5.3. Mr Edwards was getting very screwed up about his inability to drop 
his cholesterol and triglyceride and was very frightened that his new 
coronary arteries were soon to get furred up. As a result of this I referred 
him to the Brompton Hospital. He saw a consultant cardiologist, who 
told him to forget taking any tablets, to forget his cholesterol and 
triglyceride and to go away and try and live a normal life. That advice 
caused us some considerable concern, as we had been working very hard 
for the last couple of years to reduce his cholesterol. He is now on no 
medication. 
I rest my case.
Professor Chris Packard:  I will pick up the story from where you left off. I 
did my apprenticeship in lipidology in the early 1970s, a period that coincided 
with the pioneering work of the MRC Lipid Metabolism Unit. Our basic 
approach was to isolate the lipoprotein particles themselves, label them in some 
way and then re-introduce them and follow the metabolic pathway. Gilbert 
has already alluded to the work of Shlomo Eisenberg, a key worker in this 
fi eld.36 He was the fi rst person to label very low-density lipoprotein (VLDL) 
and show that the radioactivity ended up in LDL. That was the beginning of 
studies of the delipidation pathway. Terry Langer and Bob Levy, working in 
the National Institutes of Health (NIH), had performed many of the earlier 
studies looking at the metabolic defects in people with high cholesterol levels. 
35  McMichael (1979).
36  Eisenberg et al. (1973); Anonymous (1996). 
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They demonstrated a delayed clearance, while people with low cholesterol levels 
could turn over LDL much faster.37 In the 1970s Anne Soutar, Gil Thompson 
and ourselves at Glasgow began to describe the metabolic defects in familial 
hypercholesterolaemia.38 Many other labs using similar techniques documented 
what happened in people with different forms of hypercholesterolaemia. 
Shortly after that, interestingly, the nomenclature that had been introduced 
by Professor Don Fredrickson 39 – type I, type II, type III, type IV, type V – 
was simplifi ed greatly into raised cholesterol, raised triglyceride and combined 
hyperlipidaemia.40 This was a benefi t, in that common defects gave rise to 
elevations in VLDL and LDL. This work, combined with that of Tony Gotto 
and others who investigated the structure of lipoproteins, changed our picture 
of these little oil droplets fl oating around in the blood.41 We began to understand 
that cholesterol was the cargo, and the protein around the surface of the particle 
was directing its metabolic fate. I think this was a paradigm set that took us into 
the early 1980s, when we began to move into the cell biology arena.
Professor Anne Soutar:  It’s a pleasure to be here and to see so many familiar 
faces. I must say it is just like the good old days when Elspeth Smith and I 
were the only women to be seen around. It takes me back to the days of our 
Atherosclerosis Discussion Group.42 
I can’t add very much because I also came out of the Tony Gotto stable and I went 
there not as a clinician, of course, but as a biochemist and enzymologist. When 
37  Levy and Langer (1971); Langer et al. (1972). 
38  Soutar et al. (1977); Shepherd et al. (1979).
39  Fredrickson and Lees (1966). Chapter 22 on familial hyperlipoproteinaemia, pages 429–88, describes 
fi ve types of essential hyperlipoproteinaemia, including type V for the fi rst time. For greater detail of his 
thinking, see Fredrickson’s annotations on his list of publications at http://profi les.nlm.nih.gov/FF/B/B/L/
G/_/ffbblg.txt (visited 15 December 2005).
40  Goldstein et al. (1973b).
41  Smith et al. (1978).
42  Professor Michael Oliver wrote: ‘The Atherosclerosis Discussion Group was founded in 1961 by John 
French and Michael Oliver, with Lord Florey as the fi rst Chairman. Meetings were held in the spring at 
Magdalen College, Oxford, and in the autumn at Jesus College, Cambridge. The emphasis was on an 
informal exchange of views on all aspects of atherosclerosis. The twice-yearly meetings continue and the 
discussion group is now called the British Atherosclerosis Society (BAS), the UK affi liate of the International 
Atherosclerosis Society (IAS).’ Note on draft transcript, 25 November 2005. For further details see Reynolds 
and Tansey (eds) (2005): 26; and www.britathsoc.ac.uk/ (visited 12 December 2005).
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I got there, they were interested in the enzymes that were involved in carrying 
out these complex metabolic processes that were clearly going on in the transfer 
of lipids, and they were trying to understand the structure of the lipoproteins. 
While I was there Richard Jackson and Jerry Segrest did their important work 
showing that the protein part of the lipoprotein formed an amphipathic alpha 
helix, with one side hydrophobic, interacting with lipid, and on the other side 
were hydrophilic residues that would interact with the water.43 Suddenly it 
became possible to understand the structure of these particles and, of course, 
that was very important for the understanding of lipoprotein metabolism. As 
Chris [Packard] said, the proteins were the things that directed them around the 
body and allowed them to be taken up by the receptors. Those were very early 
days in Houston, when Brown and Goldstein identifi ed the fi rst LDL receptor, 
which I guess we will hear more of later.44 It was a very exciting time to be in 
Texas. I had come from England to the US for the fi rst time, to Houston, where 
you would see neon signs saying, ‘62 oz steak, free if you can eat it all’. In my 
opinion you could feed a family of six on that. But, on the other hand, if you 
went to the supermarkets, you couldn’t buy butter, you couldn’t buy cream, you 
couldn’t buy cheese, because they had got the message, even by the early 1970s, 
that you weren’t supposed to be eating saturated fat, and I think at that time 
they were trying to make a polyunsaturated cow, but I don’t know whether that 
ever came about.45 There was a particularly unattractive sort of cheese that you 
could buy, advertised as being ‘fat-free’. Coming from a typical English diet, 
this seemed quite extraordinary and a huge contrast to what was going on in 
the UK at the time.
Professor David Galton:  To go back to the early history: one of the objectives 
of this meeting is ‘to identify our failings and errors’, and one of them was that 
we completely ignored the German literature. In the early 1930s Thannhauser 
was classifying xanthomata and he was feeding cholesterol to dogs to induce 
atherosclerosis.46 I came across his work, because he was exiled at the start of 
the Nazi period to Boston, and as I worked in his old lab there I got to know 
his work. Unfortunately I can’t read German, so I don’t know exactly what he 
found, but it was very much on the cholesterol–atheroma theme.
43  Segrest et al. (1974).
44  See note 77.
45  Anonymous (1975a and b). 
46  Thannhauser (1940, 1950). See also note 49.
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Oliver:  Were xanthomata not regarded as simply a skin disease?
Galton:  Yes, xanthomata were.
Oliver:  Thinking that xanthomata might be part of a systemic disorder was not 
appreciated until the early 1950s.
Galton:  No, in the German literature it was in the 1930s.
Dr Paul Miller:  Carl Müller in the 1930s described what we would now call 
heterozygous familial hypercholesterolaemia (FH) as a cause of angina pectoris 
xanthomatosis and CHD.47
Oliver:  In the British literature? 
Miller:  In the Archives of Internal Medicine. Gil will know. 
Thompson:  1936. 
Professor Kalevi Pyörälä:  Professor Carl Müller from Oslo, Norway, carried 
out a very nice pedigree study of patients with FH and premature CHD, and 
published it in English in the late 1930s. This study sensitized the Norwegian 
medical community to cholesterol–CHD. There was another sensitization 
in Norway, namely the publication of a prospective epidemiological study 
on the relationship of serum cholesterol and CHD by Knut Westlund and 
Ragnar Nicolaysen.48
Booth:  Could I just add that there has just been written a very good biographical 
note about Thannhauser by Alan Hofmann of California, and I think it’s well 
worth getting hold of a copy.49
Professor Richard Bruckdorfer:  Like Anne [Soutar], I was bought up as a 
biochemist, and during this period, the 1960s and 1970s, there was another 
parallel activity going on in relation to cholesterol, which was the role of 
cholesterol in cell membranes. There was enormous excitement about how it 
controlled membrane fl uidity. Eventually these two paths, membrane cholesterol 
and lipoprotein cholesterol, did coalesce, but I think it was probably towards 
the end of the 1970s and the early 1980s before that happened. We didn’t meet 
47  Müller (1939). Müller’s study of 17 Oslo families began in 1936 and was published in 1939. Dr Paul 
Miller wrote: ‘It is quite clear that Müller was describing FH as a cause of coronary disease and he published 
photographs of tendon xanthomata.’ Letter to Mrs Lois Reynolds, 11 March 2006.
48  Westlund and Nicolaysen (1966).
49  Hofmann and Zöllner (2000).
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at the same meetings, but we probably could have informed each other a lot 
better how this actually happened. 
Professor Vincent Marks:  I recall an interest in cholesterol from a clinical 
laboratory point of view. We in clinical biochemistry were really only interested 
in using cholesterol as a diagnostic test for thyroid disease, mainly myxoedema, 
and for liver and kidney disease. One of the advances came with the introduction 
fi rst of paper, and then of cellulose acetate, electrophoresis for lipoproteins by 
Jim Kohn, later of Roehampton, but then at the Westminster Hospital Medical 
School.50 With electrophoresis it was possible to separate the different lipoproteins, 
which previously had only been possible by centrifugation and this was not 
generally available. Cellulose acetate electrophoresis really brought us into the 
modern era and we started to distinguish between the different lipoprotein 
fractions. It was, however, a long time before their signifi cance was generally 
appreciated. I was involved with a drug that was intended for use for lowering 
cholesterol.51 It didn’t lower cholesterol, but it did raise plasma α-lipoprotein 
[also known as α-lipoprotein, high-density lipoprotein or HDL] levels. This was 
not considered as relevant by the regulatory authorities at the time.
Oliver:  We are into pathology now. Sadly, several of the pioneers of the 
pathology of atherosclerosis in the UK have died. They include Theo Crawford, 
Jack Duguid, John French, John Poole and Colin Adams.
Amazingly, in the text of Florey’s fi rst edition in 1954, there is no mention of 
arteriosclerosis as a discrete entity and none of cholesterol. But in the second 
edition of his textbook in 1958, there is a new chapter by John French entitled 
‘Atherosclerosis’. In this there is a full account of the infi ltration of lipids from 
the blood. He wrote:
The lipid composition of the tissue fl uid is the factor, which determines 
the overall severity of tissue changes. The important factor which leads 
to clinical symptoms in atherosclerosis is thrombosis… The conclusion 
originally drawn from [animal feeding] experiments was that an 
50  Kohn (1957, 1970). Professor Jim Kohn, Queen Mary’s Hospital, Roehampton, produced a number 
of eletrophoretic techniques, which have been the cornerstone of haemoglobinopathy testing for several 
decades.
51  Professor Vincent Marks wrote: ‘The drug was candicidin, a polyene macrolide antibiotic that was 
discovered by Nobel laureate S A Waksman in 1953 at Rutgers University. It reduced the size and cholesterol 
content of the prostate of elderly dogs used in toxicological studies and led to its hypocholesterolaemic 
properties being discovered in the late 1960s [Schaffner and Gordon (1968)] and our investigations in the 
early 1970s.’ Note on draft transcript, 16 February 2006.
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abnormally high concentration of cholesterol in the blood was the 
signifi cant factor in causing the fatty intimal lesions. There is increasing 
evidence that the severity of the lesions [are] related more closely to the 
relative proportions of the different plasma lipids.52
John French’s account was exemplary and ahead of its time. Neville Woolf will 
now take up the theme.
Professor Neville Woolf:  I fi rst became interested in atherosclerosis, probably 
for the same reason that Barry Lewis and Gerry Shaper did, because I grew up in 
South Africa where you had to be a really crass observer not to notice that there 
was as much coronary disease among the white population as anywhere else in 
the world, but virtually none in the African population. In all the years I spent as 
a pathologist in Cape Town, I never carried out a post-mortem examination on 
an African who had CHD and it was only many years later in Britain that I did 
my fi rst post mortem on an African migrant who had had coronary thrombosis. 
Round about the same time, Ancel Keys paid a visit to South Africa and he 
and the late Brian Bronte-Stewart, the fi rst director of the rather short-lived 
MRC unit in Glasgow [Atheroma Research Unit, 1962–67], did some work 
together and showed how one could modify plasma cholesterol levels, not only 
by changing the lipid quantity of the diet, but also the lipid quality, so that if 
one substituted polyunsaturated fatty acids in the form of sunfl ower seed oil for 
animal fats, there was a signifi cant decline in the plasma cholesterol.53 
When I came to Britain in 1959 there was a comparative lull in the pathological 
fi eld so far as the atherosclerotic lesion was concerned and I was lucky enough 
to get a PhD studentship with the late Theo Crawford, who himself had been 
considerably infl uenced by John Duguid’s descriptive accounts of atherosclerotic 
plaques and of the contribution that mural thrombi could make to the actual 
volume of those plaques. The trouble was that it was almost impossible to 
identify platelets in atherosclerotic lesions reliably, unless they were pretty fresh, 
and the staining methods that we used for fi brin were somewhat capricious. 
I was asked by Theo Crawford to try to apply the fairly recently described 
Coons fl uorescent antibody method to the study of atherosclerosis.54 In that 
year with my colleague Kelvin Carstairs, we made reasonably pure antibodies 
52  French (1958): 376, 369. He remarked that it was impossible to state specifi cally the cause of atherosclerosis 
(page 358). 
53  Bronte-Stewart et al. (1955); Anderson et al. (1956). See also Bronte-Stewart (1965). 
54  See Glossary, page 140.
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to fi brin and to platelets.55 Monoclonal antibodies didn’t exist at that time and, 
of course, it was impossible to buy antibodies commercially; we had to make 
them ourselves and then conjugate them for ourselves. I have vivid memories 
of making the organ powders that one needed to get rid of the unconjugated 
dye. In the laboratory it looked as if there had been an elephant with diarrhoea, 
with piles of liver puree on the fl oor. Be that as it may, we did succeed in 
identifying antigen in these lesions. What was quite interesting, so far as the 
results using antifi brin antibody were concerned, was that there seemed to be 
two basic patterns in which these antigens appeared. The fi rst was a more or less 
diffuse staining of the intima, which at higher resolution could be seen as dot-
like areas of fl uorescence, whereas in many other areas there were solid bars of 
fl uorescent material that lay roughly parallel to the endothelial surface. When 
we used an antiplatelet antibody on these same lesions, the platelet antigen co-
localized with these bar-like areas within the atherosclerotic plaque. We drew 
the conclusion, rightly or wrongly, that the bar-like pattern of fi brin deposition 
represented episodes of mural thrombosis [thrombosis located on the artery 
wall] and that these thrombi had been covered over by new connective tissue 
(see Figure 3). 
One of the major objections that had always been raised against a contribution 
of thrombosis to the growth of atherosclerotic plaques was this question: ‘How 
could a thrombus be present within the depths of the plaque cap?’ I always used 
to think of it in terms of burial customs; if somebody is dead, you dig a hole, and 
then you deposit him at the bottom, and cover it up again. Now I thought that 
was only one way of burying someone. The other way, which Anglo Saxons used, 
was to place the deceased person on the ground and cover him. Of course, that’s 
exactly what happens in the artery wall where the presence of thrombus excites 
the formation of new connective tissue through the medium of proliferating 
smooth muscle. What was also interesting in a study that we did in 1972, was 
that we looked at every single, intact plaque in the aortas of patients who had 
either died from coronary disease or had died from something else. Interestingly 
enough, those who had had coronary thrombosis showed a much greater number 
of the aortic plaques with the so-called thrombotic pattern than did the others. 
It looked as if there were highly signifi cant local factors in coronary thrombosis 
to which I will allude in a moment, but nevertheless there were some general 
pro-thrombotic changes in the patients who died of coronary disease. 
55  Carstairs et al. (1964).
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Some of you will remember, of course, that at that time the question of whether 
thrombosis had anything to do with acute coronary events at all was a highly 
controversial matter: the British pathologists taking a ‘pro’ position and the 
American pathologists taking a distinctly ‘anti’ position. It was in this particular 
fi eld that my late colleague Michael Davies,56 whose early death all of us 
regret so much, was particularly important, and to which he made particular 
contributions. Largely as a result of his early studies, there is no doubt now 
that patients who die with acute coronary disease die with thrombosis, which 
is related to injury of the plaque cap. In the 1970s Michael Davies described 
two major forms of plaque cap injury – deep injury or plaque disruption, which 
counts for about 75 per cent of major coronary thromboses and superfi cial 
injury.57 It’s interesting, also perhaps salutary, to think that he obtained his 
results by the simplest of technical methods, but what he did contribute was a 
tremendous degree of energy and patience, asking simple questions in a simple 
way but in very great detail. I think this is a real contribution from pathology to 
our understanding of what happens in acute coronary events.
56  Corbishley and Burke (2003). See also Davies (1992); Lendon et al. (1992).
57  Davies et al. (1976, 1994). 
58  Lendrum (1949).
Figure 3: Photomicrograph of a transverse section through a coronary artery [x 35, c. 1970]. 
The photograph shows an eccentric plaque with a lipid-rich pool (c) covered by dark-stained 
collagen-rich neo-intima.
58      
a: intima; b: lumen; c: plaque. 
c
a
b
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Lastly, there was the question that if acute coronary events are preceded by a 
plaque injury, what are the circumstances that underlie that injury? Here, again, 
I would like to pay tribute to Mike Davies for his work in this area, where he 
measured the volume of plaques and in particular of the atheromatous pool 
in those plaques and found that there was a critical volume of pool which if 
exceeded meant that the patient was very likely to have splitting of the cap and 
consequent thrombosis.59 This was about 40 per cent of the plaque volume. 
This was accompanied by a comparative paucity of smooth muscles and a 
marked increase – which wasn’t relative but an absolute increase – in lipid-laden 
macrophages [Figure 4]. Mike brought us to the threshold of the current era, 
where he was interested in the role of infl ammatory mediators in bringing about 
pool formation and cap necrosis.
59  Davies and Thomas (1985); Davies (1996).
60  Dr Bill Fulton wrote: ‘In contrast to paraffi n sections, in which cholesterol and neutral fat are totally 
removed in the processing, they are preserved in the frozen section. Cholesterol tends to be deposited 
mainly in the amorphous material in the plaque. The distribution of cholesterol is positively demonstrated 
in scintillating fashion by polarized light (4b). This is an example of a complex atherosclerotic plaque with 
layered crescentric structure.’ Letter to Professor Michael Oliver, 17 January 2006. 
Figure 4: Frozen section of an atherosclerotic coronary artery. 
The lumen is occupied by opaque injection medium [x 15, 1953].
60
 
From Fulton (1965): 237. 
4a. Unstained section photographed by normal 
transmitted light.
4b. The same section in polarized light revealing 
the distribution of cholesterol crystals, which 
shine like stars. 
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Oliver:  Now I am sure Elspeth Smith will have a view about the infi ltration of 
the arterial wall.
Dr Elspeth Smith:  First of all I would like to remind people that the earliest 
study of atherosclerosis was by Anitschkov in 1913, who fed cholesterol to 
rabbits.61 But more recently, we became interested in lipoprotein studies in the 
1950s when Gofman had already produced some of his results.62 There were 
Oliver and Boyd, there was Fredrickson’s group, and Dangerfi eld and I, and all 
developed the electrophoresis of lipoproteins by paper and staining with Sudan 
Black.63 During the 1950s, there were sporadic studies on the lipids in the artery 
wall, but in the 1960s we began to study them in detail. In my case this was partly 
brought about by the fact that the pre-β lipoprotein seemed to be particularly 
associated with coronary disease and we were wondering what differences there 
were in the lipid content of the different lipoprotein bands in the artery wall. In 
the 1960s we started a fairly detailed and systematic study of the artery wall, and 
the main groups involved were Böttcher in Leiden, and my own group working 
on humans, and Adams, Gresham, Howard, and Bowyer, working on animals 
in this country.64 We found – in fact we disagreed strongly with Böttcher on this 
– that it was necessary to isolate intima and media, normal intima from lesions, 
and different sorts of plaques, because they all were analysed and produced 
quite different results. Meanwhile, gas chromatography was developed and this 
enabled us to study the different cholesterol ester fatty acids. It became clear 
that the extracellular perifi brous lipids in normal intima and in fi brous-type 
plaques was closely related to LDL or β-lipoprotein, whereas in the fatty streaks 
it was completely different and the fatty acid was almost entirely oleic acid; 
the fatty acid in the extracellular lipid was mainly linoleic acid, which agreed 
with the LDL.65 By the mid-1960s, I think Woolf and Pilkington did some 
immunological studies on lipoproteins, and Haust, and also Walton, certainly 
showed that they could demonstrate immunofl uorescence of LDL in intimas.66 
That led us to try to measure the amount of lipoprotein in intima. Actually we 
61  Anitschkov and Chalatow (1913).
62  For example, Gofman et al. (1952).
63  Oliver and Boyd (1955); Dangerfi eld and Smith (1955); Fredrickson et al. (1967). 
64  See, for example, Adams et al. (1963); Smith (1965); Böttcher (1967); Howard et al. (1972).
65  Smith et al. (1967).
66  See, for example, Walton and Scott (1964); Woolf and Pilkington (1965); Haust et al. (1967). 
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developed a very satisfactory method of analysing little bits of tissue put into 
an electrophoresis gel and then run directly into antibodies. In that way we 
got lipoproteins without the possible damage that occurred in trying to extract 
them. That showed us in about 1970 that there was a direct correlation between 
serum and intimal LDL in normal intima. 
In the 1970s Goldstein and Brown’s description of a receptor for LDL was 
published and many people jumped on to the bandwagon on receptors of one 
sort or another.67 One of the questions that arose was the question of permeability 
of endothelium, and it was held very fi rmly that the endothelium would not 
allow large particles such as LDL to enter the intima, and yet we found that 
the amount of lipoprotein was actually greater than the amount of plasma; the 
concentration was actually greater than in plasma.68 This was also corroborated 
by Hoff and co-workers in the US.69 There was considerable argument as to how 
it went in. 
About 1976 Werthessen and co-workers showed that the usual sort of standard 
cholesterol that was used for feeding to rabbits was actually highly oxidized 
and that if you fed them absolutely pure cholesterol it had a very much less 
atherogenic effect.70 That was another thing that was to run and run, particularly 
with the demonstration of scavenger receptors in macrophages.71 One of the 
most fascinating things that we found was that in areas containing fat-fi lled 
cells, although there was an enormously high cholesterol-only content, the 
amount of lipoproteins there was extremely low, and this led to a question of 
receptors, the macrophage receptors and what happened.72 I still fi rmly believe 
that macrophages are oxidizing their own lipoprotein, taking it up in the oxidized 
lipoprotein (LP) receptors, rather than a general oxidation. Well, the system of 
the permeability of the endothelium was fi nally solved by Simionescu, who 
showed that there was a vesicular transport and that all the large particles went 
into the intima through vesicular transport and accumulated there.73 We started 
67  Goldstein and Brown (1977).
68  Smith and Slater (1972); Smith and Staples (1980, 1982).
69  Hoff et al. (1977).
70  Imai et al. (1976).
71  Henriksen et al. (1981).
72  Smith and Ashall (1983).
73  Simionescu (1980).
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using the interstitial fl uid rather than the whole intima and we found that the 
concentrations of LDL in interstitial fl uid were consistently about twice the 
plasma concentration. This could really only be explained by the idea of being 
carried in by vesicular transport. It was then blocked by the internal elastic 
lamina and it was only when it had built up to a really high concentration that 
it went out again through the endothelium. Since then I don’t think there has 
been so much work on endothelial lipids themselves.
Professor Gustav Born:  Thank you very much, Michael, for letting me make 
a short contribution that follows on well from Elspeth’s. Having done what 
we could to help to elucidate the platelet contribution to arterial obstruction, 
notably coronary thrombosis and stroke, it was natural to turn to the 
atherosclerosis contribution, the subject of this Witness Seminar.74 As well as 
working on plaque fi ssure in the late 1980s and early 1990s,75 we turned to 
what Elspeth has been talking about, namely the transfer of LDL from the 
blood into the artery walls. The Steins in Jerusalem had followed the transport 
of radio-labelled plasma protein into rat aortic walls by autoradiography; and 
the Simionescus had demonstrated binding, endocytosis and trancytosis of 
LDL in arterial endothelium using electron microscopy.76 Goldstein and Brown 
established the LDL concentration in the plasma as presumptively the most 
important determinant of the rate of atherogenesis: the more you have the 
sooner and the worse is the disease.77 
We asked the question, whether there are any other determinants of LDL fl ux 
into artery walls? In the course of about ten years’ work we produced convincing 
experimental evidence that the arterial accumulations of LDL and of fi brinogen 
– another atherogenic plasma protein very different in size and properties from 
LDL – are very similarly infl uenced by structural and hormonal factors.78 A most 
important structural determinant turned out to be the density of free negative 
74  Born (2002, 2003); Reynolds and Tansey (eds) (2005).
75  Richardson et al. (1989).
76  Stein et al. (1973); Vasile et al. (1983).
77  Goldstein and Brown (1977). They received the Nobel Prize in Physiology or Medicine in 1985 for their 
work in identifying the low-density lipoprotein receptor pathway, the mechanism controlling how the body’s 
cells obtain cholesterol. They also determined how an inherited defect in this pathway, occurring in the 
disease familial hypercholesterolaemia, can lead to atherosclerosis, a disease resulting in cholesterol-clogged 
arteries. See http://nobelprize.org/medicine/laureates/1985/index.html (visited 2 November 2005).
78  For a review, see Born et al. (2003).
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charges on arterial endothelium. The lumenal surface is covered by a layer rich in 
glycoproteins which extend acidic sialate groups into the fl owing blood plasma. 
When intact, anaesthetized rabbits’ and rats’ large arteries were briefl y perfused 
with the enzyme neuraminidase to remove these sialic acids selectively, the 
subsequent fl ux of LDL from plasma into arterial walls was accelerated. This effect 
being demonstrable in two mammalian species, one imagines that something 
similar also happens in humans. I am now working with Michael Frenneaux, 
Professor of Cardiology in Birmingham, to see if we can obtain such evidence 
with material ethically obtained from patients undergoing bypass surgery. As 
vascular endothelia have extraordinarily high negative charge densities, and as 
circulating LDL is also negatively charged, the most likely explanation is simply 
electrostatic repulsion.79 Although endothelia do have some high affi nity LDL 
receptors, all the evidence so far is that the entry of LDL into endothelial caveoli 
and from there into arterial intima is by diffusion. The exact mechanism(s) of 
these processes have still to be worked out.
Another most interesting fi nding had to do with endogenous pressor agents, 
very relevant, of course, because hypertension is a major risk factor for the 
clinical manifestations of atherosclerotic diseases such as MI and stroke. 
In a series of papers we reported evidence on the acceleration of the fl ux of 
LDL and of fi brinogen into arterial walls induced by endogenous mediators. 
Infused adrenaline and noradrenaline accelerate the uptake of LDL in rabbit 
carotids and rat aortae in vivo.80 The experimental procedures were entirely 
different in the two species, so that the results corroborated each other. Striking 
confi rmatory evidence was the opposite effect in animals treated with reserpine, 
which removes endogenous catecholamines and which reduced the uptake of 
LDL by arterial walls. Other means of raising blood pressure had similar effects, 
viz. cortisol plus sodium chloride and, most interestingly, so did the in vivo 
inhibition by L-NAME [N(G)-nitro-L-arginine methylester] of nitric oxide 
production. Conversely, when nitric oxide production by cultured endothelial 
cells (HUVEC, human umbilical vein endothelial cells) was increased LDL 
uptake was diminished – more evidence that nitric oxide is antiatherogenic; 
an important effect demonstrated also by others using different techniques. 
Together, the experiments strongly suggest a relationship between blood pressure 
and atherogenesis. These experimental observations are now also being followed 
up clinically in Birmingham.
79  Born and Palinski (1985).
80  For review, see Born et al. (2003).
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Oliver:  One of the major contributors is Gordon Lowe. He took on the 
thrombosis theme from Jack Duguid, pathologist in Newcastle in 1953–4, 
who identifi ed the importance of thrombus. Can you take us a little bit further 
forward?
Professor Gordon Lowe:  Moving from the solid phase of thrombus to the 
fl uid phase: haemostasis laboratories, such as our own in Glasgow – which was 
set up in the 1950s by Stuart Douglas and George McNicol – were looking 
at the degree to which lipids might provoke thrombosis in circulating blood, 
looking at platelets, coagulation and fi brinolysis.81 I will just give you a minute 
on each of these three. 
In the 1970s platelets were championed as Gus Born and John O’Brien invented 
platelet aggregation techniques.82 Aspirin was shown to be an antiplatelet drug, 
and we all know from trials done over the past 30 years that aspirin and other 
antiplatelet agents are effective treatment for the acute coronary syndromes 
and also in prevention. Platelets are quite diffi cult to study, but in the 1970s a 
variety of techniques became available so that we could look at platelet function 
in vivo. That was by looking at circulating platelet aggregates, plasma levels of 
platelet release products such as β-thromboglobulin, and urinary measurement 
of thromboxane metabolites. Studies by several groups, including our own, 
showed that patients with congenital hypercholesterolaemia, but also people with 
acquired hyperlipidaemia, have activated platelets.83 Subsequent experimental 
work in the 1980s and 1990s shows that this was because oxidized LDL, which 
Elspeth mentioned, but also VLDL in particular, altered membranes in the 
platelets of such patients, and indeed, incubation of normal platelets with these 
lipid fractions could result in platelet activation. 
Moving from platelets to coagulation, it’s important to recognize that coagulation 
takes place on the surface of activated cells, not only platelets but also endothelial 
cells and monocytes, and with the development of vascular biology over the 
past 30 years, studies of isolated cells have shown that lipids and lipoproteins – 
again especially oxidized LDL – activated not only platelets but also endothelial 
cells and monocytes, changing them from a resting state into a procoagulant 
phase. In particular activated endothelial cells and monocytes produce tissue 
81  See, for example, McNicol and Douglas (1964).
82  There is some dispute over the invention and development of these techniques, see Reynolds and Tansey 
(eds) (2005): 6–10, 23.
83  Lowe et al. (1980).
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factor, which interacts with coagulation factor VII to initiate blood coagulation 
through the tissue factor pathway. The observation that increased blood lipids 
activate clotting is, in fact, rather old, it goes back to the early 1950s when H 
W Fullerton and colleagues studied the effects of postprandial lipidaemia on 
clotting times.84 And in particular, when the Russell viper venom that came 
from that common reptile was added to plasma it was particularly sensitive in 
showing that there was an effect. My old boss Colin Prentice told me it was 
suggested that this observation was only relevant to people who ate a fatty meal 
before walking into the jungle and being bitten by a snake. [Laughter.] But little 
did the critics know that the Russell viper venom is a specifi c activator of the 
tissue factor pathway and this early observation highlighted the potential role 
of this pathway in thrombosis, which is now accepted as the main way in which 
blood coagulation is activated. Over the last 25 years the work of Professors 
Tom Meade and George Miller here in London has established that factor VII is 
associated with coronary risk, and again is associated with both congenital and 
acquired hyperlipidaemias.85 Furthermore, they showed that one of the fi brates, 
gemfi brozil, reduced not only triglyceride but also reduced factor VII as well 
as levels of prothrombin activation peptide, which indicates a reduction of 
thrombin generation in vivo.86 And then fi nally, in the Thrombosis Prevention 
Trial of warfarin and aspirin organized by Tom Meade that reported a few years 
ago, warfarin, which effectively lowers factor VII levels, was shown to be an 
effective component in primary prevention of CHD, especially in fatal events, 
in this factorial trial.87 In a recent collaborative substudy in this trial between 
London and Glasgow, we showed that such effi cacy in preventing fatal MI was 
critically dependent on achieving a reduction in thrombin generation as shown 
by activation markers. And also thereby achieving a reduction in turnover of 
fi brin as shown by a reduction in plasma levels of fi brin D-dimer, which in 
studies from our laboratory over the past 15 years has been established as a 
signifi cant predictor of coronary risk.88
What about the role of lipids in fi brinolysis? Again it was Tom Meade who 
published a study showing that a prolonged blood clot lysis time, which 
84  Fullerton et al. (1953).
85  Miller et al. (1985); Miller (1999).
86  Wilkes et al. (1992).
87  Medical Research Council’s General Practice Research Framework (1998). 
88  MacCallum et al. (2004).
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indicates reduced fi brinolytic potential, was associated with coronary risk in 
a prospective study.89 Previous work in the 1960s by Fearnley and Chakrabarti 
in Gloucester had established that hyperlipidaemia was also associated with 
prolonged blood clot lysis time.90 And then in the 1980s the molecular basis 
of this connection was established by identifi cation of antiplasmin; tissue 
plasminogen activator as the main enzyme in endogenous fi brinolysis and then 
by characterization of plasminogen activator inhibitor as the major fi brinolytic 
inhibitor.91 Subsequently, very active epidemiological studies, particularly from 
Irène Juhan-Vague in France, have established that it is increased levels of these 
fi brinolytic inhibitors that are associated with hyperlipidaemia, particularly 
triglyceride in the Metabolic Syndrome as well as coronary risk.92 
Back in the 1950s, Tage Astrup in Denmark hypothesized that there was 
a physiological balance between coagulation and fi brinolysis, and that 
hyperlipidaemia and other risk factors alter the balance in favour of increased 
coagulation and decreased fi brinolysis and that would favour thrombosis.93 
In the 1980s, Hymie Nossel in New York produced radioimmunoassays of 
fi brinopeptide A as a marker of thrombin activity in vivo, and a fragment of 
fi brin that was a measure of plasmin lysis. He hypothesized that if you measured 
blood levels of these two activation products to obtain a ratio, this would be a 
balance between coagulation and fi brinolysis. David Wood and I performed a 
study in the late 1980s in which we studied people from Edinburgh, shipped 
the samples to Glasgow and measured them. We showed two basic things, that 
hyperlipidaemia would unbalance coagulation and fi brinolysis; and also that 
collaboration between Glasgow and Edinburgh was occasionally possible.94
Oliver:  To end this session on pathology, it should be recorded that there were 
three atheroma regression studies conducted in the UK in the 1980s and 1990s. 
These demonstrated that some degree of regression is possible with sustained 
reduction of raised plasma cholesterol concentrations.
89  Meade et al. (1993).
90  Chakrabarti et al. (1968).
91  Lowe et al. (1982).
92  Juhan-Vague et al. (2003).
93  Astrup (1956); Gaffney et al. (1999).
94  Lowe et al. (1991).
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In 1983, a group from St Thomas’ reported the effect of plasma lipid reduction 
on the progression of femoral atherosclerosis in 24 hyperlipidaemic patients 
with stable intermittent claudication.95 The patients were randomly assigned 
to treatment and usual-care groups, the former receiving dietary advice and 
cholestyramine, nicotinic acid, or clofi brate depending on their lipoprotein 
phenotype. Biplanar arteriography was performed when the study began and after 
a mean period of 19 months. Angiograms were assessed visually, with observer 
blinding, and by computerized image analysis. Therapy reduced mean plasma 
total cholesterol by 25 per cent, mean low density lipoprotein (LDL) cholesterol 
by 28 per cent, and mean plasma triglycerides by 45 per cent. Signifi cantly 
fewer arterial segments showed detectable progression of atherosclerosis in 
the treatment group. In both groups, changes in edge irregularity index were 
directly related to plasma LDL cholesterol concentration.96 This study was the 
fi rst randomized controlled trial of its type and provided evidence that effective 
treatment of hyperlipidaemia favourably infl uences the natural history of 
symptomatic peripheral atherosclerosis.
In 1992, using quantitative coronary angiography, the St Thomas’ Hospital 
trial (STARS) reported the effects over 39 months of dietary intervention in 90 
hypercholesterolaemic men with CHD.97 Dietary change alone retarded overall 
progression and increased overall regression of coronary artery disease. Diet 
plus cholestyramine was additionally associated with a net increase in coronary 
lumen diameter. 
In 1994, a multicentre antiatheroma trial (MAAS), in which Gilbert Thompson 
and I took part, showed that simvastatin had a similar effect on lesions in the 
coronary arteries: 381 men with CHD were randomized to simvastatin and 
placebo pills.98 Using three serial coronary angiograms over four years, measured 
by quantitative techniques, the effect of sustained lowering of LDL by 31 per 
cent reduced progression of lesions. Actual regression of coronary lesions was 
slow but became evident after four years of simvastatin treatment.
Dr Arthur Hollman:  Just a very brief comment about thrombosis and the 
coronary arteries. I don’t think we should pass on without referring to Bill 
95  Duffi eld et al. (1983).
96  See Glossary, page 141, for the edge-irregularity index used in the St Thomas’ Atherosclerosis Regression 
Study (STARS).
97  Watts et al. (1992).
98  Multicentre Anti-Atheroma Study (MAAS) (1994).
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Fulton in Glasgow.99 I will be very brief. Patients admitted with an MI were 
injected with a radioactive substance. Those that died had their coronary 
thrombosis examined and he showed that the radioactivity had accumulated 
in the thrombosis that killed them. There was no doubt that the thrombus 
preceded the MI. A fi ne bit of tuned experimentation, but I doubt whether it 
would get through a clinical trial today. 
Oliver:  I had asked Joan Slack to come in here, but unfortunately her husband 
is suffi ciently ill for her to telephone two days ago to say that she would not be 
able to come, but Joan’s paper in the Journal of Medical Genetics in 1968, on 
the mode of inheritance of xanthomata in 55 families, was probably the fi rst 
publication on genetic inheritance in the UK.100 Joan then produced a paper 
in the Lancet on ischaemic heart disease in familial hyperlipoproteinaemia, 
based on the same 55 families.101 Possibly the fi rst observation about the genetic 
susceptibility to ischaemic heart disease was by Gertler and White in the US. 
In 1954 they published a monograph entitled ‘Coronary heart disease in young 
adults’.102 In this they described 100 cases under the age of 40, of which 97 were 
males. They did not produce information about lipoproteins. Geoffrey Rose 
also recorded the importance of familial clustering, although not specifi cally 
related to hypercholesterolaemia.103
Professor Steve Humphries:  I personally am sad that Joan Slack isn’t here, 
because I have been looking forward to seeing her again. I met her 20-odd years 
ago when I fi rst started in this fi eld. We talked quite a lot about her papers. She 
started publishing in the 1960s, on various inborn errors of metabolism. Between 
1970 and 1980 she published 14 papers in collaboration with people like Nick 
Myant whom we have heard about; June Lloyd, Institute of Child Health, who 
sadly had a stroke about ten years ago; and Arvin Heiberg in Norway, who 
showed the links with Käre Berg and some of their Scandinavian colleagues,104 
all of whom were interested in this issue: what is the relative contribution of 
99  Fulton (1993). See also discussion on pages 18–19, and Figure 3.
100  Slack and Evans (1966); Slack and Nevin (1968); Nevin and Slack (1968). See page 14 for a discussion 
of Müller’s study of 17 Oslo families [Müller (1939)]. 
101  Slack (1969).
102  Gertler and White (1954).
103  Rose (1964).
104  See, for example, Heiberg and Berg (1976). 
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family history to heart disease, particularly with a focus on lipids?105 The paper 
that Michael mentioned was published by David Patterson at UCL, who is still 
working at the Whittington Hospital, in the Lancet in 1972.106 They came up 
with the estimate that roughly 5 per cent of men who had a heart attack under 
the age of 55 had this pattern of type IIa hypercholesterolaemia [elevated LDL 
cholesterol] when you looked at their relatives, and this estimate of about 5 
per cent was confi rmed in the series of three papers that came out in the US in 
1973, published in the Journal of Clinical Investigation from Arno Motulsky, 
Joe Goldstein and others.107 I am quite interested to know whether it is still the 
case that 5 per cent of young MI cases have this IIa pattern or whether that has 
changed. I am not aware of any data about that. 
I am going to say a couple more things about hypercholesterolaemia, but one of 
the genetic determinants of plasma lipids which I would like to mention is the 
gene coding for the apolipoprotein, apoE. Looking round the room, I think that 
about half of us have published a paper with apoE in it, so it is a popular gene 
to work on. From my understanding, it was possible, probably in the late 1960s 
or early 1970s, to use isoelectric focusing gels to determine that there were three 
common isoforms known as E3, E2 and E4. There is a very strong and consistent 
association between the apoE phenotype (and genotype) and plasma lipids and 
risk of heart disease. It has quite a small effect on lipids, but because it’s rather 
a common variant, it actually has a modest but quite consistent effect on CHD 
105  Dr Nick Myant wrote: ‘Joan Slack routinely saw patients at the weekly morning sessions of the Hammersmith 
Lipid Clinic. At the end of the Clinic she always came up to my offi ce, where we ate a sandwich lunch and 
discussed such topics as population genetics (Slack was one of my genetics mentors). We were both interested 
in the contribution of genetic factors to hypercholesterolaemia in the general UK population – in particular 
the possible contribution from heterozygous FH. The diffi culty was that we had no idea of the frequency of 
FH heterozygotes in the UK. One day early in 1971 it occurred to me that if one made an uneducated guess as 
to the maximum probable number of FH homozygotes in the UK (I think I suggested 40), one could estimate 
an upper limit for the frequency of FH heterozygotes using the Hardy–Weinberg equation for the frequencies 
of the three genotypes at a diallelic locus. I put this to Joan Slack at our next lunch meeting and she said she 
would discuss it with Cedric Carter, her boss in the MRC Clinical Genetics Unit. The upshot was that a day 
or two later, Carter wrote a joint letter to the Lancet (on his way home by train, so he claimed) in which we 
said that the incidence of heterozygous FH in the UK was unlikely to be more than 0.5 per cent [Carter et al. 
(1971)]. As the years went by it became obvious that we had overestimated the number of homozygotes in 
the UK. In 1976 [Myant (1990a): 405] we made another estimate based on a lower number of homozygotes, 
suggesting that the frequency of heterozygotes in the UK was about 1:500. Crude though these estimates were, 
they allowed us to conclude that only a very small fraction of people with hypercholesterolaemia in the general 
population are carriers of the FH mutation.’ Letter to Mrs Lois Reynolds, 16 February 2006.
106  Patterson and Slack (1972).
107  Goldstein et al. (1973a and b); Hazzard et al. (1973).
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risk as described by Bob Mahley in the US; Gerd Utermann in Germany; Forbes 
Robertson in Aberdeen; Jean Davignon in Canada; and Charlie Sing in the US.108 
I think it is an important gene, and defi nitely one that shouldn’t be overlooked. 
There are two things I want to say about the LDL receptor: the fi rst is the 
issue of the frequency of heterozygous familial hypercholesterolaemia (FH) in 
the UK, and I was hoping that Nick Myant and Joan Slack would be here to 
confi rm this story. I imagine that there was a conversation where it was realized 
that you could estimate the frequency of heterozygous FH if you knew how 
many homozygotes there were. And, of course, homozygous FH presents in 
childhood with very early demonstration of coronary artery disease and clear 
signs of cholesterol deposits in the skin and tendons, so essentially all paediatric 
cases would be identifi ed. It was realized that deconvoluting the Hardy–Weinberg 
equation where q is the frequency of the mutation carrier and p is the frequency 
of the noncarrier, p2 + 2pq+ q2 = 1, and so if you know q2 you can actually work 
out 2pq. My imagination is that Joan and Nick and June Lloyd and others were 
sitting around the table having a cup of tea and someone suddenly realized 
that you could do this if you knew how many homozygotes there were. June 
was looking after some cases and Gil Thompson was looking after others and 
suddenly they came up with a fi gure, added a ‘fudge factor’ for the ones that had 
died, divided by the population of Britain and came up with the estimate that 
the frequency of homozygous FH is 1 in one million, from which you could 
work out that the carrier is 1 in 500. Now maybe that is completely wrong, I 
don’t know if there’s anyone around the table here who can comment.109
108  See, for example, Utermann et al. (1975); Pitas et al. (1979); Robertson and Cumming (1985); Sing and 
Davignon (1985). 
109  Professor Steve Humphries wrote: ‘My second comment about the LDL receptor was about an incident 
that occurred in 1985 when we fi rst started working on the LDL receptor gene in FH patients in the UK. 
Dave Russell, working with Brown and Goldstein, had very kindly sent us his human LDLR probe and, 
using Southern blotting methods, we had identifi ed the fi rst common polymorphism of the gene. This 
enabled us to track the defective LDLR gene through families, which, of course, meant that it would be 
possible to use this as a DNA diagnostic tool in children. I was working with Professor Bob Williamson at 
St Mary’s Hospital, London, at the time, and we collaborated with David Galton, Mary Seed, Victor Wynn 
and others, showed that diagnosis was possible in two families, and prepared a manuscript which we hoped 
to submit to the Lancet [Humphries et al. (1985)]. I asked Gil Thompson to have a look at it for an expert 
opinion before I sent it in. He replied saying this was very interesting and hoped that the Lancet would 
like it, but he very much doubted it would ever become of widespread use in clinical practice. Here we are 
almost 20 years on and I am afraid Gil is still right about it not being in widespread use, although several 
of us around the table would hope that, if we can make the DNA methodology much cheaper, it might still 
have a place in helping give an unambiguous diagnosis of FH in families where lipid levels do not give a 
clear answer.’ Note on draft transcript, 7 September 2005. 
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Professor Hugh Tunstall-Pedoe:  I can answer that because I attended a meeting 
at the Hammersmith Hospital, London, in the 1970s which was convened to 
discuss exactly that question. British lipidologists had got together to discuss the 
number of cases of homozygous familial hypercholesterolaemia that they knew 
about in the UK. There was an impression that it was more common than it 
actually was. Each of them was aware of a handful of cases and they thought 
they would multiply them pro rata, but it turned out that they had a lot of cases 
in common, so many of the cases they were talking about were the same and far 
fewer than they had imagined.110
Oliver:  James Scott, would you like to take up the theme of genetics?
Professor James Scott:  We did molecular genetics rather than genetics. In 1970 
when introns were discovered in globin genes, I went to see Chris Booth, and 
my mentor Tim Peters, and said, ‘I want to do this molecular biology.’ They 
sent me to see Sydney Brenner, who, among others, suggested that I might join 
Bill Rutter in Biochemistry at the University of California in San Francisco. It 
was at this time quite diffi cult for a jobbing, trainee physician to get money 
to train in molecular genetics. In the end, I managed to get a fellowship from 
the European Molecular Biology Organization (EMBO). After two-and-a-half 
years with Bill Rutter working on growth factors, I came to the conclusion that 
I wanted to work on something other than growth control and cancer, and to 
do something that was highly clinically relevant. Just after this time, and after 
writing the Fellowship to come back to London, Steve Humphries came to see 
me in California and we chatted about what we both might do in London. 
Initially we pursued the smaller apolipoprotein genes and had a number of 
publications. However, at the Gordon Conference in 1984 I formed the view 
that we should have a crack at apolipoprotein B (apoB).111 
At this stage nobody even had a clue how large the protein was. It was variously 
estimated as being between 20 kDa [thousand Daltons] and 3 million kDa 
in size. The problem with apoB is that once it is delipidated it behaves like 
chewing gum on a hot summer’s day – it is virtually impossible to get a good 
protein sequence. I then came across Howard Morris and Ann Dell working at 
110  Professor Hugh Tunstall-Pedoe wrote: ‘Using the Hardy–Weinberg equation, the projected prevalence of 
heterozygous familial hypercholesterolaemia was correspondingly lower and their projection at that time of 
1 in 500 of the population is an estimate that I do not think has ever subsequently been revised.’ Note on 
draft transcript, 8 January 2006. See note 105. See also Glossary, page 142.
111  The Gordon Conference on Lipid Metabolism, Meriden, NH, July 1984.
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Imperial College. They had made a series of developments in mass spectroscopy, 
which could be used for protein sequencing, including, unusually, the carboxyl 
terminal of proteins, providing the protein could be solubilized in high 
concentrations of SDS (sodium dodecyl sulphate). I therefore went to see Chris 
Booth, then head of the MRC Clinical Research Centre at Northwick Park 
Hospital, London, and said: ‘Look, we haven’t got the technology that we need 
for this, but will you give us £10 000 so that Howard Morris can do this in 
his company, called M-SCAN?’112 After some thought, Chris agreed. We went 
off to get bits of apoB protein sequence and this facilitated the cloning of the 
extremely large apoB cDNA. To get more of this we contacted Bob Mahley, 
head of Gladstone Laboratories at the University of California, San Francisco.113 
Somewhat to Bob’s angst, we also teamed up with Jake Lusis at the University 
of California, Los Angeles. Together the three groups stitched the carboxyl 
terminal sequence of apoB and published this in Science, and then pulled the 
whole sequence together and published this in Nature.114 At the time apoB was 
the largest protein to have been sequenced with a molecular weight of over one 
half million. It had 4536 amino acids.
At the same time, we were very serious about the origins of apolipoprotein B48 
and thought that this had to be something peculiar. While we were dealing 
with cDNA, Bob Mahley and his colleagues had been dealing with the gene in 
parallel. The gene structure was published in the Journal of Biological Chemistry.115 
We found that the gene was grossly asymmetrical, and that there was one huge 
3’ exon encoding half the protein. We pinpointed the origins of the carboxyl 
terminal of apoB48, using expressed clones and monoclonal antibodies, and 
then pulled out all the cDNA clones from this region in several human cDNA 
libraries. A couple of months later I was talking with Joe Goldstein who said: ‘I 
bet there’s something odd going on to generate apoB48.’ I agreed: ‘There are a 
series of stop codons at that site where the protein ends,’ and he laughed. But 
about two months later we were able to submit to Nature that in humans and 
rabbits there was indeed a stop codon that coincided with the end of apoB48, 
but that this was not encoded in the genome. A genomically encoded C was 
transposed to U in the RNA, converting a glutamine to a stop translation codon. 
112  Operating in 2006 as M-SCAN Mass Spectrometry Research and Training Centre, Silwood Park, Ascot 
SL5 7PZ.
113  Mahley and Innerarity (1978); Innerarity and Mahley (1978).
114  Knott et al. (1985, 1986). 
115  Blackhart et al. (1986).
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We postulated that there was a site-specifi c cytidine deamination of the RNA, 
and that it was due to editing of the mRNA. Unfortunately, Nature turned 
down the manuscript. Thanks to Peter Rigby we were able to publish this in 
Cell.116 We found a number of other editing genes in 2002. These turned out to 
be very interesting, because they edit DNA and are involved in the creation of 
the antibody diversity, and appear to form an innate mechanism that destroys 
retroviral genomes. 
Oliver:  We aren’t intending to go beyond 2000.
Booth:  May I make a comment about James Scott’s work when he was at 
Northwick Park. I think that directors of institutes don’t normally get mixed 
up in the actual science that many of their science staff do. On this occasion 
I did. In James’ case when he produced this extraordinary story, I went up to 
Cambridge to see Max Perutz and I showed him James’ experiments and asked, 
‘Is there anything in your molecular model, some little change, that could make 
this happen?’ And he said, ‘No.’ And in fact I don’t think he believed it. 
Galton:  Most of British lipidology, I think, has lagged way behind the American 
effort. But there’s another fi rst which I think we can put up and that is the fi rst 
isolation of an apolipoprotein gene by Tito Baralle in Oxford, published I think 
in 1981.117 I think it was three weeks before Jan Breslow’s publication identifying 
the same gene and he had found a second one, the apolipoprotein CIII gene at 
the same locus.118 I think it was signifi cant that Tito Baralle got there fi rst. Jan 
Breslow is still a staff member working at the Rockefeller Institute. Tito Baralle 
left Oxford and is now working in Trieste in northern Italy. 119
Oliver:  Why do we lose our really talented people?
Humphries:  I would like to take up the apoAI story for a few minutes. In 
molecular biology there have been three key developments that have enabled 
us to study human disease at the DNA level: fi rst there was ‘Southern blotting’, 
which was invented in 1975 by Dr Ed Southern, and then, of course, we were able 
116  Powell et al. (1987).
117  Shoulders and Baralle (1982).
118  Zannis et al. (1981).
119  In 2005 Breslow was at the Laboratory of Biochemical Genetics and Metabolism, The Rockefeller 
University, New York; and Baralle at the International Centre for Genetic Engineering and Biotechnology, 
Trieste, Italy.
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to start looking at human genetic variation, although very slowly.120 Then came 
the polymerase chain reaction (PCR), which was invented in 1985 and enabled 
us to work at least 100 times faster in identifying mutations and screening DNA 
samples.121 Then we sprang into this century with the completion of the human 
genome sequence, which is all the science data that we need to keep us going 
for the next 20 years.
But the paper that David [Galton] has just mentioned, the cloning of the 
apoAI gene, enabled David and his colleagues to publish in the Lancet in 
1983, a milestone paper in my view, looking at the fi rst polymorphism in 
an apolipoprotein gene.122 He used the apoAI gene as a probe and found a 
polymorphic (restriction enzyme cutting) site with the enzyme SstI. The base 
change creating the polymorphism is not itself functional, but it was associated 
with hypertriglyceridaemia. They found that the SstI site was more common 
in a sample of 35 patients than it was in 75 controls. This was all done using 
Southern blotting and took weeks to produce the data. These days you wouldn’t 
be able to publish such data in a journal of any repute, unless you had ten times, 
or maybe 100 times those numbers of people. But that was a big experiment in 
those days. David and his colleagues, Carol Shoulders, Alan Rees and others, 
speculated that somehow this must mean that apoAI has something to do with 
triglyceride metabolism. Well, we know now, of course, that they were not 
correct and that the Sst site was in the end of the apoCIII gene, which is next to 
the apoAI gene, and that apoCIII has a lot to do with triglyceride metabolism.123 
It is a milestone paper. The interesting thing is that we still don’t know, 20 years 
later, what the molecular mechanism of this effect is, but it is just like apoE, in 
being a common variant of modest effect on lipid levels and risk. It is also one 
of the more consistent associations. There are 50–100 papers that have been 
published where this same observation has been confi rmed. In my opinion, it is 
one of the main pieces of work that came out of the UK in the 1980s.
Oliver:  We have to round the session off with a comment from Gilbert 
Thompson on apheresis.
Thompson:  Apheresis, as you all know, means to take away, and it was fi rst 
done in 1967 by de Gennes and colleagues when they treated a patient with 
120  Southern (1975).
121  Mullis et al. (1986); Mullis (1990). 
122  Rees et al. (1983).
123  Rees et al. (1985).
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homozygous familial hypercholesterolaemia (FH) over a period of three 
months.124 They literally took off a bottle of blood, spun it down, removed the 
plasma and put the cells back; they did this repetitively and called it traitment 
heroique. After three months they gave up and I am afraid the patient soon died, 
like so many homozygotes used to in those days. Subsequently, the continuous 
fl ow blood cell separator was invented at the National Cancer Institute.125 There 
was one at the Hammersmith, and I realized the potential of this for undertaking 
continuous fl ow plasma exchange. With a blood fl ow rate of 40ml a minute, 
over the course of three hours you can exchange 4l or so of a patient’s plasma 
for albumin, which preserves the osmotic pressure and has the advantage that 
albumin solutions have no cholesterol in them whatsoever. We were able to 
reduce cholesterol levels by more than 50 per cent in these homozygotes.126 
And in conjunction with Nick Myant and Paul Miller we were able to 
demonstrate regression of xanthomata in the homozygotes and even obtained 
some uncontrolled data suggesting that we were getting regression of their 
atheroma.127 We were also able to show that the life expectancy of the treated 
homozygotes was signifi cantly longer than that of their untreated siblings, 
who obviously had exactly the same defect.128 So this was a useful addition to 
the therapeutic armoury which basically had been pretty bare up until plasma 
exchange came in. 
Perhaps I could mention one other aspect of plasma exchange, and that was 
that, although we usually used it to treat familial hypercholesterolaemia, 
there was one exception in 1981, a patient with primary biliary cirrhosis and 
xanthomatous neuropathy.129 This is an extremely painful condition and you 
get so much hyperaesthesia that you can’t actually turn the key in your own 
front door lock. She was a patient of Neil McIntyre and Sheila Sherlock. They 
referred her for plasma exchange, to see if this could alleviate her condition, 
because it had already been shown by Les Turnberg to be successful in that 
condition.130 Anyway we had her over at the Hammersmith, and a friend of 
124  de Gennes et al. (1967). 
125  See Glossary, page 140.
126  Thompson et al. (1975).
127  Thompson et al. (1980).
128  Thompson et al. (1985).
129  Thompson (1983).
130  Turnberg et al. (1972).
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Neil’s who was a pharmacologist, Jonathan Tobert, happened to be over from 
the US and we got talking.131 This was about six months after his colleague 
Alberts had described the cholesterol-lowering potential of lovastatin (originally 
called mevinolin).132 Tobert gave me a small supply of lovastatin which we used 
in conjunction with plasma exchange in this lady and demonstrated that the 
problem we had previously of a very rapid rebound in cholesterol after plasma 
exchange could be markedly slowed by inhibiting HMG-CoA reductase at the 
same time. I think this was probably the fi rst time that a statin had ever been 
used in Britain. Subsequently I managed to continue to get supplies of lovastatin 
on a named-patient basis from Merck and we used this on our patients with 
familial hypercholesterolaemia at the Hammersmith, with considerable benefi t 
to the patients.133 We continued having this facility from Merck until 1989 
when simvastatin became licensed in the UK.134
Oliver:  What was the date you were referring to before?
Thompson:  The fi rst time we used lovastatin was in 1981 – the Alberts et al. 
paper describing it had just come out in 1980.135 So that was pretty soon after. 
And I think nowadays plasma exchange is still regarded as the treatment of 
choice, and although we are not allowed to show slides at this meeting, I can’t 
resist showing you a picture of one of the original homozygotes that we treated at 
the Hammersmith in the early 1970s; she is now in her mid-50s [died February 
2006], and this shows her doing a fun run in Athens in May 2004, just before 
the last Olympics. 
Bruckdorfer:  It was suggested that I might talk a little bit about lipoprotein 
oxidation. The oxidation hypothesis in its infancy was against a background in 
which the discussion of antioxidants and free radicals brought a wry smile to 
many faces during the 1960s and 1970s, because there was quite a lot of confl ict 
131  See Appendix 2, pages 85–6.
132  Mevinolin was introduced by Merck & Co. in 1980 in the US and changed its name to lovastatin in 1986 
[Alberts et al. (1980)]. For the background to Merck’s development of this statin, see Vagelos and Galambos 
(2004): 132–63; Hawthorne (2003): 70–81, 90–2, 100, 105, 151–8, 243.
133  Thompson et al. (1986).
134  See, for example, Walker and Tobert (1987); Tobert (1987). Simvastatin became the fi rst statin approved 
for over-the-counter sale by pharmacists for people at ‘moderate’ risk of a major coronary event. Royal 
Pharmaceutical Society, practice division (2004). 
135  Alberts et al. (1980).
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about their signifi cance to say the least, and even accusations of charlatanism 
in some cases. It was probably only the discovery of superoxide dismutase by 
Fridovich that brought it back into a sort of scientifi c acceptability.136 But all of 
this really derived from the original discovery of Brown and Goldstein and the 
ensuing work, which was to do with how LDL actually bound to its receptor. 
And the approach was by Bob Mahley and others to modify lysine residues 
using diketene to acetoacetylate the LDL, and they found that that actually 
blocked the normal binding to the LDL receptor.137 At the same time it was 
discovered that it also meant that this modifi ed LDL would actually be taken 
up readily by the macrophage. I think that was a key discovery. 
But, of course, this was just chemistry. The very important discovery by 
Fogelman, in Los Angeles at the University of California, Los Angeles (UCLA), 
is that if they modifi ed the LDL with malondialdehyde, a product of oxidation, 
then the same thing happened.138 Several people were working in this area; 
Anne [Soutar] started work on β-LDL I think at that time, with Brian Knight 
a year or two later. But the idea of the aldehyde was important, and attracted 
the attention of people such as Hermann Esterbauer.139 Esterbauer was a 
chemist who had worked on aldehydes for years and was interested in them 
in biology, and realized that perhaps he could contribute to this in some way. 
Eventually, around about 1984, he discovered that if he modifi ed LDL with 
another aldehyde, which was the major product of oxidation of fatty acids, 
essential fatty acids, 4-hydroxynonenal, that he could actually produce the same 
effect. Simultaneously, there was another strand of activity going on at San 
Diego in Steinberg’s laboratory, where he found that you could actually modify 
lipoproteins simply by incubating them with endothelial cells or later smooth 
muscle cells.140 It was realized, however, that probably they happened to choose 
a particular medium, Ham’s F-10, which contains copper ions and ferric ions, 
which were helping to accelerate that process. In fact, the standard way in which 
oxidation was performed in the test tube was often by simply using these ions 
and not the cells. Nevertheless, they were able to show that this often led to 
uptake and formation of foam cells, and this became an exciting area and was 
136  McCord and Fridovich (1969).
137  Weisgraber et al. (1978).
138  Fogelman et al. (1980).
139  Jurgens et al. (1986).
140  Henriksen et al. (1981).
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accepted. I picked that up at that particular time – Gus [Born] was talking about 
nitric oxide (NO) earlier, we didn’t know NO was released by endothelial cells 
at that time, we all called it endothelium-derived relaxing factor (EDRF) – and 
found that oxidized LDL would inhibit the relaxation of blood vessels. At high 
levels of LDL, even nonoxidized LDL was also inhibitory but LDL was much 
more potent if it was actually oxidized. This ultimately led to the discovery of 
the scavenger receptor and its structure by Monty Krieger.141 This led us almost 
to the position where we are now, to a greater understanding of gene expression 
induced by oxidized products. I think we just about get to the year 2000 level, 
the beginning of studies in which we fi nd that vitamin E simply has no benefi t 
as far as cardiovascular disease is concerned, leaving some to have egg on their 
faces on this particular issue. But, of course, they did all this work before they 
knew what the real oxidant was, and we still don’t really know which oxidant 
actually caused the lipoprotein oxidation, nor whether or not vitamin E, and in 
particular vitamin C, would actually prevent oxidation in vivo.
Galton:  Brown and Goldstein made their major discovery of lack of suppression 
of HMG-CoA reductase in fi broblasts of patients with FH. Now with the 
Hammersmith Hospital representatives at this meeting, Anne Soutar and 
Gil Thompson had patients with large families of FH, they were cultivating 
fi broblasts and I assume they knew how to measure HMG-CoA reductase in 
fi broblasts. Why didn’t they make the same observations as Brown and Goldstein, 
since they were so well placed to do the experiments? What were you doing?
Soutar:  I wasn’t there. [Laughter] I was still in Houston working on lecithin:
cholesterol acyltransferase (LCAT).
Thompson:  I was in Houston too. [Laughter.] Brown and Goldstein were up 
the road in Dallas.
Oliver:  I think we will solve that one at teatime.
Professor John Betteridge:  We owe such a lot to this inborn error of 
metabolism, this experiment of nature called familial hypercholesterolaemia 
(FH). It led to the discovery of Brown and Goldstein’s LDL receptor, etc., etc. 
Yet, it’s interesting when you look back at how little infl uence it had on the 
acceptance of cholesterol as a risk factor of vascular disease. I remember when I 
fi rst did lipid clinics with David Galton, seeing young men who had lost their 
brothers in their thirties. It really brought the cholesterol story home to me. I 
141  Krieger (1992).
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wonder why it didn’t make a bigger impact. These were young men who were 
not smoking, who had normal blood pressure, yet they were dying early of heart 
disease. I think it’s a paradox that it has helped all this research, but it didn’t help 
the cholesterol story.
Oliver:  We will move on to the next session and I am now going to ask the 
father of investigation in the UK, Jerry Morris, to open this session. We all 
know what Jerry has done and I hope that we can persuade him to talk a little 
bit about it, the London Hospital Survey and so on.142
Professor Jerry Morris:  I will start with the London Hospital story in the 
1950s. I come from social medicine, whose main method in investigation is 
epidemiology, but the emphasis is on social medicine. 
142  Morris (1951).
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Figure 5: Mortality from heart diseases at ages of 50–54 and 60–64 in men and women, England 
and Wales, 1931–48.
a: diseases of coronary arteries, angina pectoris; b: chronic myocardial diseases, but including MI; c: sum of a and b.
Morris (1951): 1.
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We were set up in 1948 by the Medical Research Council (MRC) as the Social 
Medicine Research Unit, essentially to investigate possible connections between 
people’s health and the way they live.143 We decided to deal with MI, a very 
serious disease, newly common, and which was apparently on the increase. In 
fact, when I was at UCH in the 1930s, the assumption then was that the disease 
was increasing [see Figure 5].
I will describe two early studies, published in detail in the Lancet in 1951 
and 1953, both relevant to our concerns this afternoon.144 The fi rst probed 
the underlying pathology of the apparent alarming current increase of acute 
myocardial infarction (AMI). I analysed the post-mortem records at the London 
Hospital where the great Professor H M Turnbull had instituted routine 
description of the condition of the coronary arteries and the myocardium at 
every post mortem. Turnbull himself, Professor of Morbid Anatomy there, an 
extraordinary man, told me that he had learned when he was a postgraduate 
student in Professor Georg Schmorl’s laboratory in Dresden, Germany, that in 
every post mortem you must record every abnormality you see, which Turnbull 
then proceeded to do.145 I studied post mortems conducted on people in middle 
and early-old age between 1907–49, during the period that saw the emergence 
of AMI from obscurity to national and international priority. [See Table 1.]
The main fi ndings can be summarized: fi rst, coronary atherosclerosis was 
exceedingly common, near universal, throughout. Second, during those years 
there was a steep increase of fresh coronary thrombosis and associated AMI in 
both men and women. Finally, despite intensive search I was unable to fi nd any 
indication of an increase of the underlying coronary atherosclerosis over those 
years; the indication indeed was of a decline.
Unfortunately, I was unable to replicate these observations. I could not fi nd 
another teaching hospital cum pathology department where such routine 
recording was performed at post mortem, not in London or the provinces, nor 
Scotland, or even the Massachusetts General Hospital or Johns Hopkins. What 
was defi cient everywhere else was the routine recording of the state of the coronary 
143  Dr J N (Jerry) Morris was Director of the Social Medicine Research Unit from 1948 until his offi cial 
retirement in 1975, a member of the MRC staff and later a Professor at the London Hospital and the 
London School of Hygiene and Tropical Medicine (LSHTM). R M Titmuss was his colleague in the initial 
stages. The Unit was located at the Central Middlesex Hospital (1948–56), the London Hospital (1956–66) 
and the LSHTM (from 1966). See also Berridge et al. (eds) (2006): 33, 44, 56.
144  Morris (1951); Morris et al. (1953)
145  Turnbull (1915).
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arteries and myocardium in the great mass of noncoronary, nonvascular deaths 
from injuries, infections, cancers, that provided some indication of what was 
happening in the general population.146 I gave up, much to the disappointment 
also of Harry Himsworth, the Secretary of the MRC, and in effect my boss, who 
had become deeply interested in these studies.147 
Next, more straightforward epidemiology: we set up incidence studies of 
CHD among men in a wide range of occupations to give us information to go 
alongside the national mortality statistics. The studies included a huge range of 
occupations: medical practitioners, schoolteachers, factory workers and, very 
importantly, a range of occupations in London Transport and the civil service. 
In 1949 I had a hunch that AMI could be related to occupation. It was more 
common in men than women, in middle age than in youth, there were some 
hints in the national mortality data and Osler’s ideas were often quoted, often 
by my own teacher in cardiology, the great Thomas Lewis.148 
146  Morris and Crawford (1958). Reports on a consecutive series of 25 necropsies in middle-aged males from 
an enquiry sent to all pathologists in Britain. 
147  Morris (1960). 
148  Osler (1910). See, for example, Lewis (1946). For the background to this period of clinical research in 
Britain, see Reynolds and Tansey (eds) (2000).
Years Average number of necropsies per year at age of 35–70
Males Females Total
Recent coronary 
thrombosis*
Acute myocardial 
infarction†
Both§
1907–14 1.1 0.25 0.25 1.6
1915–18 2.25 0.5 0.75 3.5
1919–23 3.4 1.6 0.8 5.8
1927–31 3.6 1.2 1.4 6.2
1935–39 4.4 1.8 1.8 8.0
1944–49 5.5 3.0 2.0 10.5
Table 1: Deaths from coronary heart disease in the London Hospital, 1907–49.
* Fresh, unorganized thrombus, with or without acute infarction.  
† Or necrosis or rupture; due to coronary atheroma; without recent thrombosis, though there was often evidence of 
old thrombosis.  
§ Recent coronary thrombosis and/or acute myocardial infarction.  
Excludes: cases of coronary embolism, occlusion by atheromatous debris and with syphilitic aortitis 
Includes: cases with recognized diabetes; in 1907–14 there were 1 in 13 cases; in 1944–49 there were 7:3 in 53 men, 
and 4 in 12 women.
Adapted from Morris (1951). 
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Within a year there was an intriguing suggestion of some protection against 
CHD, in particular against the most serious acute coronary syndrome – sudden 
death as fi rst clinical manifestation – in the conductors of London’s double-
decker buses compared with the drivers, and in postmen vs three sedentary 
grades of offi ce workers in government.149 
We tested these observations in every way we could devise. We had arrived, 
quite unready, at the most diffi cult of situations, testing in effect a causal 
hypothesis without the possibility of experiment and dealing only with data 
that we couldn’t manipulate. 
Booth:  May I just interrupt there. Sir John McMichael always told me that you 
went straightaway and showed your data to him at the Hammersmith. What 
did he say?
Morris:  I will tell you privately what John said at tea!150 
Of equal importance to our agenda today, I must report the reception of these 
observations. There was a huge media response, with which I had no idea how 
to cope. More interesting was the response or, rather, the total lack of response, 
by the cardiology community. I register this only because of the striking contrast 
with the US. The Director of the National Institutes of Health (NIH), or rather, 
the NHI (National Heart, Lung and Blood Institute), fl ew over to see me for 
discussion of a follow-up. Paul White telephoned and we soon became friends, 
indeed, family friends. I well remember our fi rst joyous dinner together, the four 
of us – at the Ritz, of course. More seriously, I hope that one of the outcomes of 
our deliberations today will be an assessment of the role of ‘clinical science’ in 
the national health and research effort, positive and negative.
I will conclude, personally, by reporting that we were soon struggling with the 
far more diffi cult issues of research into exercise in leisure time by a population 
rapidly becoming sedentary.151 At the same time, we were adjusting to the new 
149  Morris et al. (1953).
150  Professor Jerry Morris wrote: ‘On Dr Himsworth’s suggestion I showed Sir John McMichael our CHD 
fi ndings on occupation and other population data we had been gathering, such as on ruptured heart. 
All illustrated that epidemiology, which some of us in England and the US were developing, could yield 
information different from and supplementary to the clinical and that from the lab experiment. He listened 
attentively, paused, then just said: “Rubbish”. I departed. He came round, of course, in later years.’ Note on 
draft transcript, 19 February 2006.
151  See, for example, Morris et al. (1973, 1980); Chave et al. (1978). 
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world of ‘risk factors’ rapidly being established across the Atlantic. In brief, 
physical activity in time became recognized as some protection in the presence 
of one and of all of them.
Professor David Barker:  In Jerry’s unit was a young statistician called Martin 
Gardner, who moved down to Southampton. He decided to make a detailed 
map of the distribution of deaths from CHD in England and Wales over an 
11-year period from 1968 to 1978. The map was the most detailed made, and 
it didn’t discover anything new, but it did point up the paradox that CHD had 
its highest rates in the poorest parts of the country. There were two possible 
explanations for that: one is that people lived different lives, and were exposed 
to different diets and other infl uences in the areas with the highest rates, which 
were mostly in the north and west of the country; the other possibility was 
that the people in those areas were simply more vulnerable. It is not a new idea 
to think in terms of vulnerability. If you come to a place where there is a lot 
of tuberculosis, you immediately wonder: (a) are they being exposed to high 
doses of infection, or (b) are they more vulnerable to disease? At that time there 
were people interested in vulnerability to CHD, and Tony Mitchell was one. 
You will remember that Tony was Professor of Medicine in Nottingham and 
he once toured the country with his famous lecture: ‘Should every cow carry a 
government health warning?’152 He mused on the possible genetic vulnerability 
to CHD. If you think some people might be more vulnerable to CHD, then 
two questions arise: ‘Is this vulnerability acquired through the chaotic processes 
of ageing, or is it acquired through the organized processes of development?’ 
The latter would be a logical starting place. If you acquire vulnerability to 
CHD during development, at what point in development would that be? Here 
Martin’s map was extremely helpful, because on his map London had a very low 
risk of CHD and that would point circumstantially to a link between resilience 
to heart disease and good intrauterine conditions. You could not possibly argue 
that it was good conditions in childhood because growing up in London in 
the early years of the last [twentieth] century, children were exposed to the 
conditions described by Charles Dickens. So Martin’s map led to a hypothesis 
that good prenatal development is linked with resilience to CHD. The reason 
why prenatal growth in London was good was simply that London during the 
nineteenth century and early twentieth century, renewed itself constantly by 
bringing in some of the fi ttest young women from the southern and eastern 
152  See, for example, Mitchell (1984, 1985).
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seaboard, where people were well nourished. The young women came into 
domestic service. Their babies had exceptionally low neonatal mortality. 
The subsequent demonstration that people who had a low birth weight are 
at increased risk of CHD was received with some hostility.153 Thanks to the 
excellent child health records in Finland we now know that children who later 
develop CHD grow differently, both prenatally, and postnatally.154 They have 
slow prenatal growth; they have a period of two years’ slow postnatal growth, 
thereafter they start to put on weight rapidly. They do not reach the average for 
other boys and girls until around ten. It’s not the overweight child who is the 
problem, but the child who was underweight and then gains weight rapidly after 
the age of two. Hand in hand with the mounting epidemiological evidence has 
come an understanding of biological processes, which underlie the association 
between altered growth and CHD. For example, people who are six pounds 
rather than eight pounds at birth have fewer nephrons in their kidneys. We are 
beginning to understand how this may lead to hypertension, especially if it’s 
attended by rapid weight gain and increased body mass index of childhood. We 
know that people who are small at birth set their metabolism in a frugal way, 
which may be inappropriate when in later life they are exposed to adequate or 
even excessive nutrition. We know that people who did not grow well in the 
uterus and were small or thin at birth are more vulnerable to the effects of low 
income in adult life, however that effect is mediated.155 The fi eld is coming on 
very fast, because an understanding of the process is now persuading those for 
whom epidemiology was no more than circumstantial evidence. 
Oliver:  Are there some questions before we move on about this particular 
subject? If not may I ask George Davey Smith please to take up the theme.
Professor George Davey Smith:  I was asked to talk about what I was thinking 
about with regards to cholesterol from 1950 to 2000. As I was born in 1959, 
perhaps it was not very much. But I guess I will be one of the few people here 
who experienced the emergence of knowledge of this issue as a nonexpert. I 
can remember exactly where I was when I fi rst heard about cholesterol: it was 
around 1971, I was walking in the Peak District and drinking a pint of milk in 
153  For example, Paneth and Susser (1995).
154  For example, Barker and Osmond (1986); Barker et al. (1989); Barker et al. (2002); Kajantie 
et al. (2005). 
155  Barker (1972); Barker and Rose (1976).
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every village, and the friend I was walking with said, ‘This is going to give us 
fat on the heart, drinking these pints of milk’. So lower-middle class kids from 
Warrington harboured an opinion in 1971 and had heard about cholesterol, 
and I guess the knowledge was pretty widespread. 
And indeed, the fi rst work I did in this fi eld, in 1985, was a survey of public 
attitudes about the causes of CHD, with 20 000-odd people in Wales being asked 
what they thought caused heart disease and two-thirds of them said saturated 
fat, high blood pressure and smoking.156 When the same thing was done a few 
years later, even higher percentages chose them. So as far as the general public 
were concerned, I think there was reasonably widespread knowledge of at least 
what they were supposed to think caused CHD. 
Talking about the epidemiology of cholesterol, by that stage large-scale pooling 
projects had been carried out, where all the big observational studies came 
together, and these had shown that there was a very strong consistent association 
between blood cholesterol levels and CHD.157 I think that the fi rst study done 
in Britain – but Jerry [Morris] might correct me here – was prospective by Ian 
Higgins and Archie Cochrane, who started measuring cholesterol in the Rhondda 
Fach studies in the late 1950s.158 Then more prospective studies in Britain came 
out and the fi rst major international pooling project appeared in 1978.159 
The issue that I got involved with was one which I think became important 
in terms of thinking about strategies to deal with CHD, the observation in 
epidemiological studies that low cholesterol was associated with increased 
levels of mortality from causes other than CHD. This certainly became an 
aspect of the equation: what was the appropriate strategy for dealing with the 
positive association of cholesterol and heart disease? We carried out a study on 
brain cancer, my fi rst prospective observational study, and showed a positive 
association of cholesterol with brain cancer.160 One of my next papers was a 
study showing that there was no positive correlation in a different study, so 
it wasn’t an auspicious start.161 I was working on cholesterol and noncoronary 
156  Davey Smith and Nutbeam (1988). 
157  Pooling Project Research Group (1978).
158  Higgins et al. (1963). See also Ness et al. (eds) (2002).
159  Pooling Project Research Group (1978).
160  Davey Smith and Shipley (1989).
161  Davey Smith et al. (1992b).
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mortality, and this was a popular issue since the apparent detrimental effects of 
low cholesterol had been reported in 1974 when the fi rst major paper on low 
cholesterol predicting colon cancer had appeared.162 The National Heart, Lung, 
and Blood Institute in the US organized a mass pooling project in the same way 
that had been done for CHD, bringing together all the major prospective studies 
to try to see if they could make any sense of these observations.163 Geoffrey Rose 
and Michael Marmot were too busy to represent the fi rst Whitehall study at this 
conference, so I was sent.164 Our perspective came from looking at the Whitehall 
study, which was different from many of the other studies, as it had data on social 
factors: civil service employment grade (which was very strongly predictive of 
CHD mortality, and mortality from other causes), data on marital status, and 
data on health status and respiratory function. We showed that if you didn’t 
take all these things into account then it did, indeed, appear that people with 
low cholesterol did badly with respect to a whole range of noncoronary causes 
of death. If you took into account all those confounding factors, however, then 
it appeared that these were noncausal associations, the association between low 
cholesterol and non-CHD mortality being due to the confounding factors and 
to the fact that being ill, or having conditions that led to poor lung function 
also led to low cholesterol.165 Other reports came out regarding this association, 
however. But the early cholesterol-lowering trials with drugs – although not 
diet – also suggested an increase in the risk of non-CHD mortality, which we 
proposed might be due to effects of the drugs then in use to lower cholesterol, 
162  Rose et al. (1974).
163  Pooling Project Research Group (1978).
164  The fi rst Whitehall study in 1967 involved 17 718 men, aged from 40–64 years, in the British civil 
service. Men in the lowest employment grades were more likely to die from CHD and other causes than 
those in the highest grades. After controlling for standard risk factors it was found that those in the lowest 
grade still had a relative risk of 2.1 for CHD compared with those in the higher employment grades. 
In 1985 the Whitehall II study was set up to determine the underlying causes for these differences, and 
included women. All non-industrial civil servants, aged 35–55 years, in the London offi ces of 20 civil 
service departments were invited to take part in a cardiovascular screening examination at their workplace. 
Of those invited, 10 308 (73 per cent) participated in the baseline survey. In addition to the screening, 
the participants were given a self-completion questionnaire. From the initial survey it was found that 
employment grade was associated with work control and job demand with lack of control related to long 
periods of absence. Since its inception there have been a further six phases of the Whitehall II study, the 
most recent completed in September 2004. See www.phis.org.uk/doc.pl?fi le=pdf/Heart%20Health%20Pra
ctice-primary%20prevention.doc (visited 2 November 2005). 
165  Davey Smith et al. (1992a).
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not to low cholesterol itself.166 This effect has not been seen in the statin trials. 
In the end, the trials resolved that issue, rather than the observational studies. 
We thought we demonstrated to our satisfaction that there was no causal link 
between low cholesterol and noncoronary causes of death, but it wasn’t to 
everyone’s satisfaction.167 
I would like to fi nish by agreeing with John Betteridge’s point about the lack of 
strength that people put on the observation of genetic hyperlipidaemias. Looking 
back now with respect to cholesterol and non-CHD mortality, there’s a letter by 
Martijn Katan in the Lancet in 1986, which pointed out that it’s very diffi cult to 
identify causal effects in observational studies. People who get sick end up with 
low cholesterol and people who smoke have low cholesterol levels, and these 
would lead low cholesterol levels to be related to increased mortality. However, 
Katan argued that being sick doesn’t change your genotype and your genotype 
is unrelated to smoking and all the other confounding factors. Therefore, if low 
cholesterol was causally related to increased risk of colon cancer, people whose 
genotype was associated with lower cholesterol levels should have an increased 
risk of colon cancer.168 I can remember reading Martijn Katan’s Lancet letter 
at the time and thinking, ‘This is nonsense’, but now I think that the concept 
it advanced is probably one of the most important additions to observational 
epidemiology in the past half century.169
Barker:  The fi rst time I spoke to the American Heart Association meeting I had 
a remarkably small audience. I said to the organizer that considering there were 
15 000 cardiologists attending the meeting, remarkably few were in the room. 
‘What am I competing with?’ He replied that there was a lecture in the next hall 
on income tax for cardiologists.
Pyörälä:  As you said, David, cardiologists showed very little interest in the 
results of epidemiological studies. It was, however, interesting that with the 
publication of the fi rst angiographic trials on the effect of lipid-lowering on the 
progression of coronary atherosclerosis, their attitudes to the cholesterol issue 
began to change, perhaps because these studies were carried out using their own 
166  Principal Investigators (1984); Davey Smith and Pekkanen (1992b).
167  Davey Smith et al. (1992a, 1993); Davey Smith and Pekkanen (1992b).
168  Katan (1986).
169  Keavney (2004); Davey Smith and Ebrahim (2003).
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tools.170 One reason why repeated observations from epidemiological studies 
on a continuous relationship between serum cholesterol and CHD extending 
over the whole cholesterol distribution did not ring any bells in the minds of 
cardiologists and other clinicians, may have been the way of expressing ‘normal’ 
values for biochemical measurements as ±2 standard deviations around the 
mean in healthy subjects. Thus, even very high cholesterol levels were within 
the ‘normal range’. 
Oliver:  In no way would I even think of defending cardiologists, since they were 
the source of much inertia for a long time. Why is this? Having run two cardiac 
departments, I think the answer is two-fold: the fi rst is that most cardiologists are 
not academically trained. I am not even sure how inquisitive they are. Second, 
they are very busy pushing tubes into patients. I can remember when I was in 
Sweden, Lars Carlson came up with the phrase: ‘Of course, cardiologists are 
two-parameter men, aren’t they? Not three-parameter men.’ By two parameters, 
he meant fl ow and pressure. I had a lot of people in my team doing cardiac 
catheterization, but they did not think much about the causes of coronary 
disease.
Scott:  I don’t think we can blame the cardiologists for what was happening in 
the early 1980s. There was huge resistance in the popular press to the idea that 
diet and cholesterol might really cause CHD. That might have come from the 
cardiologists, but I think it was more general. I think that maybe we in Britain 
are offshore islanders, who are not going to be told what to do! It wasn’t until 
the big statin trials that this view was reversed.171
Tunstall-Pedoe:  This is getting into the area that I am going to talk about 
after tea, but I think British academic medicine had as much to answer for as 
cardiologists in terms of resistance to coronary disease prevention. 
Professor John S Yudkin:  Is it not a resistance to this diet–cholesterol–heart 
hypothesis that we are talking about, rather than resistance to the cholesterol 
hypothesis? I agree with John Betteridge that until the 1980s we had no 
effective pharmacological tools to lower cholesterol. The diet studies were all on 
polyunsaturated fatty acids, which were all a little bit iffy, as they may have had 
other effects on the heart independently. So I think confl ating diet and heart 
and cholesterol was probably where the problems lay.
170  Brensike et al. (1984); Blankenhorn et al. (1987); Brown et al. (1990).
171  Scandinavian Simvastatin Survival Study (4S) (1994).
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Oliver:  I think that’s right and I don’t think that the World Health Organization 
clofi brate trial helped – for which I was responsible and to which I will make 
reference later – it added to the uncertainty because of its largely negative 
fi ndings. Cardiologists and many internal medicine physicians rather rubbed 
their hands and said, ‘I told you so.’
Booth:  May I just interject with a point, because it’s probably an interesting fact 
of modern history that the word fi bre has not been mentioned.
Oliver:  Tom Sanders is going to talk about diet later. 
Betteridge:  I remember when I fi rst started seeing patients with what was called 
‘maturity onset’ diabetes in the early 1970s, the main focus was on glucose. 
Blood lipids were not routinely measured. Even other important risk factors, 
such as blood pressure and cigarette smoking, were not addressed. 
I remember being taught that the disease in the arteries of people with diabetes 
was somehow different from the atheromatous disease in people without 
diabetes. It seemed to me at the time that it was accepted that people with 
diabetes would die of heart disease and stroke, and there was nothing that could 
be done about it. 
In terms of research in lipids and diabetes there was a focus on adipose tissue, 
lipolysis and free fatty acids and David Galton was at the forefront of this in the 
UK.172 It is of interest that this area of research has come full circle and currently 
is a hot topic in relation to the Metabolic Syndrome. 
I remember that there was interest in plasma triglycerides and vascular risk in 
diabetes, and the name of Dr M J Albrink in the US comes to mind.173 Of 
course, the importance of low HDL as a vascular risk factor was ‘rediscovered’ 
by Miller and Miller in their Lancet paper in the 1970s.174 They referred to 
the early work of David Barr in the US in the 1950s and subsequently 
Esko Nikkilä in Finland. Professor Nikkilä also highlighted the low HDL levels 
in diabetes.175
172  Clifton-Bligh and Galton (1976); Reckless and Galton (1980).
173  Albrink and Man (1958); Albrink et al. (1963); Albrink (1964). 
174  Miller and Miller (1975).
175  Barr and Russ (1951); Nikkilä and Hormila (1978).
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Lipid and lipoprotein turnover studies were in their infancy, but increased 
hepatic lipoprotein synthesis was described in diabetes, together with decreased 
clearance due to reduced activity of lipoprotein lipase.176 Around this time 
new, more simple techniques were becoming available for the measurement of 
individual lipoproteins and the calculation of LDL by the Friedewald formula.177 
In addition, the measurement of cholesterol (and triglyceride) became easier 
with the development of enzyme assays. In this regard, the name of Dr Bill 
Richmond, consultant clinical chemist at St Mary’s, deserves mention as 
contributing to the development of the assay for cholesterol.178 This, of course, 
liberated laboratories from all the acid needed for the Lieberman–Burchard 
reagent;179 Dr John Reckless, Professor David Galton and I contributed one of the 
fi rst cross-sectional studies relating the presence of symptomatic concentrations 
in diabetic people, published in the British Medical Journal.180
The idea of qualitative changes was emerging. Some of the early studies with 
electrophoresis suggested that some patients with diabetes had the broad beta 
band suggestive of remnant particle accumulation. Then, of course, the LDL 
subfractions described by Ron Kraus appeared.181 I think it was the US Multiple 
Risk Factor Intervention Trial (MRFIT) screenees study that showed us the risk 
of cardiovascular disease in diabetes in relation to cholesterol, very important 
in the mid-1980s.182 People with diabetes with a low cholesterol level had a risk 
two to three times higher than a nondiabetic person with a high cholesterol 
level. I think that’s very important and the US Framingham Study contributed 
to that.183 Then there was the issue of clustering of multiple risk factors and 
everyone claims this as their own as far as I can see. It was put on the map by 
176  Oliver and Boyd (1953b).
177  See Glossary, pages 141–2.
178  Richmond (1973, 1974, 1976).
179  Robertson and Cramp (1970). This required a substantial amount of concentrated sulphuric acid.
180  Reckless et al. (1978).
181  Austin et al. (1988, 1990).
182  Multiple Risk Factor Intervention Trial (MRFIT) (1976). 
183  The Framingham Heart Study started in 1948 with a sample of 5209 men and women aged from 30–62 
years in Framingham, Massachusetts, US, and was directed by the National Heart Institute. The subjects 
have returned every two years for further tests and 5124 children of the original sample were recruited in 
1971. Gordon et al. (1977). See www.nhlbi.nih.gov/about/framingham (visited 18 November 2005). 
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Gerald Reaven’s 1988 Banting Lecture, but you know Markold Hanefeld in 
Dresden published on it in 1981, and Crepaldi earlier.184 We have all seen this 
associated risk factor clinically, but I think it was Reaven who put that together, 
and, of course, acknowledged Himsworth, of whom we have heard already, who 
was one of the fi rst to point to the difference in diabetes, the insulin-resistant 
diabetes, compared with the insulin-defi cient diabetes.185 Then, of course, the 
relationship of clustering of risk factors to insulin resistance, which may be 
the central abnormality, was identifi ed and, I think, an important player was 
Edwin Bierman in Seattle.186 Another thing that came out of Finland was the 
idea that the dyslipidaemia is present when diabetes is diagnosed, and that again 
suggested a phase before diabetes, where you have dyslipidaemia developing. 
Now, of course, we talk about Metabolic Syndrome pre-diabetes and that’s 
where the focus of attention is.187
I was taken by Elliot Joslin, the diabetes physician and my hero in diabetes, who 
in 1927 said something that I thought was fantastic.188 He asked if it was possible, 
chemically, that the high prevalence of atherosclerosis in diabetic patients could 
be attributed to the high-fat diets patients had received and particularly those 
rich in cholesterol? He thought this was the case and was determined to keep 
the cholesterol in the blood of his patients at a normal level. He suggested 
that this therapeutic procedure be open to experimental investigation and that 
it should not take long to solve. He said that in 1927. When I fi rst talked 
about cholesterol in diabetes, my colleagues attacked me because people with 
diabetes had enough to contend with. Cheese was freely available on the diet, 
carbohydrates were restricted, but cheese with saturated fat was free and patients 
could eat as much as they liked. 
Galton:  I agree with everything that John Betteridge said, because after all I 
taught him most of it! [Laughter.]
Betteridge:  He taught me all he knew. [Laughter.]
Yudkin:  If we are concentrating on the cholesterol–heart hypothesis, I said earlier 
that I think where a lot of doubt existed was the belief that the cholesterol–heart 
184  Crepaldi (1971); Julius et al. (1981); Reaven (1988); UK Prospective Diabetes Study (UKPDS) (1991).
185  Himsworth (1936).
186  New et al. (1963).
187  Laakso (1995). 
188  Joslin (1927). See also Joslin (1956).
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000
52
hypothesis would be exactly the same paradigm as the diet–heart hypothesis.189 
I think they mean two different things: cholesterol being only one of the 
mechanisms whereby diet can infl uence CHD. But I suspect that I am not 
the only person to continue to see patients who ask, ‘How can I have a high 
cholesterol? I hardly eat any fatty foods, animal foods, drink any milk?’ Or my 
diabetic patients who say, ‘My sugar can’t be high, because I haven’t had any 
carbohydrates.’ There is that misunderstanding. 
I think the other is something where I would agree with John Betteridge, that 
there has been a growing recognition of the multiplicity of risk factors that 
cluster together, especially in people with diabetes. But you don’t need diabetes 
to have all the diabetic risk factors. So the classic diabetic dyslipidaemia of the 
high triglyceride, low HDL, the microalbuminuria, central obesity, the high 
plasminogen activator inhibitor type 1 (PAI-1) levels, a whole range of things 
that are almost universally linked with type 2 diabetes, are pretty common 
indeed in the 25–50 per cent of the UK, and 98 per cent of the population of 
the US, with obesity, as a Metabolic Syndrome.190 I think there is something 
about obesity that ties these together, superimposed on what is a little switch in 
the blood glucose, which makes you diabetic. But as John said, that probably 
doesn’t make that much difference to cardiovascular risk. 
I think that the one thing that we haven’t considered or haven’t mentioned 
anywhere this afternoon, is the growing fi eld of low grade infl ammation with 
C-reactive protein as a marker – whether this is completely independent of the 
cholesterol–heart link or whether it ties in somehow, perhaps in terms of LDL 
oxidation, or some other effect on scavenger receptor uptake. My belief is that 
there is a link between adipose tissue composition and low-grade infl ammation, 
which underlies links between these various things that cluster together as the 
insulin resistance syndrome and I think that that is completely independent of 
the cholesterol–heart link. My view is that lipids are important in diabetes, but 
different lipids. The whole of the recognition of risk in Metabolic Syndrome is a 
separate construct from the diet–cholesterol–heart relationship. It complements 
it, but comes from a completely different direction and the two factors together 
may well have some bearing on the diet–heart paradigm. Chairman, you quoted 
from John French at the beginning of the meeting, that in CHD there are 
changes in the vessel wall on the one hand, and prothrombotic changes on the 
189  For a view of butter and the diet–heart link in New Zealand, see Steel (2005).
190  Yudkin J S (1993, 2000); Foyle et al. (1995); Yudkin et al. (Caerphilly Study) (2002). 
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000
53
other hand. It may well be that these infl ammatory things are more to do with 
the plaque complication, its rupture or thrombosis, while the cholesterol may 
be more to do with vessel wall damage.
Professor Paul Durrington:  I think that John [Betteridge] did a very nice 
summary and I entirely agree with everything he said. I must say I have some 
reservations about this multiplicity thing when it comes to coronary disease. 
I fully recognize that in a society like Britain coronary disease clearly has a 
number of different risk factors. However, cholesterol is pre-eminent and is 
the permissive factor allowing other risk factors to operate. I think one of the 
things that we have not really covered today is the transnational epidemiology of 
CHD. Something that greatly disturbs me is that those nations where coronary 
disease is really still rare, are beginning to acquire a higher rate of coronary 
disease, and the big thing that is happening there is a nutritional change leading 
to a rise in their cholesterol. In most countries where there is coronary disease, 
by and large the middle-aged male population has cholesterol of more than 
4mmol/l.191 Fat, particularly saturated, comprises a high proportion of dietary 
energy and obesity is common. In those countries where coronary disease is 
uncommon, they derive most of their dietary energy from carbohydrate and 
obesity is uncommon. Yet we know that in China and India, all that is changing 
and they are very populous countries. We are actually on the verge of a pandemic 
of coronary disease far greater than we have ever seen before. We think we are 
beating it here, and we are, but coronary disease is not due to defi ciency of 
statins. It is also not, by and large, a defi ciency of genes; it is nutritional. I think 
that was why people had a lot of trouble accepting the cholesterol hypothesis in 
Britain. When all we could do to lower cholesterol was to criticize the food and 
agricultural industries, and to talk about diets, there were great forces ranged 
against people who wanted to lower cholesterol. These industries killed a lot of 
the enthusiasm for nutritional change by their promotion of negative views. I 
don’t want to talk about individuals, but it was very obvious that if you had certain 
speakers at a medical meeting their lectures would be organized and arranged 
by the food industry. In the early days of gene work as well, the suggestion that 
coronary disease was genetic was publicized because it was a distraction from 
nutrition. When statins came along then we had a big industrial force raised 
behind cholesterol-lowering with drugs. Statins have undoubtedly been a great 
boon. They have been a great success and we haven’t yet seen their full benefi ts, 
but we shouldn’t lose sight of the fact that one casualty of statins has actually 
191  See Glossary, pages 139–40, for a comparison of US and European measures of cholesterol. 
See also note 198.
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been the nutritional hypothesis. For most parts of the world where coronary 
disease is going to be important in the future, it is a nutritional problem. It can 
only be tackled nutritionally: drugs are too expensive there. I think that point 
has been lost sight of and it worries me greatly.
Oliver:  In view of the subject of the meeting, were you thinking that way 25 
years ago?
Durrington:  I didn’t have much choice then, Michael. We had no very effective 
cholesterol-lowering drugs. I was always very impressed by the differences 
between different nations in their coronary rates: rural Africa, South America, 
Asia as I have mentioned, and Britain. It seemed to be a message that we weren’t 
taking up and we should have done then and still need to do now. 
Born:  It’s a very good discussion. I wonder whether it’s permissible to draw brief 
attention to an experimental contribution to the aetiology of diabetes? Professor 
Yarom and her colleagues in Israel showed that when rats are made diabetic with 
streptozotocin, the density of negative electric charges on arterial endothelium 
is reduced within a month by about a third – very signifi cant indeed.192 So on 
the basis of our evidence presented earlier that this charge slows the movement 
of LDL into arterial walls, I think that there is very likely a causative connection 
between these experimental observations and the well-established fact that the 
clinical manifestations of atherosclerosis occur earlier in diabetics. 
Scott:  Our own interest in the Metabolic Syndrome of insulin resistance has 
increased progressively over the past several years. This was initially driven by the 
recognition that we were going to get on top of cholesterol as a risk factor, and 
that obesity was driving the Metabolic Syndrome of insulin resistance and all 
of its serious downstream consequences (including proatherogenic lipoproteins, 
high blood pressure, hypercoagulation, type 2 diabetes, atherosclerosis) and was 
emerging as the dominant risk factor. Thus I echo and re-emphasize everything 
that John [Betteridge] said.
Oliver:  I think we will move on from this session. I should say that this morning 
I had a telephone call from Gerry Shaper who said that he had been tying his 
shoelaces and got an extreme pain in his back and couldn’t possibly move. I asked 
him what he was doing, and he replied, ‘Can’t you hear, I am sitting in a chair 
groaning?’ That’s his apology because he was scheduled to speak at this point.193
192  Raz et al. (1998).
193  See Appendix 2, pages 85–6.
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Tunstall-Pedoe:  I am pleased to be here. I have two problems. One is that I 
haven’t made any earth-shattering discoveries myself. I have just tried to fi nd how 
to put things into perspective and perhaps to help others as well, by doing so. 
The second is that I tend to like people I disagree with more than those who agree 
with me. I intend to upset everyone who is here and if there’s anyone who’s left 
out, I apologize. What I would like to do is to set the medical–cultural scene in 
coronary disease and cholesterol when I got into coronary disease epidemiology 
in the late 1960s and subsequently. 
Dr Wallace Brigden, my consultant cardiologist boss at the London Hospital, 
took me to visit Professor Jerry Morris at the London School of Hygiene and 
Tropical Medicine (LSHTM) in 1969 to talk about Jerry’s proposal to recruit 
someone to set up a heart attack register in the London Borough of Tower 
Hamlets in east London. At that time I was training as a cardiologist and in 
general medicine. I was a registrar hoping for promotion to senior registrar, but 
had been told to do some research fi rst.
Like other hospital doctors in training and medical students at that time, I 
knew exactly where coronary disease came from. It came out of ambulances 
and disappeared about three weeks later, leaving a box of chocolates behind it 
if it had survived. Hospital doctors had nothing to do with angina. Angina was 
dealt with by GPs; hospital doctors dealt with acute emergencies, rather than 
chronic diseases, which were rather undignifi ed and also were more properly 
dealt with by GPs. I was a bit puzzled when I started working with Jerry Morris 
to discover that coronary disease was offi cially classifi ed by epidemiologists 
as a chronic disease, because I had only seen acute medical emergencies. Dr 
Wallace Brigden warned me on the way to the meeting that epidemiology was 
not considered quite respectable by many cardiologists, particularly those at the 
Hammersmith. By implication such research might be considered a waste of my 
fi rst-class Cambridge degree and I should really be going into a laboratory. To 
be fair he did not press this argument too hard or say he agreed with it, but he 
thought I ought to know.
Epidemiology also was equated with drains, rather disparagingly. The other 
thing at that time that respectable doctors were not into was prevention. A 
doctor was concerned, traditionally, with diagnosis and treatment and anything 
else was snake-oil salesmanship. If you were an academic, you were not supposed 
to be enthusiastic about preventing disease. It was a bit like an accusation under 
the Joseph McCarthy era [1940s–50s] in the US that those of doubtful politics 
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had been prematurely antifascist; if you were in favour of prevention you were 
unbalanced, lacking in judgment and an object of deep suspicion. What was 
needed was more and more research. 
The burning academic argument at that time was that if you didn’t know all the 
causes of a disease, you couldn’t do anything about it, and it had the convenient 
logical consequence that it was never the right time to do anything about the 
disease, but always right to call for more research. Of course, that was utter 
nonsense, but it was based on a false concept of disease causation that risk 
factors were additive, so tackling one alone was tinkering at the edges, rather 
than a multiplicative model, where if you can affect one risk factor in a big way 
you can have a major effect on disease rates, which is what prevention is about, 
now belatedly substantiated by the effect of statins.
Going back to when Winston Churchill was Prime Minister in the 1940s, it was 
said that the British Cabinet was divideded between ‘war-wagers’, or ‘better-
notters’.194 I think you could classify most medical academics in the 1960s and 
1970s as ‘better-notters’; there were always arguments why you shouldn’t do 
anything about coronary disease and why you couldn’t prevent it. At the top 
of the ivory tower of academia, were the lipodologists. They existed only in 
major teaching hospitals in large centres of population, collecting extremely rare 
conditions. They lived in a sort of Alice-in-Wonderland world confusing the 
very big and the very small; the very rare and the very common. If you read a 
chapter on cholesterol by lipidologists there would be a photograph of a patient 
with bizarre skin and joint lesions caused by FH, which was allegedly responsible 
for the most common cause of death, CHD, killing one person in three. Most 
photographs would be of the same patient, because they were so rare. You were 
supposed to be looking out for him or her in the outpatient clinic, but they 
never turned up. Meanwhile epidemiologically raised cholesterol levels were so 
common they were classifi ed as ‘normal range’.
Cholesterol was something that Americans had; it defi nitely wasn’t British. 
Anyone who talked about cholesterol was obviously suffering from American-
style hypochrondria. If a patient asked what they should do to stop themselves 
from getting coronary disease, it was evidence that they were mentally 
unbalanced. No fi t person, it was thought, should worry about becoming ill. 
As for measurement, only a fool would measure cholesterol, because you couldn’t 
smell it, you couldn’t taste it, it didn’t hurt you, and also you couldn’t measure it 
194  Gilbert (1991).
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000
57
at all reliably. If you measured it twice in the same patient, you got two different 
answers. When I was studying people from South Asia in my coronary register in 
Tower Hamlets I produced the original results showing that they had an excess 
of coronary disease over the cockney natives, I was puzzled by why the two 
branches of the London Hospital seemed to have different cholesterol levels.195 
I split samples between them and they were 20 per cent higher in Mile End 
than in Whitechapel, enough to be of enormous signifi cance epidemiologically. 
When I asked the physicians about it, they said they knew. The two chemical 
pathologists concerned both insisted that they were getting it right and the 
other one was wrong. But for that I might have done a pioneering study of risk 
factors in British Asians, as it was I could not trust the results.196
The other thing about risk factors – remembering that this was the era when 
there was an argument about whether blood pressure was a mixture of two 
populations or whether it was continuously distributed197 – was that clinicians 
divided things into normal and abnormal. If it was normal, you could go 
away and forget about it; if it was abnormal, then it justifi ed the enormous 
indignities and treatments piled upon you. This was an era when normal was a 
diastolic blood pressure of 104mmHg – sorry I mentioned blood pressure – and 
normal cholesterol was below 300mg/dl (7.8mmol/l).198 There was no point in 
measuring it if most people had normal cholesterol anyway. 
An epidemiologist should not be quoting case histories, but just very briefl y. 
Three patients and the presence or absence of cholesterol readings: one I saw 
in the London Hospital medical unit’s outpatients’ clinic. There was a young 
woman who had been put on a most ferocious diet as the result of a high 
cholesterol reading (over 300mg/dl). I didn’t believe that she could have got 
her cholesterol down to just over 200mg/dl on this diet in one go, and had 
great diffi culty in persuading her to come off it for three months so I could see 
whether the original reading was right. She had been put on this ferocious diet, 
195  Tunstall-Pedoe et al. (1975); Tunstall-Pedoe (1975, 1978). 
196  Professor Hugh Tunstall-Pedoe wrote: ‘Cholesterol standardization came later, after similar problems 
were experienced in the clofi brate studies, which involved Michael Oliver and Jerry Morris and his unit.’ 
Note on draft transcript, 8 January 2006.
197  Swales (ed.) (1985).
198  Cholesterol readings are expressed in two ways: the European Système Internationale (SI) unit (one 
millimole is a value expressed per litre as mmol/l and gives information about the concentration of a 
solution) and the US expression mg/dl [milligram per decilitre]. See Glossary for normal cholesterol levels, 
pages 139–40. 
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which meant that she couldn’t eat with anyone else, or ever eat out, on the basis 
of one cholesterol reading. When I took her off the diet, the cholesterol was 
only slightly higher, but it was perfectly satisfactory. The original reading was 
wrong and had never been replicated.
I saw a man in the Tower Hamlets heart attack register that I did with Jerry 
Morris.199 Well, I didn’t see him, but I interviewed his widow. He had had an 
attack of chest pain in the night and the emergency doctor had come along and 
said that it was indigestion, and nothing to worry about, and he died before 
morning, his wife fi nding him dead, downstairs on the sofa at daylight. He had 
been admitted three years earlier to St Bartholomew’s Hospital and I noticed 
on his notes that his cholesterol had not been measured when he had his MI or 
afterwards. The interesting thing was that he was only 28 years old when it fi rst 
happened, but it was not considered necessary in 1968 to measure the cholesterol 
levels in a young man with a coronary in a London teaching hospital. 
Later in the 1970s at St Mary’s Hospital, London, among the patients referred 
for various reasons I saw an airline pilot in his forties whose cholesterol had been 
measured in a research project. It was over 300mg/dl and the team referring him 
wanted to take him off fl ying completely and planned to do some coronary 
angiograms. His other risk factors were normal, apart from his cholesterol, and 
he ran three miles every day, with no family history. There was this idea that 
cholesterol levels over 300mg/dl were terrible, and that nothing need be done 
when the levels were under 300mg/dl. 
Then there was diet. The Seven Countries Study complemented the US 
Framingham Heart Study and showed a good triangular relationship between 
diet, cholesterol levels and coronary disease.200 The treatment for elevated 
cholesterol in those days, apart from some perfectly disgusting drugs that have 
now been replaced, was to give people a diet sheet. When they came back 
nothing much had happened unless you got regression to the mean from the 
initially high readings. Failure to respond to diet sheets created a myth of a diet-
resistant type of hypercholesterolaemia. It was not the cholesterol resisting the 
diet, but the patient resisting the diet sheet. 
As has been pointed out, there was an enormous amount of negative propaganda 
going on, which, to me, is of as much historical interest as the discoveries that 
challenged it. We see progress as papers published in prestigious journals and 
199  Tunstall-Pedoe (1978). 
200  Keys (1970).
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‘miracles of modern medicine’, but the negative propaganda going on through 
the 1970s and 1980s in give-away medical magazines and brochures was quite 
incredible.201 Much of this was directly or indirectly sponsored by vested interests 
that sought out mischievous mavericks, who would be given equal or greater 
prominence than everybody else. Even respectable medical journals like the 
BMJ and the Lancet liked to publish comments and articles from mischievous 
mavericks. [Lots of laughter] Even as late as 1993, I can remember attending 
a meeting that I had organized with Douglas Chamberlain, then President of 
the British Cardiac Society, on risk factors for cardiologists. This was when 
secondary prevention wasn’t well established, and cardiologists were thoroughly 
suspicious of the term ‘prevention’ anyway. The meeting was told by an eminent 
cardiologist from a teaching hospital not too far from here (outside London), 
that the BMJ had proved that cardiologists could forget about cholesterol. That 
was 1993, just before the results from the Scandinavian 4S study came out.202 
Since then cardiologists have not been allowed to forget cholesterol, but 90 per 
cent of the evidence was there already. It was not just cardiologists, but academic 
medicine which had inertia and resistance as well. I rest my case there.
Oliver:  Can I make a comment there, substantiating what you were saying. I 
don’t think that it was really recognized by the majority of cardiologists that 
cholesterol needed to be measured until about 1980, maybe a bit before. This 
was not a routine in Britain and as you rightly say if you did it you were a 
suspect American.
Tunstall-Pedoe:  There was also the argument that after you had had your 
coronary heart attack, your cholesterol was irrelevant to your prognosis. That 
was an argument that went on until very recently, and it is wrong. The same 
applies to other major risk factors after MI. 
Booth:  I was taught my biochemistry in the University of Dundee, then the 
University of St Andrews, and the biochemist who taught me in the 1940s was 
R P Cook, the man who wrote the Cook book.203 I have no doubt whatever that 
201  See Butter Information Council pamphlet, ‘The Search’: A fi lm review of research and diet and coronary 
heart disease. Notes and summary script (undated). Among the specialists appearing in the fi lm, presented by 
Dr Tom Margerison, was Dr Elspeth Smith. A copy of this pamphlet, provided by Professor Hugh Tunstall-
Pedoe, will be deposited along with other records of the meeting in Archives and Manuscripts, Wellcome 
Library, London.
202  Scandinavian Simvastatin Survival Study (4S) (1994).
203  Cook (ed.) (1958).
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my memory is absolutely correct in saying that cholesterol was thrust down 
our throats, and furthermore he used to wave the corpses of rabbits that had 
been fed cholesterol at us and their blood vessels were stained a vivid red, I can 
remember it to this day. Obviously R P Cook should not be forgotten. Three 
cheers for R P Cook.
Oliver:  He’s not been forgotten. I actually mentioned him in the introduction.204 
He wrote his book in 1958, which was on the physiology and biochemistry of 
cholesterol and that as far as I know was the fi rst book in this country on the 
subject of cholesterol.
Marks:  I think one of the reasons why cardiologists thought cholesterol had 
nothing to do with them was because normally they would only have their 
patients’ cholesterol measured immediately or soon after the patient arrived 
at hospital following a MI, when, of course, it was low. Some of us tried to 
suggest that they might repeat the measurement when the patient had recovered 
completely; but this was seldom done. It is a fact, scarcely recognized at the 
time, that plasma cholesterol – or more properly, lipoprotein – levels go up and 
down, just like any other acute phase proteins in response to injury. That’s why 
cardiologists couldn’t see the association, because their patients never had high 
plasma cholesterol levels at the time it was measured. 
Oliver:  Of course in the cardiological literature even as late as the early 1980s, 
certainly in the 1960s and 1970s, there was very little about cholesterol and 
nothing about lipoproteins. The Journal of Lipid Research, or the Journal of 
Clinical Investigation, were the main fora, but that sort of journal was too erudite 
for most cardiologists to read.
Davey Smith:  Briefl y on this point, observational studies had established that 
high blood cholesterol levels caused CHD by the 1970s. The trials which we are 
going on to talk about, caused concern about the effects of lowering cholesterol 
on noncoronary mortality. All the meta-analyses of trials showed that cholesterol 
reduction was associated with reduced CHD, so the issue wasn’t so much whether 
cholesterol was a risk factor for CHD. The question was whether the methods 
available for lowering cholesterol, which includes some of the drugs that have 
been mentioned (that is, fi brates and resins), were producing benefi ts? And that 
was the issue, I think, not whether cholesterol was a strong causal factor for CHD. 
I think from most epidemiological perspectives, as Paul Durrington was saying, 
the very strong determinancy of cholesterol with respect to population differences 
204  See note 24.
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in CHD was clear and recognized. However, some population differences could 
not be attributed to cholesterol. There’s Paul McKeigue’s very important work on 
CHD among people with Indian heritage, who as a group had lower cholesterol 
levels than a group of European-origin people, and who had very high levels of 
CHD despite this.205 If you looked in the Whitehall Study, at the large social class 
differences in CHD, there was a four-fold difference in CHD risk between the 
lowest grade of civil servants (high) and the administrators (low). However, the 
administrators had higher cholesterol levels than the lower-grade civil servants.206 
Similarly in the studies that Victor Hawthorne started in Scotland in 1964, there 
were big social class differences in CHD, and there were social class differences 
in cholesterol.207 The problem was the social class gradient in cholesterol ran 
in the opposite direction to the social class differences in CHD.208 Cholesterol 
levels were higher in people who could afford more meat. The third population 
difference which, I think, is important here was the very sudden emergence 
of a big gender difference in CHD in Britain. In Jerry Morris’ book, Uses of 
Epidemiology, the fi rst edition of which appeared in 1957, it is clear that the 
CHD epidemic was largely seen in men, a fi nding confi rmed in later editions 
of the issue.209 Now the coronary epidemic was an epidemic in men and there’s 
no evidence of a sudden emergence of a cholesterol difference between men and 
women. So there were some population differences that couldn’t be explained by 
cholesterol. But I think the general agreement would now be that cholesterol was 
the most important risk factor concerning population differences, but it did not 
account for all population differences.
Oliver:  It would be incorrect if I didn’t mention Geoffrey Rose, whom we haven’t 
mentioned in the entire meeting yet.210 He was the leader in cardiovascular 
epidemiology in the UK in the late 1960s and the 1970s. Many will have read 
his book and his papers, and I just want to place on record that Geoffrey Rose 
was an architect of great importance in this fi eld.211
205  McKeigue et al. (1985).
206  Marmot et al. (1978).
207  Hawthorne et al. (1969); Furst et al. (1972); Hawthorne (1977); Hart et al. (1999).
208  Davey Smith et al. (1997).
209  Morris (1957); Lawlor et al. (2001).
210  See notes 103 and 162.
211  Rose (1981).
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Professor Thomas Sanders:  I want to comment on a few key papers, particularly 
George and Norman Miller’s paper in the Lancet, which really drew attention 
to low levels of high density lipoprotein cholesterol (HDL) as a risk factor and 
its relationship to insulin resistance or the Metabolic Syndrome, particularly in 
the Asian population.212 I think it started a different way in which we looked 
at blood cholesterol and paved the way to look at the fractions that carried 
cholesterol. 
Until that time it was believed that the higher the blood cholesterol, the greater 
the risk. It is worth recording that Barry Lewis’ research on LDL synthesis and 
metabolism clearly showed that the higher the level of LDL cholesterol, the 
greater the severity of disease (atherosclerosis), and that this was driven by the 
rate of very low density lipoprotein cholesterol (VLDL) synthesis and the rate 
of LDL catabolism. What emerged from the Millers’ paper was that low levels 
of HDL cholesterol were a more powerful, predictive factor than total or LDL 
cholesterol. The paradox of the lower risk of cardiovascular diseases in females 
in spite of their higher levels of blood cholesterol (at least post-menopause) 
could, in part, be explained by this. There was also discordance between men 
and women in the pattern of changes in risk of CHD in the postwar period: 
it is interesting to note that the rates of CHD fell in women from about 1956 
while they were rising in men.213 One of the potential explanations for this may 
have been a change in oestrogen-related diseases, which were actually rising 
at the same time, such as breast and ovarian cancers. It is well known that 
serum oestradiol levels increase with increasing body fat levels, particularly in 
post-menopausal women. We now know that oestradiol helps keep total blood 
cholesterol levels low by increasing LDL receptor numbers, but at the same 
time it increases HDL cholesterol, which is protective. I suspect many of the 
changes in blood cholesterol initially attributed to diet can be explained by 
hormonal effects.214
212  Miller and Miller (1975).
213  DHSS, Committee on Medical Aspects of Food Policy (COMA) (1984). Professor Philip Randle, Chairman. 
See also Randle et al. (1990). Professor Tom Sanders wrote: ‘The 1984 COMA report was the fi rst report that 
advocated changes in dietary fat composition and followed on from the Royal College of Physicians Report 
in 1976. Professor Tony Mitchell dissented from the main recommendation to decrease saturated and total 
fat. Although he is not named, it is stated: “The tenth member believes that this evidence is insuffi cient but 
that benefi t may accrue insofar as the recommended change in diet contributes to the avoidance of obesity.” 
Section 4.1.11.’ E-mail to Mrs Lois Reynolds, 7 March 2006. See also Truswell (1984).
214  Grundy (1991).
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Scott:  I have listened with interest to what George Davey Smith has said, and 
think that the Metabolic Syndrome of insulin resistance emerges as two to three 
times more prevalent and a dominant risk factor in the absence of smoking. I 
don’t know about prevalence in women, but smoking is an issue for them too. 
Diet is of poor quality in those with low income and those that are economically 
deprived, a common feature in the past in parts of north-west Britain and in 
many of the large cities. This contrasts with the much better diet of those 
who are better off, such as those in the civil service. If one looks at the British 
national food survey215 then the real difference between north-western cities 
such as Glasgow and Belfast is not in the amount of cholesterol and saturated 
fat consumed in these cities relative to London, but rather in the small quantity 
of fresh fruit and vegetables, and grain in the diet.
Oliver:  Well, it still applies doesn’t it?
Scott:  Yes.
Thompson:  I would like to comment briefl y on Hugh Tunstall-Pedoe’s broad 
spectrum criticism of virtually everybody in the place. I wasn’t quite sure 
which he thought was the bigger crime: lipidologists measuring cholesterol, or 
cardiologists not measuring it. But as far as the dismissive attitude of the latter 
towards the diet–cholesterol hypothesis goes, I entirely agree with you. One 
of my colleagues at the Hammersmith, not Sir John McMichael, used to say a 
cholesterol-lowering diet won’t make you live longer, it will just make life seem 
longer. 
Tunstall-Pedoe:  If I could just comment further on lipidologists. The problem 
was that lipidologists made things extremely complicated with systems of 
classifi cation. Any document on coronary prevention produced for other doctors 
was dominated by lipidologists from lipid clinics, was about 80 pages long and 
virtually unreadable, through all the subclassifi cations it had. No two of these 
ever agreed with each other, but you were expected to know and understand 
them or you weren’t safe treating cholesterol. You were expected to defer to 
215  The Dietary and Nutritional Survey of British Adults, 1986–87 was a one-off cross-sectional survey of 
2197 individuals aged 16–64 living in private households in Great Britain, undertaken by the Social Survey 
Division of the Offi ce of Population Censuses and Surveys (OPCS) and the Ministry of Agriculture, Fisheries 
and Food (MAFF). The National Diet and Nutrition Survey programme (NDNS) was established in 1992 
by MAFF and the Departments of Health to provide a comprehensive cross-sectional picture of the dietary 
habits and nutritional status of the population of Great Britain, to be repeated every eight to ten years. 
For an overview of health benefi ts of physical activity in 2001, see www.parliament.uk/post/pn162.pdf 
(visited 12 January 2006).
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the specialists, but there was no way that the tertiary specialist clinics in major 
teaching hospitals were going to be able to tackle the causes of coronary disease 
in the whole population.
I think it’s a problem. I am being really provocative now. If you are a high priest 
to a mystery, you don’t want to simplify things, because if there’s no need for 
complexity, you don’t need any high priests.
Booth:  I am very sorry that Gerry Shaper is not here to present his own 
position.216 I remember meeting Gerry in Kampala, Uganda, in the early 1960s 
when Denis Burkitt, his colleague, was doing his work on the lymphoma that 
bears his name. Gerry found a tribe in northern Kenya called the Samburu 
and they were an interesting tribe, because they chased a herd of cattle all day, 
and lived on milk, so they had an extremely high milk diet, and a cholesterol 
intake well above normal. The argument, I believe, was that they ran 40 miles 
a day, chasing their cattle. If anybody can corroborate that statement, I would 
be grateful.217 
Durrington:  I was only going to point out that there is a gene variant proprotein 
convertase subtilisin/kexin type 9 (PCSK9), which has only recently been 
described in people from the African continent and causes low cholesterol.218 
Some of those tribes that you referred to, I suspect, may have a gene that stops 
them having high cholesterol. For example, their women during pregnancy 
don’t have a rise in cholesterol either. This is a fascinating area. Years ago it was 
used as evidence that a high fat diet did not cause coronary disease. I think 
what this does illustrate, therefore, is one of the problems that we had in this 
fi eld, which George Davey Smith also has highlighted. Although the bulk of the 
evidence is blindly pointing us in one direction; people argue by fi nding small 
minutiae and odd things that don’t quite fi t with the main part of the evidence, 
and somehow their views have become prominent. I think that is a problem 
that we have had over the years. 
One other thing: this business about gender difference, which again was big 
during the period that we have been discussing, this belief that oestrogen protects 
us against coronary disease.219 I am pleased to see that we are now learning from 
216  See Professor Shaper’s brief comments in Appendix 1, pages 81–4.
217  Shaper (1962).
218  Cohen et al. (2005).
219  Oliver and Boyd (1953a); Boyd and Oliver (1956).
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the error in this. It is not oestrogen that protects against coronary disease, it’s 
androgens which predispose to it. That’s what all the clinical trial evidence tells 
us.220 If you look at the gender difference in coronary risk it is the amount of 
HDL in women compared with men that seems best to explain their different 
risk. Boys and girls have very similar lipids until puberty, and it’s at puberty in 
the boys that the HDL drops and then remains lower throughout life.221 It is not 
that the women have oestrogen to protect them, it’s that men have androgens 
that predisposes them to coronary disease.222 There was a dominant belief that 
somehow oestrogen and femininity were protective against coronary disease in 
the period that we are talking about. Now randomized controlled clinical trials 
have shown that this is not the case.
Oliver:  We are going to move on now to the fi nal session about drugs and diet 
developments and I am going to ask Tom Sanders to talk about diet.
Sanders:  In order to understand the main drivers for changes in food production 
it is worth considering the backdrop of postwar Britain when there were food 
shortages and rationing. A major aim was to attain self-suffi ciency in food 
from Britain and to develop modern technologies to produce substitutes for 
existing natural products that depended upon imports. That the National 
Institute of Research in Dairying at Shinfi eld in Reading employed over 200 
scientists underscores the commitment to improving the production of milk 
and milk products. Unilever Research and Development at Colworth House, 
Bedford, had major research programmes focusing on producing cocoabutter 
substitutes.223 Some of the technologies developed facilitated lipid research, in 
particular the invention of gas–liquid chromatography and its application to 
analysing lipids by Tony James at Unilever and Archer Martin at NIMR, who 
received a Nobel Prize for his earlier work on liquid–liquid chromatography.224 
220  Hulley et al. (1998); Writing Group for the Women’s Health Initiative Investigators. (2002); Grady et al. 
for the HERS Research Group (2002).
221  Christensen et al. (1980); Rifkind and Segal (1983).
222  Durrington (2003).
223  For early background of the National Institute for Research in Dairying, see Kay (1951); for Unilever 
work, see, for example, Padley and Timms (1978). Unilever holds a 1960 patent, GB827172, covering their 
early work on cocoabutter substitutes. 
224  Archer Martin and Anthony T James developed gas–liquid (partition) chromatography (GLC) in 1950. 
He and James used the new column to separate a variety of natural products, which he announced in his 
Nobel Prize lecture in 1952. See James and Martin (1954, 1956); Martin and James (1956).
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An odd ball, Hugh Sinclair wrote an extremely long letter entitled ‘Defi ciency 
of essential fatty acids and atherosclerosis et cetera’, published in the Lancet 
in 1956, where he expounded the view that atherosclerosis was related to a 
defi ciency of essential fatty acids and he proposed that the hydrogenation of fats 
produced trans-fatty acids that caused essential fatty acid defi ciency.225 Sinclair 
proposed that atherosclerosis was due to a defi ciency primarily of linoleic acid. 
It was a rambling letter that touched on many facets. Kinsell and Sinclair later 
expounded the view that the essential fatty acid content of dietary fat was the 
primary factor responsible for lowering blood cholesterol. In this paper he clearly 
refers to linoleic acid as being the ‘essential fatty acid’.226 Hugh Sinclair in later 
times referred back to that original Lancet letter with different interpretations, 
particularly to suggest that CHD was due to a defi ciency of n-3 fatty acids. He 
appeared to embellish his story as he went along. However, this idea that the 
type of fat, rather than the total amount of fat in the diet, matters stimulated a 
lot of controversy and research on the relationship between the type of fat and 
blood cholesterol. 
The work in the South African group, led by Bronte-Stewart, showed 
that fi sh oil, which did not contain linoleic acid but was rich in long-chain 
polyunsaturated fatty acids of the n-3 series, lowered blood cholesterol.227 In 
the 1960s and the 1970s, outside the UK, there was a lot of research going 
on by Ancel Keys, Francisco Grande and Mark Hegsted, who came up with 
predictive equations for the effects of saturated fatty acids, 12 to 16 carbon 
atoms long, on blood cholesterol, and the lowering effect of polyunsaturated 
fatty acids.228 Monounsaturates were seen to be neutral. In the UK the Keys 
view was rejected as being involved in type of fat, or level of fat. You need to 
appreciate the backdrop in the UK and the view that butter, cheese – dairy 
225  Sinclair (1956). See also Ewin (2001); Sanders (2001).
226  Kinsell and Sinclair (1957).
227  Bronte-Stewart et al. (1956).
228  Professor Tom Sanders wrote: ‘The Keys predictive equations are: Δ plasma cholesterol = (2.3ΔS-ΔP) 
+ SQRT(Δ dietary cholesterol/1000kcal) Δ plasma cholesterol where ΔS is the change in energy provided 
by saturated fatty acids and ΔP is the change in energy provided by polyunsaturated fatty acids. These 
equations have been modifi ed by Mensink and Katan [(1992)] who have estimated the effects of different 
fatty acids on LDL and HDL cholesterol. These showed that the equations of Keys tended to overestimate 
the effect of saturated fatty acids on LDL cholesterol.’ E-mail to Mrs Lois Reynolds, 7 March 2006. Keys 
et al. (1957); Hegsted (1959).
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products – were presented as being healthy food.229 The view that these foods 
may be linked to increased risk of heart disease was seen as an attack on British 
farming achievements as well as eating habits and were ridiculed by several 
eminent researchers, such as Professor Tony Mitchell at Nottingham and Sir 
John McMichael at the Hammersmith.230 Professor John Yudkin, the uncle of 
the John Yudkin here, had argued that there had been no change in fat intake 
in the postwar period when the epidemic of CHD had occurred.231 He said 
the main dietary change was an increase in sugar, not dietary fat. He pointed 
the fi nger at sugar, which he later referred to as ‘pure, white and deadly’.232 He 
argued that hyperinsulinaemia induced by high intakes of sugar was responsible 
for the epidemic of cardiovascular disease. His views on sugar were not accepted 
because they did not affect total cholesterol levels. 
In the early 1970s, Jim Mann’s group at Oxford, Stewart Truswell and David 
Jenkins in London reported on the cholesterol-lowering effects of dietary fi bre. 
They showed that some forms of dietary fi bre, particularly the soluble type, 
lowered blood cholesterol. At that time I worked with Frey Ellis at Kingston 
Hospital, London, and we were able to show that strict vegetarians (vegans) had 
astonishingly lower serum cholesterol concentrations, about two-thirds of the 
values seen in the general population.233 The argument turned on how much 
of this was due to a low dietary saturated fatty acid intake, lack of cholesterol, 
lower body weight and also ingestion of dietary fi bre and plant proteins, such as 
that provided by soy. Our own data suggest that most of the difference could be 
explained in terms of saturated fatty acid and cholesterol intakes. It is now quite 
well established that if you put people on these extreme sorts of diet, you can 
achieve very big reductions in serum cholesterol, equivalent to those achieved 
with drugs such as statins.234 The real problem is that it is diffi cult to get people 
to conform to such diets in the long term. 
229  See note 201.
230  McMichael (1979); Mitchell (1985). Professor Tom Sanders wrote: ‘Sir John McMichael aggressively 
attacked the lipid hypothesis. At the time it was widely alleged that he acted as a consultant for dairy 
interests.’ E-mail to Mrs Lois Reynolds, 7 March 2006.
231  Yudkin (1964). 
232  Yudkin (1972). 
233  Professor Tom Sanders wrote: ‘David Jenkins, Stewart Truswell and Jim Mann [Simpson et al. (1981); 
Mann et al. (2001);  Venn and Mann (2004)] showed that soluble fi bre lowered plasma cholesterol, but that 
cereal fi bre such as wheat fi bre did not have this property.’ E-mail to Mrs Lois Reynolds, 7 March 2006. 
Sanders et al. (1978).
234  Jenkins et al. (2005).
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The other driver in this has been the food industry, which developed modifi ed 
products to lower blood cholesterol. Unilever developed a margarine rich 
in linoleic acid that was called ‘Becel’, short for blood cholesterol-lowering 
margarine, but they weren’t allowed to call it that here in the UK and introduced 
it as Flora in the UK in 1965.235 There were all sorts of implied claims put on 
the label – low in cholesterol, free from cholesterol, high in polyunsaturates or 
pictures of an electrocardiogram on the package or a logo of one of the heart 
charities – and this engendered a lot of confusion between dietary cholesterol and 
blood cholesterol in the mind of the public and among health professionals.236 
Foods containing cholesterol, such as eggs and shellfi sh, were labelled as 
potentially bad and people started to get the idea that cholesterol was bad for 
you, and that there was a direct link between dietary cholesterol and blood 
cholesterol. There had been work in the US, but not so much here, showing 
that cholesterol in large amounts increased blood cholesterol. Jim Mann’s work 
in Oxford showed that it made very little difference whether you ate three eggs a 
week or six eggs a week.237 This added to the public’s confusion regarding diet and 
blood cholesterol. In retrospect, perhaps there was too much expected from the 
replacement of butter with margarine. Indeed, work by researchers at Unilever 
published in the 1990s showed that the substitution of 25g of polyunsaturated 
margarine for 25g of butter only lowered total cholesterol by 2.6 per cent and 
LDL cholesterol by 4 per cent.238 So although there was abundant evidence 
that modifying the intake of saturated fatty acids and cholesterol could lower 
blood cholesterol, in practice it was diffi cult to achieve reduction greater than 
5 per cent in blood cholesterol by replacing high fat dairy products with low 
fat varieties and using polyunsaturated margarine in place of butter.239 However, 
this is hardly surprising if the impact of the relatively minor dietary changes 
are compared with the various predictive equations.240 Peter Elwood’s work in 
235  Unilever Health Institute [Vlaardingen, The Netherlands] developed Becel at the request of Dutch 
physicians for a margarine rich in linoleic acid and low in saturated fatty acids. Launched in 1960 it 
was sold at pharmacies in a can. For further background details, see Upritchard et al. (2005). See also 
the history of Unilever’s involvement with margarine at www.unilever.com/ourvalues/sciandtech/
How_where/ufhri/our_history/ (visited 12 January 2006).
236  Sanders (1987, 1988).
237  Edington et al. (1989).
238  Hendriks et al. (1999).
239  Tang et al. (1998).
240  Sanders (1988).
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the Caerphilly heart disease study showed that very little (about 5 per cent) of 
the variation between individuals in blood cholesterol levels could be explained 
by variations in the intakes of saturated fatty acid or cholesterol.241 A fi nding 
later confi rmed in the Dietary and Nutritional Survey of Adults in 1988.242 
We now recognize that cholesterol, particularly LDL cholesterol, increases with 
age independently of changes in the fat composition of the diet, which may 
be due to a decline in thyroid activity as well as changes in oestradiol levels in 
women following the menopause. Insulin resistance, which is associated with 
central obesity, increases LDL levels and lowers HDL cholesterol. These and 
other factors seem to explain much more of the variance in blood cholesterol 
within the UK population than differences in saturated fatty acid and 
cholesterol intakes.
Returning to the point made by Paul Durrington, that between-country studies, 
such as the Seven Countries Study, show that two-thirds of the variation in 
median cholesterol level appear to be explained by the difference in saturated 
fats intake and cholesterol intake.243 In the southern Mediterranean diet 70 per 
cent of fat comes from olive oil, which is low in saturated fatty acids, and they 
eat little fatty meat and dairy produce. The changes that we are seeing in many 
developing countries, which tends towards a northern European diet high in 
animal fat, are accompanied by an increase in blood cholesterol.
Oliver:  Now if anybody wants to add their experiences with diet.
Tunstall-Pedoe:  I will mention the Masai. If Gerry Shaper was here he would 
say that one of the points about these people in these areas is that they are on 
the verge of malnutrition for a large part of the year while being very active 
physically. Therefore trying to extrapolate from them to a sedentary population 
is a mistake.244 But the Masai and the Inuit were produced as the jokers in the 
pack by the food industry and the resistance movement of ‘better-notters’ until 
very recently. When my daughter went to an interview for entrance to Oxford 
University some years ago she was asked about risk factors, because of me, and 
241  Fehily et al. (1994). See also Ness et al. (eds) (2002): 79–82, 86, 127–9; Reynolds and Tansey (eds) 
(2005): 81–4.
242  For background of the survey, which confi rmed the lack of a strong relationship with saturated fatty acid 
intake and cholesterol, see note 215.
243  Keys (1970); Keys et al. (1984).
244  See Appendix 1, pages 81–4.
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gave an orthodox account. The response was: ‘What about the Masai? (giggle, 
giggle, giggle)’. I think the answer is: ‘Well, what about the Masai?’ That’s the 
end of the argument. But the Masai and the Inuit were quoted right through to 
the end of the 1990s as the wild cards that showed that nothing could or should 
be done about coronary disease, and ‘we need more research’, right up until the 
statin trials came out. Now they appear marginalized and you do not hear about 
them any more, although they remain of theoretical interest. 
Oliver:  I think I should make an unprepared comment about Hugh Sinclair. I 
was at one of the Magdalen College meetings of the Atherosclerosis Discussion 
Group and Hugh asked me to stay in his house, Elspeth [Smith] was there too, 
and we had a rather late night, and the next morning we were given eggs and 
bacon. Hugh had some fi lthy stuff that he was drinking, which he said was 
tea. Well, it wasn’t tea, it was seal oil. Elspeth – never short of a remark or two 
– in the kitchen, which was piled with fi lthy dishes because Hugh lived alone, 
asked, ‘What is that? What is in the fridge, Hugh?’ And Hugh was forced, very 
reluctantly, to fi nd a key. Having spotted an ice pick hanging by the side of the 
fridge, Elspeth and Hugh opened it and inside was a frozen seal, at which he 
had been picking away. So he turned himself into a seal over a period of about 
three months. 
The story doesn’t quite fi nish there, because one day when I was doing something 
unimportant at home, the telephone went and it was Hugh saying, ‘I want to 
have a liver biopsy tomorrow for fatty acid analysis. A doctor in Oxford doesn’t 
think it is very wise. He said my bleeding time is 60 minutes. Is that high?’ I 
replied, ‘Well, you do what you like, Hugh, but it will be the last time you will 
be talking to me, or anybody else for that matter.’ He didn’t have it.
Hollman:  Just a very quick clip on diet which you may not have read in the 
New Scientist.245 Pekka Puska, born in Vaasa, northern Finland, in 1945, was 
director of the North Karelia Project in eastern Finland from 1972 to 1997.246 
He related a story of an elderly man from a small village near the Russian border 
who spoke to him after his talk: ‘Doctor, you have spent a long time telling us 
what kind of fat we should put on our bread, but you haven’t asked us what we 
do use.’ ‘Oh,’ said Puska, ‘What do you put on your bread?’ Answer: bear’s fat 
[very saturated fat]. 
245  Neroth (2005). 
246  Puska et al. (1981).
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Barker:  To remind you about the origin of margarine.247 Margarine was fi rst 
used by the French army for lubricating pistols. Then Napoleon III advertised a 
competition in order to get more fat into the peasants’ diet, but he didn’t want 
them to eat anything as expensive as butter. Somebody cleaning his pistol with 
margarine thought, ‘Why don’t we submit this for the competition?’ It won, 
and that is how we got margarine.248
Scott:  I have to say that the explorer Sir Ernest Henry Shackleton is one of my 
heroes. He had tremendous survival skills in bringing his shipwrecked crew to 
safety after two years of privation on the southern polar ice. It is a story full 
of irony. Some of the crew, after their rescue, were rapidly sent to the front in 
the First World War, where they died. Shackleton himself died in 1922 at the 
age of 48 of a massive coronary on his journey back to the southern ice, while 
making a stop at the island of St Georgia. This may not have been helped by 
his diet of penguin and seal meat in the absence of any fruit and vegetables, but 
the most notable thing about Shackleton is that he always had a cigarette in the 
photographs.
Pyörälä:  May I mention that the late Professor Geoffrey Rose, a famous lecturer 
in epidemiology, used to say that even small changes in lifestyles, when taken 
up in the population, may result in large benefi ts. My friend, Arthur Hollman, 
has told the story of North Karelia in Finland. We had the world record, not 
only in CHD mortality, but also in the population mean for cholesterol, almost 
7 mmol/l, in the beginning of the 1970s. Now our population mean-cholesterol 
levels are down to 5.5 and CHD mortality has gone down by more than 70 per 
cent in men and women. Calculations done some time ago have shown that 
about 50 per cent of that decline is due to the change in the distribution of 
cholesterol, which is explained by dietary changes.
Sanders:  May I briefl y comment on the Finnish North Karelia study. It is often 
cited as a demonstration that a population approach to modifying fat intake 
is effective in reducing the average blood cholesterol concentration. One very 
big confounding factor in Norway and Finland was the consumption of boiled 
coffee, which is found to have a very potent hypercholesterolaemic effect and 
changes in the type of coffee preparations may also be a factor in that study.249
247  For a cultural history of margarine, see van Stuyvenberg (1969).
248  Fernandez-Armesto (2001).
249  Aro et al. (1987); Pietinen et al. (1990).
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Pyörälä:  This has been taken into account in the published statistics. 
Betteridge:  I just wanted to say that we haven’t really mentioned functional 
foods, which raised hackles among dieticians. My own view is that we have 
something that actually works, is acceptable and lowers LDL cholesterol. The 
evidence is good for the stanol esters and plant sterols incorporated into spreads 
and other products.250 Of course they give extra benefi t in patients on statins. 
I think those are interesting developments. They raised a lot of issues because 
they are expensive, but I think they are useful.
Oliver:  We will move on to drugs. In 1956, George Boyd and I embarked on 
the fi rst clinical trial in the UK of the effects of lowering plasma cholesterol in 
patients with CHD.251 It was a fairly disastrous pilot study that would never 
have been permitted now. We recruited 100 male patients and gave 200µg 
ethinyl oestradiol (a large dose) to 50 and lactose to the other 50. All the treated 
men developed gynaecomastia. After fi ve years, total cholesterol had fallen in 
the oestrogen-treated group by 18 per cent and was unchanged in the control 
group. But there was no difference in coronary morbidity and mortality between 
the groups. We concluded in 1961 on this minimal evidence that reduction of 
serum lipids after MI did not improve prognosis.
The fi rst cholesterol-lowering drug to be tested in the UK was 
chlorophenoxyisobutyrate (CPIB), which was initially called Atromid® 
or Atromid-S® and later was named clofi brate. The story behind this is 
interesting.
In 1954, ICI had developed phenyl ethyl acetic acid as an insecticide. When 
sprayed from the air over fi elds near Clermont-Ferrand, France, many farm 
workers became ill and were admitted to hospital. Jean Cottet, the physician 
there, found that their blood cholesterol levels were extraordinarily low.252 A 
chemist working in ICI at Macclesfi eld, Jeff Thorp, recognized the potential of 
this substance and later synthesized the analogue, chlorophenoxyisobutyrate or 
CPIB.253 He approached George Boyd and me, and for three years we studied 
its effect on plasma cholesterol and lipoproteins in animals. In the early 1960s, 
250  Law (2000). 
251  Oliver and Boyd (1961).
252  Cottet et al. (1954).
253  Thorp and Waring (1962).
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we reported its lipid-lowering effect in man.254 As a result, several fi brates 
were developed and continue to be used particularly for treatment of mixed 
hyperlipidaemia. Chris Packard will take up the theme later. We weren’t able to 
measure triglycerides in those days. The fi brates are much more effective, as we 
now know, on triglyceride levels. That led us into the WHO clofi brate trial, in 
which a key person was, of course, Jerry Morris. When it turned out that we 
could actually lower cholesterol using clofi brate – I am talking about 1964 – I 
took myself off to the Central Middlesex Hospital, where Jerry was working 
to discuss what we might do about it. And he brought in Austin Heady as our 
statistician, and to cut the story short, in 1978 we published the results.255 The 
comparisons were between the two high cholesterol groups, each with 5000 
otherwise healthy men. 
The clofi brate trial was the fi rst primary prevention trial. It was conducted in 
Edinburgh, Prague and Budapest and recruited 15 700 men. There were 5 300 
in each of two hypercholesterolaemic groups – one received 2g clofi brate daily 
and the other identical capsules containing 400mg olive oil. There were two 
control groups, a high cholesterol and a low cholesterol group, [three groups 
in all]. There was a 9 per cent reduction in total cholesterol, a signifi cant 20 
per cent reduction in nonfatal MI but no decrease in fatal events. There was, 
however, a signifi cant increase in noncardiovascular mortality. This was not 
specifi c but caused much concern. There was also an increase in the incidence 
of gallstones.
These results were encouraging but worrying, leading to the question as to 
whether reduction of raised plasma cholesterol would lead to a trade-off, as it 
were, between less MI and an increase in noncardiovascular mortality. Indeed, 
these results from the biggest primary prevention trial at that time (the 1970s) 
acted as a brake against intervention for another 16 years when the results of the 
fi rst statin trial, the 4S study, were published.256
There were other drugs: MER 29 and triparanol. I hope that Chris Packard will 
say a word or two about them. I think it would be true to say that from about 
1978 to the results of the 4S trial in 1994, there was a limited enthusiasm for 
trying to lower cholesterol, and that was largely due to the anomalous and still 
unexplained result of the WHO clofi brate trial. 
254  Oliver (1962a and b).
255  Principal Investigators (1978).
256  Scandinavian Simvastatin Survival Study (4S) (1994); Strandberg et al. (2004).
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Professor Stuart Pocock:  Not a British trial, but you could just, remember 
cholestyramine in the Lipid Research Clinics (LRC) trial, which is an example of 
over-placed enthusiasm I think possibly, because they were showing reductions 
in protein lipids, but very borderline signifi cance for the actual reduction of 
coronary deaths.257 And that’s the trial I saw more of as a sales pitch than any 
other trial that I have seen. Cholestyramine was not a great idea, was it? 
Packard:  I think it is worth spending a moment on the intellectual landscape 
at the time. When the Lipid Research Clinics (LRC) trial came out, there 
was heavy promotion of cholesterol lowering.258 American cardiologists and 
lipidologists became aggressive interventionist communities, whereas the British 
were more reserved. This is, perhaps, a noble interpretation. Certainly we were 
being dubious of the full benefi ts of cholesterol lowering and wanted more data 
than the LRC trial provided. 
The other thing that was important at the time was the picture that we had of 
the progress of coronary disease, that is the growth from small lesions to big 
lesions that eventually blocked the artery. What mattered, we believed, was how 
to make the lesion smaller, and so produce clinical benefi t. To go back to what 
Professor Woolf was saying earlier, that paradigm shifts are the key. Between the 
time of publication of the LRC trial and the fi rst statin trials there was a major 
paradigm shift in the fi eld of atherosclerosis. We began to understand that it was 
the fragility, not the size, of a plaque that mattered.259 When we put together 
the protocol for the West of Scotland Coronary Prevention Study (WOSCOPS) 
trial we borrowed heavily from the Helsinki Heart Study trial, because it was 
very well done.260 We also knew we were going to have to persuade the great and 
the good in the UK, and so decided to have some sceptical people on our team, 
and there was no one better than yourself, Chairman [Michael Oliver], having 
had the experience of the clofi brate trial. We were testing the benefi ts of primary 
prevention, because we knew that the 4S trial, a secondary prevention trial, was 
underway, the CARE and LIPID studies were being done at the same time by 
Squibb [Bristol-Myers Squibb], the company that marketed the statin, Pravachol® 
257  Brensike et al. (1984).
258  The Lipid Research Clinics (LRC) Coronary Primary Prevention Trial was a National Heart, Lung and 
Blood Institute (NHLBI) primary prevention trial using the drug cholestyramine. See LRC (1984). For 
further details of the trial, see www.clinicaltrials.gov/ct/show/NCT00000488 (visited 24 January 2006). 
See also Table 2, page 76.
259  Davies (1996). 
260  Frick et al. (1987); WOSCOPS Study Group (1995); Shepherd et al. (1995). See also Table 2, page 76.
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(pravastatin sodium),261 and we felt that primary prevention was the single biggest 
question that would need to be answered between 1995 and 2000. The onus 
was on us, not only to prove benefi t, but also that cholesterol lowering carried a 
low level of risk. The need to do this was emphasized by bad press, just after we 
started.262 The intellectual climate now became one in which people were looking 
for the benefi t-to-risk ratio, recognizing that the drugs had risks associated with 
their use. That mood continues to the present day. We are still trying to fi nd what 
benefi t-to-risk ratio is acceptable if we intervene to produce very low cholesterol 
levels. In 1995 we all sat in the University of Glasgow halls and heard the results, 
and we were surprised at how good they were. The trial showed that statin use 
gave a third risk reduction in CHD and, against all predictions, a reduction in 
total mortality, although the P values were the most cruel that one could observe 
at P = 0.051: a P value of 0.049 is signifi cant, while 0.051 is not. If we adjusted 
for risk factors, total mortality was reduced, with a P value of 0.039. So there was 
a 20 per cent reduction in mortality.263 [See Table 2.]
These results helped change the landscape for coronary prevention and made 
it on to the front pages of most newspapers in the Western world. What was 
important for medicine was that the mood had changed. The 4S trial was the big 
watershed for cardiologists and WOSCOPS was a strong addition to that. One 
of the most remarkable things that came out of the trial when we examined the 
data carefully was that there was no lag period before benefi t began. In the LRC 
and Helsinki nonstatin studies, there was a period of about two years before 
benefi t began, and that was in line with the idea that regression of the lesion 
in size was critical.264 Ours was the fi rst trial to show clearly the benefi ts started 
within months of starting therapy, and those who saw the data unblinded early 
on found that it started from almost day 0. It is what I call a true ‘intention 
to treat’ analysis, as soon as you ‘intended to treat’ the person got the benefi t. 
The reduction in risk continued as a straight line for the next fi ve years. What 
is going on? Either the reduction in LDL is so powerful that you get benefi t 
straightaway with stabilization of plaque, or the pleotropic effects of the statin 
start acting immediately; that is, the drug causes plaque stabilization directly 
within months of starting therapy. So WOSCOPS was a landmark trial like 4S. 
261  Sacks et al. (1992); Prospective Pravastatin Pooling (PPP) project (1995); LIPID (Long-Term Intervention 
with Pravastatin in Ischemic Disease) Study (1995).
262  Davey Smith and Pekkanen (1992a).
263  WOSCOPS Study Group (1997).
264  Lipid Research Clinics (LRC) Coronary Primary Prevention Trial (1984); Frick et al. (1987).
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Trial Drug, diet or 
intervention
Patients Reference
Oslo diet–heart 
study (1970) 
changes in diet: low 
saturated fats; low 
cholesterol; high 
polyunsaturated fats
412 M; 30–64 yrs; post MI; 
11 yr follow-up; Norway 
Circulation (1970) 42: 
935–42.
WHO clofi brate 
study (1978)
clofi brate 10 627 M; 
hypercholesterolaemia; 
30–59 yrs; free of CHD; 
5.4 yr follow-up; UK
British Heart Journal 
(1978) 40: 1069–118; 
Lancet (1984) ii: 600–04.
Lipid Research 
Clinics (LRC) study
(1984)
cholestyramine resin; fat-
restricted diet
3806 M; 35–59 yrs; Type 
II hyperlipoproteinaemia; 
free from CHD; USA
Journal of the American 
Medical Association (1984) 
251: 351–64; 365–74.
Helsinki heart 
study
(1987) 
gemfi brozil 600mg twice 
daily
4081 M; 40–55 yrs; 
dyslipidaemia; primary-
prevention trial; Finland
New England Journal of 
Medicine (1987) 317: 
1237–45.
DART
(1989) 
changes in dietary fat, fi sh, 
and fi bre intakes
2033 M; <70 yrs; post MI; 
2 yr follow-up, UK 
Lancet (1989) ii: 757–61.
POSCH 
(1990) 
partial ileal bypass 838 M + F patients; post 
MI hypercholesterolaemia; 
7 yr follow-up; USA
New England Journal of 
Medicine (1990) 323: 
946–55.
4S
(1994)
simvastatin 20–40mg 4444 patients, 81% M; 
mean age 60; angina or 
previous MI; cholesterol 
5.5–8.0mmol/L; 5.4 yr 
follow-up; Scandanavia
Lancet (1994) 344: 
1383–9.
WOSCOPS
(1995)
pravastatin 20–40mg 6 595 M; 45–64 yrs; 
elevated LDL; UK
New England Journal of 
Medicine (1995) 333: 
1301–7. 
CARE
(1996)
pravastatin 40mg 3583 M and 576 F; 21–75 
yrs; previous MI; elevated 
LDL; USA
New England Journal of 
Medicine (1996) 335: 
1001–9.
LIPID
(1998)
pravastatin 40mg 9 014 M + F; 31–75 yrs; 
previous AMI or unstable 
angina; Australia
New England Journal of 
Medicine (1998) 339: 
1349–57.
Table 2: Double-blind randomized controlled trials before 2000.
265
 
265  Leren (1970); Principal Investigators (1978); Lipid Research Clinics (LRC) Coronary Primary Prevention 
Trial (1984); Frick et al. (1987); Burr et al. (1989); Buchwald et al. (1990); Scandinavian Simvastatin 
Survival Study (4S) (1994); Shepherd et al. (1995); Sacks et al. (1996); Long-Term Intervention with 
Pravastatin in Ischemic Disease (LIPID) Study Group (1998).
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It changed medical practice, and, I think, it changed our thinking about what 
was possible with cholesterol lowering.
Oliver:  On a point of history: when was the WOSCOPS trial conceived?
Packard:  It was conceived in about fi ve minutes in 1988. I was away when my 
colleague Jim Shepherd went to a meeting at the Glasgow Western Infi rmary 
and the story goes as follows. A senior director from the sponsoring company, 
Squibb, was visiting Scotland, his home country. He got together with the local 
cardiologists and asked for suggestions for prevention studies. The cardiologists 
said they wanted to do a secondary intervention trial, which Squibb was planning 
elsewhere. As this director was putting on his coat to leave, Jim said, ‘Wait a 
minute, we want to do a primary prevention trial.’ Jim had worked on the LRC 
trial, a primary prevention trial in Houston, Texas, and I had been there with 
him. We were invited to submit a protocol and within a few days we sent it by 
courier. The rest is history. I think Squibb deserves a lot of praise because it went 
looking worldwide for ideas and groups to do this sort of thing. This was long 
before the publication of the 4S trial. 
Oliver:  Stuart, you were the statistician and a very important part you had 
throughout the trial.
Pocock:  It’s not for me to say, but it was a fascinating trip to Glasgow every six 
months, with Michael chairing our data monitoring committee and I think the 
main issue, which Chris mentioned briefl y, was that in the background there 
was some terrible newspaper coverage about low cholesterol causing cancer 
going on at the time, which at one point we thought would seriously damage 
the trial. I think the other thing about a data monitoring committee is that it 
is more important who you have on it than what your boundaries are for when 
you stop. I think Michael nurtured us through some exciting times, because 
we were seeing these dramatic benefi ts and I think that before the end, we 
had crossed any effi cacy stopping boundary for benefi t. But given the concerns 
about noncardiovascular deaths, we decided to go beyond such a boundary and 
I think that meant that as a result we got much more exciting solid evidence that 
had been pulled out earlier. The other thing is the benefi t of having such trials 
independently run and it was Squibb who made that possible and, indeed, we 
should defi nitely encourage more companies in more fi elds nowadays to allow 
trials to be completely independent of their own company. 
Durrington:  I think those early statin trials were very courageous: 4S undoubtedly 
was, because at the time it was designed, many authoritative articles were saying 
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that secondary prevention would be hopeless with cholesterol-lowering drugs.266 
It wasn’t just the statin drugs themselves that were important in proving this 
wrong. I think it was also the fact that clinical trial design had reached a pinnacle 
of perfection. It had been informed by the mistakes of earlier trials, like the 
WHO clofi brate trial and people knew a lot of the pitfalls. The blood pressure 
trials had helped as well, so the statin trials coincided with greater knowledge of 
how to conduct a clinical trial, how to do the power calculations and all the rest 
of it, which I think was critical. Another important aspect was the intention-to-
treat analysis, briefl y mentioned by Chris [Packard].267 One of the problems you 
[Michael Oliver] had with the WHO trial was that we never really got to grips 
with the actual results, because the intention-to-treat analysis was published only 
in a letter to the Lancet about ten years after the trial was fi nished.268 Although 
we were led to believe that there was this increase in noncardiovascular mortality 
in the main report, I am not sure whether there really was. Despite subsequent 
fi brate trials, such as Veterans Affairs High Density Lipoprotein Cholesterol 
Intervention Trial (VAHIT), for historical reasons we unfortunately still need 
another convincing fi brate trial.269 I think we may get it with the Fenofi brate 
Intervention and Event Lowering in Diabetes (FIELD) study: we need more 
evidence before we can know whether that fascinating group of drugs actually 
does any good, overall.270 
Oliver:  Well, Jerry Morris and I sweated blood about that letter, but we had to 
publish it, and nobody was going to accept another article, because the main 
results had already been published.
Morris:  I think it was a nightmare. I would say that we knew little, at least I 
knew little, about such structure of a clinical trial in the middle 1960s. 
Galton:  Just a comment about the early origin of statins.271 Another great missed 
British opportunity arose, because Beechams had the franchise for the early 
266  Scandinavian Simvastatin Survival Study (4S) (1994).
267  Califf (2002).
268  Heady et al. (1992). 
269  Rubins et al. for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study 
Group (1999).
270  Keech et al. for FIELD study investigators (2005).
271  Endo et al. (1977).
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fungal metabolite, which they called compactin.272 John Reckless with a great 
deal of enterprise – I am only sorry he is not here today – managed to get some 
from Beechams and actually showed that it inhibited HMG-CoA reductase in 
leucocytes from normal and FH patients. Perhaps John [Betteridge] might like 
to talk about this, since he did some of the experiments.273 But compactin gave a 
lot of complications in vivo, so Beechams sold it to Merck, Sharpe and Dohme, 
who developed lovastatin and the others from it.274 
Davey Smith:  I wanted to ask people who were around at the time about the 
clofi brate issue, as it has been mentioned frequently. If this meeting was in the 
US and people were talking about the slow introduction of cholesterol drugs, 
they would discuss triparanol (otherwise known as MER 29) that was introduced 
as an effective cholesterol-lowering agent and marketed very strongly in the US 
in the early 1960s.275 However, it caused serious eye problems and there was 
some suggestion of increased death. Surely the triparanol story was something 
that inhibited the introduction of these drugs without trial evidence? It wasn’t 
marketed in Britain, perhaps because triparanol was MER 29 and MER 30 was 
thalidomide.276
Packard:  It was a huge issue when we were designing the WOSCOPS study. 
Everybody who was randomized and everybody who went to the end of year 1 
had to undergo corneal screening. We used every ophthalmologist in the west of 
Scotland. After the fi rst year we went back to the Food and Drug Administration 
(US FDA) and said, ‘There’s no issue here’ and fortunately they accepted that. 
They released us from what would have been annual corneal screens. 
Sanders:  I want to make a comment really about lifestyle modifi cation trials, 
which basically starred diet, smoking, blood pressure, and they really have been 
a total failure on an individual basis, compared with the drug trials. But if we 
look at changes that have occurred in the food chain which haven’t involved 
individual choice, what has happened is that saturated fat intake has fallen by 
about 20 per cent down to about 12 per cent. The average blood cholesterol level 
in the population has fallen, even if you allow for changes in methodology, and 
272  Brown et al. (1976). 
273  Betteridge et al. (1978).
274  The development of lovastatin is described in Appendix 2, pages 85–6.
275  Fine (1972).
276  For the background to the thalidomide tragedy, see Tansey and Reynolds (eds) (1997): 106–30. 
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CHD incidence has fallen. So I think although the drug trials demonstrate very 
clear effects, we can also see effects where changes in the food chain and changes 
in things like smoking prevalence have occurred.277 They occur not because of 
the individual choice, they occur because of polity changes in society.
Thompson:  I was just going to respond to the triparanol story by saying that 
the fi rst homozygote that we ever plasma-exchanged had bilateral cataracts 
removed because she had been treated with triparanol.278 And certainly in the 
days when we were using statin on a named-patient basis, we had to get the 
ophthalmologists to look at their lenses every month.
Oliver:  Well I think we probably have covered quite a lot of the history. Anyone 
burning to say anything? I am sorry that one or two of the key people haven’t 
been able to come, but many of you have provided additional information. I am 
very grateful to you and I hope that you have enjoyed it as much as I have.
Booth:  On behalf of Tilli Tansey, I would like to thank you for coming to this 
exciting meeting. I have been an observer at these meetings for many years, and 
one can always tell how successful they are by the number of people who leave 
after tea. I don’t think anybody did today and the discussion has been lively, 
encouraging and extremely interesting. I think we should thank Dr Daphne 
Christie for all the hard work she has done with Michael Oliver in organizing 
this meeting. 
We have been discussing a British disease, fi rst described, if you didn’t know 
this, in 1776, when the surgeon John Hunter, whose patient had died suddenly 
with angina pectoris, reported of the heart that the coronary arteries from their 
origins upon their aorta and to their ratifi cations upon the heart surface were 
converted to one piece of bone.279 To my knowledge, that is the fi rst description 
of CHD. 
I think fi nally we should thank Michael Oliver, who has been a wonderful 
Chairman; he has done a great deal of work. 
277  Principal Investigators (1978); Multiple Risk Factor Intervention Trial Research Group (1982). The 
intervention trials have been systematically reviewed by Hooper et al. (2001a and b). Responses, Mann 
et al. (2001) Hu et al. (2001), with reply by Hooper et al. (2001c).
278  See Glossary, page 146.
279  Elliot (1782). See also Morgagni (1762): xxiii, xxvi, xxvii. 
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Appendix 1 
The ‘diet–heart’ hypothesis by Gerry Shaper 
I was and am still concerned that the ‘diet–heart’ hypothesis, which is deeply 
entrenched and widely accepted in the statements of the American Heart 
Association and other North American bodies, has not been endorsed or denied 
by British authorities but allowed to fl oat in the background without any fi rm 
statement being made by major offi cial bodies, government or other.
The ‘diet–heart’ hypothesis states that a particular type of diet (specifi cally 
one high in saturated fatty acids) leads to high levels of blood cholesterol 
in individuals and populations and that this phenomenon is the necessary 
(essential) factor for increasing susceptibility to atherosclerosis and CHD in 
populations, although it may not be suffi cient by itself to produce CHD. All 
other factors, such as tobacco smoking, physical inactivity and diabetes mellitus, 
are aggravating factors. However, if there is not a high blood cholesterol level, 
these factors, however injurious to other systems and conditions, have a small 
impact on the risk of CHD in a population. In this model, CHD is affected 
by a wide variety of genetic and environmental factors (i.e. it is multifactorial) 
but the dietary factors leading to a high blood cholesterol level are fundamental 
and necessary for a high level of CHD in a population. There are, of course, 
conditions in which a high blood cholesterol in individuals is not dietary in 
origin – for example in familial hypercholesterolaemia and chronic renal failure 
– but this does not negate the concept as applied to populations. 
In the UK, the concept of CHD as a multifactorial disease is widely accepted 
and forms the basis of most scientifi c research and public health action towards 
the prevention of CHD. However, the term multifactorial is interpreted and 
used as meaning that atherosclerosis and CHD can arise from many different 
causes, usually in combination, rather than that there is any one fundamental 
(essential) cause for the condition in a population.
It is the history of this hypothesis, its promulgation and its dissemination, and 
the opposition, scientifi c and political, to the hypothesis that require to be 
discussed and documented.
Personal comment
My fi rst period in the UK was in 1953–56 inclusive, fi rst in Liverpool and 
then at the Hammersmith in London as Registrar to Sir John McMichael and 
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Professor John Shillingford. The research emphasis was on clinical cardiology 
and catheters, and there was little interest in the nature of atherosclerosis, in 
the lipid hypothesis or in possible nutritional aspects of cardiovascular disease. 
Coming from a medical school (Cape Town), where interethnic studies in blood 
lipids and cardiovascular disease (Bronte-Stewart), nutrition and chronic disease 
(Brock, see Figure 1) and coagulation and fi brinolysis (Merskey) were in full 
swing, with stimulating visits from Ancel Keys and other American workers, 
the lack of interest in this area in the UK was marked and disappointing. 
The atmosphere in the UK at that time was hostile to the American views on 
nutrition as a fundamental factor in atherosclerosis. 
There followed a long period in Uganda with work in different ethnic groups 
(African, Asian, European) on lipid patterns, body build, coagulation and 
fi brinolysis and studies in nomadic groups of blood lipids and blood pressure.280 
At this time, in the early 1960s, work was also emerging from South Africa, 
Ceylon, Polynesia and New Guinea as well as East Africa about lipids, coagulation, 
platelet behaviour and fi brinolysis, with important UK contributions from 
Fearnley and Chakrabarti (fi brinolysis) and from Helen Payling Wright (platelet 
adhesiveness).281
It became apparent from the international studies that body weight, blood 
pressure and blood lipids did not necessarily increase with increasing age, and that 
levels regarded as ‘normal’ in Western societies were not ‘biologically normal’, 
that is, conducive to a healthy vasculature and an absence of atherosclerotic 
disease. In addition, in populations with low blood lipids, fi brinolytic activity 
was very marked compared with groups with higher blood lipids and with a 
high risk of cardiovascular disease.
I returned to the UK in 1970 to join Jerry Morris’ MRC Social Medicine Unit, 
where there was a major focus on CHD with interests ranging from all aspects 
of physical activity, to the effects of water hardness, of diet, regional variations 
in cardiovascular disease (CVD) and drug treatments for lowering blood 
cholesterol levels. With Jean Marr, we studied the effects of dietary change 
on blood cholesterol levels in civil servants and showed that, without recourse 
to strict diets or to the family, these men were able to make signifi cant and 
sustained reductions to their cholesterol levels over a four-year period. 
280  Shaper et al. (1963, 1966).
281  Chakrabarti and Fearnley (1962); Wright (1941). See note 90.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – Appendix 1
83
The RCP/BCS Report
A key happening at this time was the setting up of a Joint Working Party of 
the Royal College of Physicians of London and the British Cardiac Society on 
prevention of coronary heart disease, brought about by Keith Ball and Dick 
Turner and including in its membership Michael Oliver, Geoffrey Rose, John 
Goodwin, Walter Somerville and others, and with contributions to the report 
from Harry Keen and Hugh Tunstall-Pedoe.282 The report was published in 1976 
and was distributed by the Chief Medical Offi cer [Sir Henry Yellowlees] to all 
doctors in the UK. There is little in the report that would not be acceptable 
today, with a focus on diet and with dietary recommendations for the whole 
community. 
At this time, there were prominent individuals in British cardiology who 
vigorously opposed the dissemination of this report, and throughout the late 
1970s, 1980s and into the 1990s, there was continued concern that lowering 
blood cholesterol by any means, including dietary change, might have a 
deleterious effect on human biological systems. The implication has been that 
Figure 6: A model of community susceptibility and the incidence of CHD, 1972.
From Shaper (1972): 297. 
282  Royal College of Physicians of London and the British Cardiac Society (1976).
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lower blood cholesterol levels, however achieved, might be dangerous. It is of 
considerable interest to note that these concerns have not subsided, and with 
the widespread use of drugs for lowering blood lipids, there is renewed concern 
in this direction.
Observational population studies
In 1975, the MRC awarded a programme grant for studying the regional 
variations in cardiovascular disease with a particular interest in the effects of 
water quality (softness and hardness) and this study developed into the British 
Regional Heart Study (BRHS) involving some 8 000 middle-aged men in 24 
British towns.283 It rapidly emerged that blood lipid levels were uniformly high 
in every town studied, so that risk related to blood lipids was equally high 
everywhere in Britain. Variations in prevalence and incidence were related to 
the other risk factors, which varied considerably from town to town. The BRHS 
has continued to the present day and has made contributions to many aspects 
of cardiovascular disease, including observations on diabetes, the Metabolic 
Syndrome, overweight and obesity and physical activity, and with studies 
extending to children and women throughout the UK. 
283  For details and full bibliography of the British Regional Heart Study, recruited in 1978–80, see www.ucl.
ac.uk/primcare-popsci/brhs (visited 12 January 2006).
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Appendix 2
The discovery and development of lovastatin
by Jonathan Tobert284
Inhibitors of HMG-CoA reductase (statins) are widely prescribed, and one, 
simvastatin, can now be obtained without a prescription in the UK. However, 
the development of the fi rst member of the class, lovastatin, was far from 
straightforward.
HMG-CoA reductase is the rate-limiting enzyme in the cholesterol biosynthetic 
pathway. Natural products with a powerful inhibitory effect on HMG-CoA 
reductase, including ML236B (compactin), were fi rst discovered by the Japanese 
microbiologist Akira Endo.285 The compound was highly effective in reducing 
LDL cholesterol in patients with heterozygous familial hypercholesterolaemia 
(FH).286 In 1978, Alberts, Chen and others at Merck Research Laboratories 
found a potent inhibitor of HMG-CoA reductase in a fermentation broth of 
Aspergillus terreus, which they named mevinolin; later, the offi cial name (US 
Adopted Name or USAN) was established as lovastatin.287 
Merck began clinical trials of lovastatin in healthy volunteers in April 1980. 
Lovastatin was shown to be remarkably effective for lowering LDL cholesterol in 
healthy volunteers, with no obvious adverse effects.288 However, this encouraging 
start was soon interrupted. For reasons that have never been made public (but 
which were believed to include serious animal toxicity), clinical trials with 
compactin were stopped by its developer Sankyo in September 1980. Because 
of the close structural similarity between compactin and lovastatin, Merck 
promptly suspended clinical studies with lovastatin, and initiated additional 
284  Prepared by Dr Jonathan Tobert at the request of Professor Oliver for the Witness Seminar held on 8 
March 2005, based on Tobert (2003).
285  Endo et al. (1976b, 1977).
286  Mabuchi et al. (1981).
287  Alberts et al. (1980). The USAN of a drug can be found in the US Pharmacopeia (USP) Dictionary of 
US Adopted Names and International Drug Names, which contains US adopted names, offi cial drug names 
for the USP and the National Formulary, previously used offi cial names, international and nonproprietary 
names, British approved names, Japanese approved names, miscellaneous older names, and trade names. See 
www.cas.org/ONLINE/DBSS/usanss.html (visited 25 January 2006).
288  Tobert et al. (1982a and b). 
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animal safety studies. The viability of the drug was in serious doubt. However, 
in 1982 studies resumed outside Merck in a small number of patients with 
severe FH refractory to existing therapy; they showed dramatic reductions in 
LDL cholesterol with very few adverse effects.289
In 1983, after the additional animal safety studies with lovastatin revealed no 
toxicity of the type believed to be associated with compactin, Merck decided 
to re-initiate the clinical development programme, initially in patients at very 
high risk of MI. Because of concerns about patient safety, this was a diffi cult 
decision. Notwithstanding the excellent tolerability to date in small, short-term 
clinical studies, it was quite possible that more clinical experience, as well as 
long-term animal toxicology studies, would uncover serious safety issues. 
In randomized, double-blind phase IIb placebo-controlled studies, lovastatin 
was as effective in patients with heterozygous FH and patients with CHD and 
nonfamilial hypercholesterolaemia as it had been in healthy volunteers.290 In 
larger phase III studies, lovastatin produced much greater reductions in LDL 
cholesterol than the control agents cholestyramine and probucol, with very 
few adverse effects.291 There was a profound reduction of apolipoprotein B-
containing lipoproteins, especially LDL cholesterol (average reduction of 40 
per cent at the maximal dose of 80mg daily) and, to a lesser extent, plasma 
triglycerides, together with a small increase in HDL cholesterol. Observed 
tolerability continued to be excellent, with very few patients withdrawing 
from treatment due to adverse effects. In November 1986, Merck applied for 
regulatory approval of lovastatin, which was obtained on 31 August 1987 from 
the US FDA; Merck had patent rights only in certain other countries, all of 
which later granted approval. More details on the complex history of lovastatin 
(and other statins), including the evaluation of potential and actual adverse 
effects, may be found in a recent review.292
289  Bilheimer et al. (1983); Illingworth and Sexton (1984).
290  Havel et al. (1987); Lovastatin Study Group II (1986); Tobert et al. (1982b).
291  Lovastatin Study Group III (1988); Lovastatin Study Group IV (1990).
292  Tobert (2003).
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
87
References 
Adams C W, Bayliss O B, Ibrahim M Z. (1963) The distribution of lipids 
and enzymes in the aortic wall in dietary rabbit atheroma and human 
atherosclerosis. Journal of Pathology and Bacteriology 86: 421–30.
Alberts A W, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, 
Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley 
E, Albers-Schonberg G, Hensens O, Hirshfi eld J, Hoogsteen K, Liesch 
J, Springer J. (1980) Mevinolin: a highly potent competitive inhibitor 
of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-
lowering agent. Proceedings of the National Academy of Sciences of the USA 
77: 3957–61. 
Albrink M J. (1964) Clinical evaluation of drugs for the treatment of diabetes. 
Diabetes 13: 429–30.
Albrink M J, Man E B. (1958) Serum triglycerides in health and diabetes. 
Diabetes 7: 194–201.
Albrink M J, Lavietes P H, Man E B. (1963) Vascular disease and serum lipids in 
diabetes mellitus. Observations over 30 years (1931–61). Annals of Internal 
Medicine 58: 305–23. 
Anderson J T, Aresu M, Biorck G, Brock J F, Bronte-Stewart B, Del Vecchio 
A, Fidanza F, Keys A, Keys M H, Malmros H, Poppi A, Posteli T, Swahn 
B. (1956) Physical activity and the diet in populations differing in serum 
cholesterol. Journal of Clinical Investigation 35: 1173–81. 
Anitschkov N, Chalatow S. (1913) [On experimental cholesterin steatosis 
and its signifi cance in the origin of some pathological processes.] German. 
Zentralblatt fur Allgemeine Pathologie und Pathologische Anatomie 24: 1–9. 
Reproduced as Anon. (1983).
Anonymous. (1968) Hubert Maitland Turnbull. Munk’s Roll 5: 425–6. 
Anonymous. (1975a) Letter: does polyunsaturated fat beef work? Medical 
Journal of Australia 2: 68–9.
Anonymous. (1975b) Editorial: polyunsaturated beef-eaters. Lancet ii: 960–1.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
88
Anonymous. (1983) Classics in arteriosclerosis research: On experimental 
cholesterin steatosis and its signifi cance in the origin of some pathological 
processes by N Anitschkov and S Chalatow, translated by Mary Z Pelias, 
1913. Arteriosclerosis 3: 178–82.
Anonymous. (1996) Frontiers of atherosclerosis and lipoprotein research. 
Special issue in memory of Professor Shlomo Eisenberg. Israel Journal of 
Medical Sciences 32: i, 345–508.
Aro A, Tuomilehto J, Kostiainen E, Uusitalo U, Pietinen P. (1987) Boiled 
coffee increases serum low density lipoprotein concentration. Metabolism 
36: 1027–30. 
Astrup T. (1956) Fibrinolysis in the organism. Blood 11: 781–806. 
Austin M A, King M C, Vranizan K M, Krauss R M. (1990) Atherogenic 
lipoprotein phenotype. A proposed genetic marker for coronary heart disease 
risk. Circulation 82: 495–506.
Austin M A, Breslow J L, Hennekens C H, Buring J E, Willett W C, Krauss R 
M. (1988) Low-density lipoprotein subclass patterns and risk of myocardial 
infarction. Journal of the American Medical Association 260: 1917–21.
Barker D J P. (1972) Practical Epidemiology. Edinburgh: 
Churchill Livingstone.
Barker D J P, Osmond C. (1986) Infant mortality, childhood nutrition, and 
ischaemic heart disease in England and Wales. Lancet i: 1077–81. 
Barker D J P, Rose G. (1976, 1979, 1984, 1990) Epidemiology in Medical 
Practice. Edinburgh; New York, NY: Churchill Livingstone.
Barker D J P, Eriksson J G, Forsen T, Osmond C. (2002) Fetal origins of adult 
disease: strength of effects and biological basis. International Journal of 
Epidemiology 31: 1235–9. 
Barker D J P, Winter P D, Osmond C, Margetts B, Simmonds S J. (1989) 
Weight in infancy and death from ischaemic heart disease. Lancet 
ii: 577–80. 
Barr D P, Russ E M. (1951) Protein-lipid relationships in diabetes mellitus. 
Transactions of the Association of American Physicians 64: 297–303.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
89
Barr D P, Russ E M, Eder H A. (1951) Protein-lipid relationships in human 
plasma. II. In atherosclerosis and related conditions. American Journal of 
Medicine 11: 480–93. 
Berridge V, Christie D A, Tansey E M (eds) (2006) Public health in the 1980s 
and 1990s: Decline and rise? Wellcome Witnesses to Twentieth Century 
Medicine, volume 26, London: The Wellcome Trust Centre for the History 
of Medicine at UCL. Freely available online at www.ucl.ac.uk/histmed 
following the links to Publications/Wellcome Witnesses.
Betteridge D J, Krone W, Reckless J P, Galton D J. (1978) Compactin inhibits 
cholesterol synthesis in lymphocytes and intestinal mucosa from patients 
with familial hypercholesterolaemia. Lancet ii: 1342–3.
Bilheimer D W, Grundy S M, Brown M S, Goldstein J L. (1983) Mevinolin and 
colestipol stimulate receptor-mediated clearance of low density lipoprotein 
from plasma in familial hypercholesterolemia heterozygotes. Proceedings of 
the National Academy of Sciences of the USA 80: 4124–8. 
Blackhart B D, Ludwig E M, Pierotti V R, Caiati L, Onasch M A, Wallis S C, 
Powell L, Pease R, Knott T J, Chu M-L, Mahley R W, Scott J, McCarthy 
B J, Levy-Wilson B. (1986) Structure of the human apolipoprotein B gene. 
Journal of Biological Chemistry 261: 15364–7. 
Blankenhorn D H, Nessim S A, Johnson R L, Sanmarco M E, Azen S P, 
Cashin-Hemphill L. (1987) Benefi cial effects of combined colestipol-niacin 
therapy on coronary atherosclerosis and coronary venous bypass grafts. 
Journal of the American Medical Association 257: 3233–40. Erratum in: 
JAMA (1988) 259: 2698.
Born G V R. (2002) Afterword: Platelets, a personal story, in Gresele P, Page 
C P, Fuster V, Vermylen J. (eds) Platelets in Thrombotic and Non-thrombotic 
Disorders: Pathophysiology, Pharmacology and Therapeutics. Cambridge and 
New York: Cambridge University Press, 1063–72.
Born G V R. (2003) Update on platelets: a personal story. Platelets 14: 333–4.
Born G V R, Palinski W. (1985) Unusually high concentrations of sialic acids on 
the surface of vascular endothelia. British Journal of Experimental Pathology 
66: 543–49.
Born G V R, Medina R, Shafi  S, Cardona-Sanclemente L E. (2003) Factors 
infl uencing the uptake of atherogenic plasma proteins by artery walls. 
Biorheology 40: 13–22.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
90
Böttcher C J. (1967) Chemical factors in atherogenesis. Pathologia et 
Microbiologia (Basel) 30: 619–28. 
Boyd G S. (1954) The estimation of serum lipoproteins; a micromethod based 
on zone electrophoresis and cholesterol estimations. Biochemical Journal 
58: 680–5.
Boyd G S, Oliver M F. (1956) Endocrine aspects of coronary sclerosis. Lancet 
ii: 1273–6. 
Brenner S. (2001). My Life in Science. London: BioMed Central.
Brensike J F, Levy R I, Kelsey S F, Passamani E R, Richardson J M, Loh I K, 
Stone N J, Aldrich R F, Battaglini J W, Moriarty D J, Fisher M R, Friedman 
L, Friedewald W, Detre K M, Epstein S E. (1984) Effects of therapy with 
cholestyramine on progression of coronary arteriosclerosis: results of the 
NHLBI Type II Coronary Intervention Study. Circulation 69: 313–24. 
Bronte-Stewart B. (1965) Certain etiologic aspects of atherosclerosis. Angiology 
16: 427–32.
Bronte-Stewart B, Keys A, Brock J F. (1955) Serum-cholesterol, diet, and 
coronary heart disease; an inter-racial survey in the Cape Peninsula. Lancet 
269: 1103–8. 
Bronte-Stewart B, Antonis A, Eales L, Brock J F. (1956) Effects of feeding 
different fats on serum-cholesterol level. Lancet 270: 521–6.
Brown A G, Smale T C, King T J, Hasenkamp R, Thompson R H. (1976) 
Crystal and molecular structure of compactin, a new antifungal metabolite 
from Penicillium brevicompactum. Journal of the Chemical Society [Perkin 1]: 
1165–70.
Brown G, Albers J J, Fisher L D, Schaefer S M, Lin J T, Kaplan C, Zhao X Q, 
Bisson B D, Fitzpatrick V F, Dodge H T. (1990) Regression of coronary 
artery disease as a result of intensive lipid-lowering therapy in men with high 
levels of apolipoprotein B. New England Journal of Medicine 323: 1289–98.
Brunt J N, Watts G F, Lewis B, Smith L D, Coltart D J. (1995) Quantitative 
coronary cineangiography for the study of atherosclerosis. Medical Engineering 
and Physics 17: 356–65.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
91
Buchwald H, Varco R L, Matts J P, Long J M, Fitch L L, Campbell G S, Pearce 
M B, Yellin A E, Edmiston W A, Smink R D Jr, et al. (1990) Effect of 
partial ileal bypass surgery on mortality and morbidity from coronary heart 
disease in patients with hypercholesterolemia. Report of the Program on the 
Surgical Control of the Hyperlipidemias (POSCH). New England Journal of 
Medicine 323: 946–55.
Burr M L, Fehily A M, Gilbert J F, Rogers S, Holliday R M, Sweetnam P M, 
Elwood P C, Deadman N M. (1989) Effects of changes in fat, fi sh and fi bre 
intakes on death and myocardial reinfarction: diet and reinfarction trial 
(DART). Lancet ii: 757–61.
Califf R M. (2002) Chapter 15. Large clinical trials in clinical research institutes. 
In Gallin J I. (ed.) Principles and Practice of Clinical Research. San Diego, CA: 
Academic Press, 225–50.
Carstairs K C, Woolf N, Crawford T. (1964) Immunohistochemical cross-
reaction between platelets and fi brin. Journal of Pathology and Bacteriology 
88: 537–40.
Carter C O, Slack J, Myant N B. (1971) Genetics of hyperlipoproteinaemias. 
Lancet i: 400–1.
Chakrabarti R, Fearnley G R. (1962) The ‘fi brinolytic potential’ as a 
simple measure of spontaneous fi brinolysis. Journal of Clinical Pathology 
15: 228–30. 
Chakrabarti R, Bielawiec M, Evans J F, Fearnley G R. (1968) Methodological 
study and a recommended technique for determining the euglobulin lysis 
time. Journal of Clinical Pathology 21: 698–701.
Chave S P, Morris J N, Moss S, Semmence A M. (1978) Vigorous exercise in 
leisure time and the death rate: a study of male civil servants. Journal of 
Epidemiology and Community Health 32: 239–43.
Christensen B, Glueck C, Kwiterovich P, Degroot I, Chase G, Heiss G, 
Mowery R, Tamir I, Rifkind B. (1980) Plasma cholesterol and triglyceride 
distributions in 13 665 children and adolescents: the Prevalence Study of the 
Lipid Research Clinics Program. Pediatric Research 14: 194–202. 
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
92
Christie D A, Tansey E M. (eds) (2003) Genetic Testing. Wellcome Witnesses to 
Twentieth Century Medicine, vol. 17. London: Wellcome Trust Centre for the 
History of Medicine at UCL. Freely available from www.ucl.ac.uk/histmed/ 
following links to Publications/Wellcome Witnesses.
Clifton-Bligh P, Galton D J. (1976) The esterifi cation of exogenous fatty acids 
by adipose tissue of hypertriglyceridaemic subjects with or without diabetes 
mellitus. Clinical Science and Molecular Medicine 51: 257–65.
Cohen J, Pertsemlidis A, Kotowski I K, Graham R, Garcia C K, Hobbs H H. 
(2005) Low LDL cholesterol in individuals of African descent resulting from 
frequent nonsense mutations in PCSK9. Nature Genetics 37: 161–5. Epub 
Jan 16 2005. Erratum in: Nature Genetics 37: 328.
Cook R P. (ed.) (1958) Cholesterol: Chemistry, biochemistry and pathology. New 
York, NY: Academic Press. 
Corbishley C, Burke M. (2003) Obituary: Michael John Davies. British Medical 
Journal 326: 1270. 
Cornforth J W. (1959) Biosynthesis of fatty acids and cholesterol considered as 
chemical processes. Journal of Lipid Research 1: 3–28.
Cornforth J W. (1973) The logic of working with enzymes. Chemical Society 
Reviews 2: 1–20.
Cornforth J W, Youthotsky I, Popják G. (1954) Absolute confi guration of 
cholesterol. Nature 173: 536. 
Cottet J, Mathivat A, Redel J. (1954) Therapeutic study of a synthetic 
hypocholesterolaemic agent: phenyl ethyl acetic acid. La Presse Medicale 
62: 939–41.
Crepaldi G. (1971) [Relations between diet and atherosclerosis] Italian. Minerva 
Medica 62: 3433–51.
Dangerfi eld W G, Smith E B. (1955) An investigation of serum lipids and 
lipoproteins by paper electrophoresis. Journal of Clinical Pathology 
8: 132–9.
Davey Smith G. (2004) A conversation with Jerry Morris. Epidemiology 
15: 770–3.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
93
Davey Smith G, Ebrahim S. (2003) ‘Mendelian randomization’: can genetic 
epidemiology contribute to understanding environmental determinants of 
disease? International Journal of Epidemiology 32: 1–22.
Davey Smith G, Nutbeam D. (1988) Public attitudes and knowledge regarding 
coronary heart disease. In Catford J C. (ed.) Coronary Heart Disease 
Prevention: Action in the UK 1984–87. London: National Forum for CHD 
Prevention, 97–102.
Davey Smith G, Pekkanen J. (1992a) Should there be a moratorium on the use 
of cholesterol-lowering drugs? British Medical Journal 304: 431–4.
Davey Smith G, Pekkanen J. (1992b) The cholesterol controversy. British 
Medical Journal 304: 913.
Davey Smith G, Shipley M J. (1989) Plasma cholesterol concentration and 
primary brain tumours. British Medical Journal 299: 26–7. 
Davey Smith G, Song F, Sheldon T A. (1993) Cholesterol lowering and 
mortality: the importance of considering initial level of risk. British Medical 
Journal 306: 1367–73.
Davey Smith G, Shipley M J, Marmot M G, Rose G. (1992a) Plasma cholesterol 
concentration and mortality. The Whitehall Study. Journal of the American 
Medical Association 267: 70–6. 
Davey Smith G, Neaton J D, Ben-Shlomo Y, Shipley M, Wentworth D. (1992b) 
Serum cholesterol concentration and primary malignant brain tumors: a 
prospective study. American Journal of Epidemiology 135: 259–65.
Davey Smith G, Hart C, Blane D, Gillis C, Hawthorne V. (1997) Lifetime 
socioeconomic position and mortality: prospective observational study. 
British Medical Journal 314: 547–52. Erratum in BMJ (1997) 314: 1012.
Davies M J. (1992) Anatomic features in victims of sudden coronary death. 
Coronary artery pathology. Circulation 85: I19–24.
Davies M J. (1996) Stability and instability: two faces of coronary atherosclerosis. 
The Paul Dudley White Lecture 1995. Circulation 94: 2013–20.
Davies M J, Thomas A C. (1985) Plaque fi ssuring – the cause of acute myocardial 
infarction, sudden ischaemic death, and crescendo angina. British Heart 
Journal 53: 363–73.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
94
Davies, M J, Woolf N, Robertson W B. (1976) Pathology of acute myocardial 
infarction with particular reference to occlusive coronary thrombi. British 
Heart Journal 38: 659–64. 
Davies M J, Woolf N, Rowles P, Richardson P D. (1994) Lipid and cellular 
constituents of unstable human aortic plaques. Basic Research in Cardiology 
89: 33–9.
de Gennes J L, Touraine R, Maunand B, Truffert J, Laudat P. (1967) 
[Homozygous cutaneo-tendinous forms of hypercholesteremic xantho-
matosis in an exemplary familial case. Trial of plasmapheresis an heroic 
treatment.] French. Bulletins et memoires de la Société médicale des hopitaux 
de Paris 118: 1377–402.
Department of Health and Social Security (DHSS), Committee on Medical 
Aspects of Food Policy, Panel on Diet in Relation to Cardiovascular Disease 
(COMA). (1984) Diet and Cardiovascular Disease: Report of the Panel on 
Diet in Relation to Cardiovascular Disease. Health and social subjects series 
No. 28. London: HMSO.
Dollery C. (1995) Sir John McMichael 1904–93. Biographical Memoirs of 
Fellows of the Royal Society 41: 283–96.
Drury A N, Grant R T. (1945–48) Sir Thomas Lewis. Obituary Notices of Fellows 
of the Royal Society 5: 179–202.
Duffi eld R G, Lewis B, Miller N E, Jamieson C W, Brunt J N, Colchester A 
C. (1983) Treatment of hyperlipidaemia retards progression of symptomatic 
femoral atherosclerosis. A randomized controlled trial. Lancet ii: 639–42.
Durrington P N. (2003) Chapter 16. Gender and coronary heart disease. In 
Durrington P N, Mackness M I, Miller J P, Rees A. (eds). Year in Dyslipidaemia 
2003. Oxford: Clinical Publishing, 297–306.
Durrington P N. (2004) Statin policy and target populations: evidence-based 
or evidence-biased? Current Opinion in Lipidology 15: 381–6.
Edington J D, Geekie M, Carter R, Benfi eld L, Ball M, Mann J. (1989) Serum 
lipid response to dietary cholesterol in subjects fed a low-fat, high-fi ber diet. 
American Journal of Clinical Nutrition 50: 58–62.
Eisenberg S, Bilheimer D W, Levy R I, Lindgren F T. (1973) On the metabolic 
conversion of human plasma very low density lipoprotein to low density 
lipoprotein. Biochimica et Biophysica Acta 326: 361–77.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
95
Elliot J. (1782) A Complete Collection of the Medical and Philosophical Works of 
John Fothergill with an Account of his Life; and Occasional Notes. London: 
G Robinson: 531–6. 
Endo A, Kuroda M, Tsujita Y. (1976a) ML-236A, ML-236B, and ML-236C, 
new inhibitors of cholesterogenesis produced by Penicillium citrinium. 
Journal of Antibiotics 29: 1346–8. 
Endo A, Kuroda M, Tanzawa K. (1976b) Competitive inhibition of 3-hydroxy-
3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal 
metabolites, having hypocholesterolaemic activity. FEBS Letters 72: 323–4.
Endo A, Tsujita Y, Kuroda M, Tanzawa K. (1977) Inhibition of cholesterol 
synthesis in vitro and in vivo by ML-236A and ML-236B, competitive 
inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. European 
Journal of Biochemistry 77: 31–6.
Evans W. (1948) Diseases of the Heart and Arteries. Edinburgh; London: E and 
S Livingstone.
Ewin J H. (2001) Fine Wines and Fish Oils: The Life of Hugh Macdonald Sinclair. 
Oxford: Oxford University Press. 
Fehily A M, Pickering J E, Yarnell J W, Elwood P C. (1994) Dietary indices 
of atherogenicity and thrombogenicity and ischaemic heart disease risk: the 
Caerphilly Prospective Study. British Journal of Nutrition 71: 249–57.
Fernandez-Armesto F. (2001) Food: A history. London: Macmillan.
Fine R A. (1972) The Great Drug Deception: The shocking story of MER 29 and 
the folks who gave you thalidomide. New York, NY: Stein and Day.
Florey H. (ed.) (1970) General Pathology. 4th edn. London: Lloyd-Luke Medical 
Books Ltd.
Fogelman A M, Shechter I, Seager J, Hokom M, Child JS, Edwards P A. (1980) 
Malondialdehyde alteration of low density lipoproteins leads to cholesteryl 
ester accumulation in human monocyte-macrophages. Proceedings of the 
National Academy of Sciences of the USA 77: 2214–18.
Foyle W J, Carstensen E, Fernandez M C, Yudkin J S. (1995) Longitudinal 
study of associations of microalbuminuria with the insulin resistance 
syndrome and sodium-lithium countertransport in nondiabetic subjects. 
Arteriosclerosis, Thrombosis, and Vascular Biology 15: 1330–7. 
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
96
Frantz I D Jr, Moore R B, (1969) The sterol hypothesis in atherogenesis. 
American Journal of Medicine 46: 684–90. 
Fredrickson D S, Lees R S. (1966) The Metabolic Basis of Inherited Disease. 
2nd edn. New York, NY: McGraw-Hill. Chapter 22 on familial 
hyperlipoproteinaemia, pages 429–88. 
Fredrickson D S, Levy R I, Lees R S. (1967) Fat transport in lipoproteins – an 
integrated approach to mechanisms and disorders. New England Journal of 
Medicine 276: 34–42; 94–103 148–56; 215–25; 273–81.
French J E. (1958) Chapter 17: Atherosclerosis, in Florey H. (ed.) General 
Pathology: Based on lectures delivered at the Sir William Dunn School of 
Pathology, University of Oxford. 2nd edn. London: Lloyd-Luke (Medical 
Books) Ltd: 351–77.
Frick M H, Elo O, Haapa K, Heinonen O P, Heinsalmi P, Helo P, Huttunen 
J K, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, 
Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, 
Nikkilä E A. (1987) Helsinki Heart Study: primary-prevention trial with 
gemfi brozil in middle-aged men with dyslipidemia. Safety of treatment, 
changes in risk factors, and incidence of coronary heart disease. New England 
Journal of Medicine 317: 1237–45.
Friedewald W T, Levy R I, Fredrickson D S. (1972) Estimation of the 
concentration of low-density lipoprotein cholesterol in plasma, without use 
of the preparative ultracentrifuge. Clinical Chemistry 18: 499–502.
Fullerton H W, Davie W J, Anastasopoulos G. (1953) Relationship of alimentary 
lipaemia to blood coagulability. British Medical Journal ii: 250–3.
Fulton W F M. (1965) The Coronary Arteries. Springfi eld, IL: 
Charles C Thomas. 
Fulton W F M. (1993) Pathological concepts in acute coronary thrombosis: 
relevance to treatment. British Heart Journal 70: 403–8.
Furst A L, Greaves D A, Hawthorne V M, McCartney H, Stewart G T. (1972) 
Candidates for coronaries. British Medical Journal iv: 366–7. 
Gaffney P J, Edgell T A, Whitton C M. (1999) The haemostatic balance – 
Astrup revisited. Haemostasis 29: 58–71.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
97
Galton D J. (2003) Dyslipidaemia. Edinburgh: Churchill Livingstone. [Revised 
and expanded edn of Galton D J, Krone W. (1990) Hyperlipidaemia in 
Practice. London: Gower Medical Publishing.]
Gertler M M, White P D. (1954) Coronary Heart Disease in Young Adults: 
A multidisciplinary study. With the aid, advice, and editorial assistance 
of E F Bland. Cambridge, MA: Harvard University Press for the 
Commonwealth Fund.
Gilbert M. (1991) Churchill: A life. London: William Heinemann.
Gofman J W, Lindgren F T, Elliot H. (1949) Ultracentrifugal studies of 
lipoproteins of human serum. Journal of Biological Chemistry 179: 973–9. 
Gofman J W, Jones H B, Lindgren F T, Lyon T P, Elliott H A, Strisower B. 
(1950) Blood lipids and human atherosclerosis. Circulation 5: 161–78. 
Gofman J W, Jones H B, Lyon IP, Lindgren F T, Strisower B, Colman D, Herring 
V. (1952) Blood lipids and human atherosclerosis. Circulation 5: 119–34. 
Goldstein J L, Brown M S. (1977) The low-density lipoprotein pathway and its 
relation with atherosclerosis. Annual Review of Biochemistry 46: 897–930.
Goldstein J L, Hazzard W R, Schrott H G, Bierman E L, Motulsky A G. (1973a) 
Hyperlipidemia in coronary heart disease: 1. Lipid levels in 500 survivors of 
myocardial infarction. Journal of Clinical Investigation 52: 1533–43. 
Goldstein J L, Schrott H G, Hazzard W R, Bierman E L, Motulsky A G. 
(1973b) Hyperlipidemia in coronary heart disease: 2. Genetic analysis of 
lipid levels in 176 families and delineation of a new inherited disorder, 
combined hyperlipidemia. Journal of Clinical Investigation 52: 1544–68. 
Gordon T, Castelli W P, Hjortland M C, Kannel W B, Dawber T R. 
(1977) Predicting coronary heart disease in middle-aged older persons. 
The Framingham study. Journal of the American Medical Association 
238: 497–9.
Gordon T, Kannel W B, Castelli W P, Dawber T R. (1981) Lipoproteins, 
cardiovascular disease, and death. The Framingham study. Archives of Internal 
Medicine 141: 1128–31. 
Gould R G, Popják G. (1957) Biosynthesis of cholesterol in vivo and in vitro 
from DL-β-hydroxy-β-methyl-δ -[2-14C]-valerolactone. Biochemical Journal 
66: 51P.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
98
Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, 
Hsia J, Hulley S, Herd A, Khan S, Kristin Newby L, Waters D, Vittinghoff 
E, Wenger N, for the HERS Research Group. (2002) Cardiovascular disease 
outcomes during 6.8 years of hormone therapy: Heart and Estrogen/
Progestin Replacement Study Follow-up (HERS II). Journal of the American 
Medical Association 288: 49–57.
Gray J, Booth C. (1994) Sir Harold Himsworth. Munk’s Roll 9: 238–41.
Grundy S M. (1991) George Lyman Duff Memorial Lecture. Multifactorial 
etiology of hypercholesterolemia. Implications for prevention of coronary 
heart disease. Arteriosclerosis and Thrombosis 11: 1619–35.
H(ampton) J R. (1991) Obituary: J R A Mitchell. British Medical Journal 
302: 843.
Hart C L, Davey Smith G, Hole D J, Hawthorne V M. (1999) Alcohol 
consumption and mortality from all causes, coronary heart disease, and 
stroke: results from a prospective cohort study of Scottish men with 21 years 
of follow-up. British Medical Journal 318: 1725–9.
Haust M D, More R H, Bencosme S A, Balis J U. (1967) Electron microscopic 
studies in human atherosclerosis extracellular elements in aortic dots and 
streaks. Experimental and Molecular Pathology 6: 300–13. 
Havel R J, Hunninghake D B, Illingworth D R, Lees R S, Stein E A, Tobert J 
A, Bacon S R, Bolognese J A, Frost P H, Lamkin G E, Lees A M, Leon A S, 
Gardner K, Johnson G, Mellies M J, Rhymer P A, Tun P. (1987) Lovastatin 
(mevinolin) in the treatment of heterozygous familial hypercholesterolemia. 
A multicenter study. Annals of Internal Medicine 107: 609–15.
Hawthorne F. (2003) The Merck Druggernaut: The inside story of a pharmaceutical 
giant. Hoboken, NJ: John Wiley & Sons, Inc.
Hawthorne V M. (1977) Diet and coronary heart disease. British Medical 
Journal ii: 186–7. 
Hawthorne V M, Gillis C R, Lorimer A R, Calvert F R, Walker T J. (1969) 
Blood pressure in a Scottish island community. British Medical Journal 
iv: 651–4. 
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
99
Hazzard W R, Goldstein J L, Schrott M G, Motulsky A G, Bierman E L. (1973) 
Hyperlipidemia in coronary heart disease: 3. Evaluation of lipoprotein 
phenotypes of 156 genetically defi ned survivors of myocardial infarction. 
Journal of Clinical Investigation 52: 1569–77.
Heady J A, Morris J N, Oliver M F. (1992) WHO clofi brate/cholesterol trial: 
clarifi cations. Lancet 340: 1405–6.
Heart Protection Study Collaborative Group. (2002) MRC/BHF Heart 
Protection Study of cholesterol lowering with simvastatin in 20 536 high 
risk individuals: a randomized placebo-controlled trial. Lancet 360: 7–22.
Hegsted M. (1959) Comparative studies on the effect of dietary fats on serum 
cholesterol levels. Federation Proceedings 18: 52–4. 
Heiberg A, Berg K. (1976) The inheritance of hyperlipoproteinaemia with 
xanthomatosis. A study of 132 kindreds. Clinical Genetics 9: 203–33. 
Hendriks H F, Weststrate J A, van Vliet T, Meijer G W. (1999) Spreads enriched 
with three different levels of vegetable oil sterols and the degree of cholesterol 
lowering in normocholesterolaemic and mildly hypercholesterolaemic 
subjects. European Journal of Clinical Nutrition 53: 319–27.
Henriksen T, Mahoney E M, Steinberg D. (1981) Enhanced macrophage 
degradation of low density lipoprotein previously incubated with cultured 
endothelial cells: recognition by receptors for acetylated low density 
lipoproteins Proceedings of the National Academy of Sciences of the USA 
78: 6499–503. 
Higgins I T, Cochrane A L, Thomas A J. (1963) Epidemiological studies 
of coronary disease. British Journal of Preventive and Social Medicine 
17: 153–65. 
Himsworth H P. (1936) Diabetes mellitus: its differentiation into insulin-
sensitive and insulin-insensitive types. Lancet i: 127–30. 
Himsworth H P. (1982) Thomas Lewis and the development of support for 
clinical research. The Pharos of Alpha Omega Alpha 45: 15–19.
Hoff H F, Heideman C L, Gotto A M Jr, Gaubatz J W. (1977) Apolipoprotein B 
retention in the grossly normal and atherosclerotic human aorta. Circulation 
Research 41: 684–90.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
100
Hofmann A F, Zöllner N. (2000) Siegfried Thannhauser (1885–1962): Physician 
and scientist in turbulent times. Freiburg: Falk Foundation.
Hooper L, Summerbell C D, Higgins J P T, Thompson R L, Clements G, 
Capps N, Davey Smith G, Riemersma R A, Ebrahim S. (2001a) Reduced or 
modifi ed dietary fat for preventing cardiovascular disease. Cochrane Database 
Systematic Review 2001 (3): CD002137. 
Hooper L, Summerbell C D, Higgins J P, Thompson R L, Capps N E, Davey 
Smith G, Riemersma R A, Ebrahim S. (2001b) Dietary fat intake and 
prevention of cardiovascular disease: systematic review. British Medical 
Journal 322: 757–63. 
Hooper L, Summerbell C D, Thompson R L, Capps N E, Davey Smith G, 
Riemersma R A, Ebrahim S. (2001c) Author’s reply. British Medical Journal 
323: 1001–2.
Howard A N, Patelski J, Bowyer D E, Gresham G A. (1972) Aortic lipolytic 
enzymes in atherosclerosis. Biochemical Journal 128: 41P.
Hu F B, Sacks F, Willett W C. (2001) Dietary fats and prevention of cardiovascular 
disease. Patient compliance should have been considered. British Medical 
Journal 323: 1001–2.
Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff 
E. (1998) Randomized trial of estrogen plus progestin for secondary 
prevention of coronary heart disease in postmenopausal women. Heart and 
Estrogen/progestin Replacement Study (HERS) Research Group. Journal of 
the American Medical Association 280: 605–13. 
Humphries S E, Kessling A M, Horsthemke B, Donald J A, Seed M, Jowett N, 
Holm M, Galton D J, Wynn V, Williamson R. (1985) A common DNA 
polymorphism of the low-density lipoprotein (LDL) receptor gene and its 
use in diagnosis. Lancet i: 1003–5.
Illingworth D R, Sexton G J. (1984) Hypocholesterolemic effects of mevinolin 
in patients with heterozygous familial hypercholesterolemia. Journal of 
Clinical Investigation 74: 1972–8.
Imai H, Werthessen N T, Taylor C B, Lee K T. (1976) Angiotoxicity and 
arteriosclerosis due to contaminants of USP-grade cholesterol. Archives of 
Pathology and Laboratory Medicine 100: 565–72.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
101
Innerarity T L, Mahley R W. (1978) Enhanced binding by cultured human 
fi broblasts of apo-E-containing lipoproteins as compared with low density 
lipoproteins. Biochemistry 17: 1440–7.
James A T, Martin A J. (1954) Gas-liquid chromatography; a technique for 
the analysis and identifi cation of volatile materials. British Medical Bulletin 
10: 170–6. 
James A T, Martin A J. (1956) Gas-liquid chromatography: the separation and 
identifi cation of the methyl esters of saturated and unsaturated acids from 
formic acid to n-octadecanoic acid. Biochemical Journal 63: 144–52.
Jenkins D J, Kendall C W, Marchie A, Faulkner D A, Wong J M, de Souza R, 
Emam A, Parker T L, Vidgen E, Trautwein E A, Lapsley K G, Josse R G, 
Leiter L A, Singer W, Connelly P W. (2005) Direct comparison of a dietary 
portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic 
participants. American Journal of Clinical Nutrition 81: 380–7.
Joslin E P. (1927) Atherosclerosis and diabetes. Annals of Clinical Medicine 5: 
1061–80. 
Joslin E P. (1956) Diabetes for the diabetics: Ninth Banting Memorial Lecture 
of the British Diabetic Association. Diabetes 5: 137–46.
Juhan-Vague I, Alessi M C, Mavri A, Morange P E. (2003) Plasminogen 
activator inhibitor-1, infl ammation, obesity, insulin resistance and vascular 
risk. Journal of Thrombosis and Haemostasis 1: 1575–9.
Julius U, Leonhardt W, Schulze J, Schollberg K, Hanefeld M, Haller H. 
(1981) Hyperinsulinemia in patients with low fractional catabolic rate of 
triglycerides. Acta Diabetologica Latina 18: 217–23.
Jurgens G, Lang J, Esterbauer H. (1986) Modifi cation of human low-density 
lipoprotein by the lipid peroxidation product 4-hydroxynonenal. Biochimica 
et Biophysica Acta 875: 103–14.
Kajantie E, Osmond C, Barker D J, Forsen T, Phillips D I, Eriksson J G. (2005) 
Size at birth as a predictor of mortality in adulthood: a follow-up of 350 000 
person-years. International Journal of Epidemiology 34: 655–63.
Katan M B. (1986) Apolipoprotein E isoforms, serum cholesterol, and cancer. 
Lancet i: 507–8. Reprinted in the International Journal of Epidemiology 
(2004) 33: 9.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
102
Kay H D. (1951) The National Institute for Research in Dairying, Shinfi eld, 
Reading. Proceedings of the Royal Society of London. Series A, Mathematical 
and Physical Sciences 205: 453–67.
Keavney B. (2004) Commentary: Katan’s remarkable foresight: genes and 
causality 18 years on. International Journal of Epidemiology 33: 11–14.
Keech A, Simes R J, Barter P, Best J, Scott R, Taskinen M R, Forder P, Pillai A, 
Davis T, Glasziou P, Drury P, Kesaniemi Y A, Sullivan D, Hunt D, Colman P, 
d’Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. 
(2005) Effects of long-term fenofi brate therapy on cardiovascular events in 
9795 people with type 2 diabetes mellitus (the FIELD study): randomized 
controlled trial. Lancet 366: 1849–61.
Keys A. (1950) The Biology of Human Starvation, 2 vols. Minneapolis, MN: 
University of Minnesota Press. Collaborators from the Laboratory of 
Physiological Hygiene, School of Public Health, University of Minnesota, 
include: J Brozek, A Henschel, O Mickelsen, H L Taylor, E Simonson, A S 
Skinner, S M Wells. 
Keys A. (1951) Cholesterol, ‘giant molecules’, and atherosclerosis. Journal of the 
American Medical Association 147: 1514–19. 
Keys A. (ed.) (1955) Arteriosclerosis: A Symposium. Minnesota Medicine 
38: 731–808; 829–935. Also as Keys A. (ed.) (1956) Arteriosclerosis: A 
symposium presented by the Minnesota Heart Association and the University 
of Minnesota, 7–9 September 1955. Minneapolis, MN: University of 
Minnesota Press.
Keys A. (1970) Coronary heart disease in seven countries. Circulation 41: 1–211. 
Keys A. (1980) Seven Countries: A multivariate analysis of death and coronary 
heart disease. London: Harvard University Press.
Keys A, Anderson J T, Grande F. (1957) Prediction of serum cholesterol 
responses of man to changes in fats in the diet. Lancet ii: 959–66. 
Keys A, Kimura N, Kusukawa A, Bronte-Stewart B, Larsen N, Keys M H. 
(1958) Lessons from serum cholesterol studies in Japan, Hawaii and Los 
Angeles. Annals of Internal Medicine 48: 83–94.
Keys A, Taylor HL, Blackburn H, Brozek J, Anderson JT, Simonson E. (1963) 
Coronary heart disease among Minnesota business and professional men 
followed 15 years. Circulation 28: 381–95.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
103
Keys A, Menotti A, Aravanis C, Blackburn H, Djordevicˇ B S, Buzina R, Dontas 
A S, Fidanza F, Karvonen M J, Kimura N, Mohacˇek I, Nedeljkovicˇ S, Puddu 
V, Punsar S, Taylor H L, Conti S, Daan Kromhout D, Toshima H. (1984) 
The seven countries study: 2 289 deaths in 15 years. Preventive Medicine 
13: 141–54.
Kinsell L W, Sinclair H M. (1957) Fats and disease. Lancet 272: 883–4.
Knott T J, Rall S C Jr, Innerarity T L, Jacobson S F, Urdea M S, Levy-Wilson B, 
Powell L M, Pease R J, Eddy R, Nakai H, Byers M, Priestley L M, Robertson 
E, Rall L B, Betsholtz C, Shows T B, Mahley R W, Scott J. (1985) Human 
apolipoprotein B: structure of carboxyl-terminal domains, sites of gene 
expression, and chromosomal localization. Science 230: 37–43. 
Knott T J, Pease R J, Powell L M, Wallis S C, Rall S C Jr, Innerarity T L, 
Blackhart B, Taylor W H, Marcel Y, Milne R, Johnson D, Fuller M, Lusis 
A J, McCarthy B J, Mahley R W, Levy-Wilson B, Scott J. (1986) Complete 
protein sequence and identifi cation of structural domains of human 
apolipoprotein B. Nature 323: 734–8.
Kohn J. (1957) An immuno-electrophoretic technique. Nature 180: 986–7. 
Kohn J. (1970) Electrophoresis and immunodiffusion techniques on cellulose 
acetate membrane. Methods in Medical Research 12: 243–60.
Krieger M. (1992) Molecular fl ypaper and atherosclerosis: structure of the 
macrophage scavenger receptor. Trends in Biochemical Sciences 17: 141–6. 
Kyle R A, Shampo M A. (1997) Theodor Svedberg and the ultracentrifuge. 
Mayo Clinic Proceedings 72: 830.
Laakso M. (1995) Epidemiology of diabetic dyslipidaemia. Diabetic Review 
3: 408–22.
Langer T, Strober W, Levy R I. (1972) The metabolism of low density lipoprotein 
in familial type II hyperlipoproteinemia. Journal of Clinical Investigation 
51: 1528–36.
Law M. (2000) Plant sterol and stanol margarines and health. British Medical 
Journal 320: 861–4.
Lawlor D A, Ebrahim S, Davey Smith G. (2001) Sex matters: secular and 
geographical trends in sex differences in coronary heart disease mortality. 
British Medical Journal 323: 541–5. Erratum in BMJ (2002) 325: 580.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
104
Lendon C, Born G V R, Davies M J, Richardson P D. (1992) Plaque fi ssure: 
the link between atherosclerosis and thrombosis. Nouvelle revue Francaise 
d’hematologie 34: 27–9.
Lendrum A C. (1949) The staining of erythrocytes in tissue sections a new 
method and observations on some of the modifi ed mallory connective tissue 
stains. Journal of Pathology and Bacteriology 61: 443–8.
Leren P. (1970) The Oslo diet–heart study. Eleven-year report. Circulation 42: 
935–42.
Levy R I, Langer T. (1971) Hypolipidemic drugs and hyperlipoproteinemia. 
Annals of the New York Academy of Sciences 179: 475–80. 
Lewis S M, Collier I C. (1992) Appendix B: Laboratory Values. In Ladig 
D J, Van Schaik T. Medical Surgical Nursing, Assessment and Management of 
Clinical Problems. 3rd edn. St Louis, MO: Mosby-Year Book Inc.
Lewis T. (1932) The relation of clinical medicine to physiology from the 
standpoint of research. British Medical Journal ii: 1046–9.
Lewis T. (1946) Diseases of the Heart: Described for practitioners and students. 4th 
edn. London: Macmillan.
Lipid Research Clinics (LRC) Coronary Primary Prevention Trial. (1984) 
The Lipid Research Clinics Coronary Primary Prevention Trial results. 
I. Reduction in incidence of coronary heart disease; II. The relationship of 
reduction in incidence of coronary heart disease to cholesterol lowering. 
Journal of the American Medical Association 251: 351–64; 365–74.
Logan W P D, Morris J N. (1952) Letter to the Editor: cooperation in research 
on heart disease. Lancet i: 1116.
Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study 
Group. (1988) Prevention of cardiovascular events and death with pravastatin 
in patients with coronary heart disease and a broad range of initial cholesterol 
levels. New England Journal of Medicine 339: 1349–57. 
Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. 
(1995) Design features and baseline characteristics of the LIPID (Long-Term 
Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial 
in patients with previous acute myocardial infarction and/or unstable angina 
pectoris. American Journal of Cardiology 76: 474–9.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
105
Lovastatin Study Group II. (1986) Therapeutic response to lovastatin (mevinolin) 
in nonfamilial hypercholesterolemia. A multicenter study. Journal of the 
American Medical Association 256: 2829–34. 
Lovastatin Study Group III. (1988) A multicenter comparison of lovastatin and 
cholestyramine therapy for severe primary hypercholesterolemia. Journal of 
the American Medical Association 260: 359–66. 
Lovastatin Study Group IV. (1990). A multicenter comparison of lovastatin and 
probucol for treatment of severe primary hypercholesterolemia. American 
Journal of Cardiology 66: 22b–30b.
Lowe G D, McArdle B M, Stromberg P, Lorimer A R, Forbes C D, Prentice 
C R. (1982) Increased blood viscosity and fi brinolytic inhibitor in type II 
hyperlipoproteinaemia. Lancet i: 472–5.
Lowe G D, Drummond M M, Third J L, Bremner W F, Forbes C D, Prentice C 
R, Lawrie T D. (1980) Increased plasma fi brinogen and platelet-aggregates 
in type II hyperlipoproteinaemia. Thrombosis and Haemostasis 42: 1503–7.
Lowe G D, Wood D A, Douglas J T, Riemersma R A, Macintyre C C, Takase T, 
Tuddenham E G, Forbes C D, Elton R A, Oliver M F. (1991) Relationships 
of plasma viscosity, coagulation and fi brinolysis to coronary risk factors and 
angina. Thrombosis and Haemostasis 65: 339–43.
Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T, Watanabe 
A, Koizumi J, Takeda R. (1981) Effect of an inhibitor of 3-hydroxy-3-
methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-
10-levels in patients with familial hypercholesterolemia. New England Journal 
of Medicine 305: 478–82.
MacCallum P K, Rudnicka A R, Rumley A, Meade T W, Lowe G D. (2004) 
Low-intensity warfarin reduces thrombin generation and fi brin turnover, 
but not low-grade infl ammation, in men at risk of myocardial infarction. 
British Journal of Haematology 127: 448–50.
Mahley R W, Innerarity T L. (1978) Properties of lipoproteins responsible 
for high affi nity binding to cell surface receptors of fi broblasts and smooth 
muscle cells. In Kritchevsky D, Paoletti R, Holmes W L. (eds) Drugs, 
Lipid Metabolism and Atherosclerosis. New York, NY: Plenum Publishing 
Corporation, 99–127.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
106
Mann J, Skeaff M, Truswell S. (2001) Dietary fats and prevention of 
cardiovascular disease. Conclusion may have been underplayed. British 
Medical Journal 323: 1000–1; author reply 1001–2.
Marmot M G, Rose G, Shipley M, Hamilton P J. (1978) Employment grade 
and coronary heart disease in British civil servants. Journal of Epidemiology 
and Community Health 32: 244–9.
Martin A J, James A T. (1956) Gas–liquid chromatography: the gas-density 
meter, a new apparatus for the detection of vapours in fl owing gas streams. 
Biochemical Journal 63: 138–43.
McCord J M, Fridovich I. (1969) Superoxide dismutase. An enzymic 
function for erythrocuprein (hemocuprein). Journal of Biological Chemistry 
244: 6049–55.
McKeigue P M, Marmot M G, Adelstein A M, Hunt S P, Shipley M J, Butler 
S M, Riemersma R A, Turner P R. (1985) Diet and risk factors for coronary 
heart disease in Asians in northwest London. Lancet ii: 1086–90.
McMichael J. (1979) Fats and atheroma: an inquest. British Medical Journal 
i: 173–5.
McNicol G P, Douglas A S. (1964) Epsilon-aminocaproic acid and other 
inhibitors of fi brinolysis. British Medical Bulletin 20: 233–9.
Meade T W, Ruddock V, Stirling Y, Chakrabarti R, Miller G J. (1993) 
Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic 
heart disease in the Northwick Park Heart Study. Lancet 342: 1076–9.
Medical Research Council’s General Practice Research Framework. (1998) 
Thrombosis prevention trial: randomized trial of low-intensity oral 
anticoagulation with warfarin and low-dose aspirin in the primary prevention 
of ischaemic heart disease in men at increased risk. Lancet 351: 233–41.
Mensink R P, Katan M B. (1992) Effect of dietary fatty acids on serum lipids 
and lipoproteins. A meta-analysis of 27 trials. Arteriosclerosis and Thrombosis 
12: 911–19.
Miller G J. (1999) Lipoproteins and the haemostatic system in atherothrombotic 
disorders. Bailliere’s Best Practice and Research: Clinical Haematology 
12: 555–75. 
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
107
Miller G J, Miller N E. (1975) Plasma-high-density-lipoprotein (HDL) 
concentration and development of ischaemic heart disease. Lancet i: 16–19. 
Miller G J, Walter S J, Stirling Y, Thompson S G, Esnouf M P, Meade T W. 
(1985) Assay of factor VII activity by two techniques: evidence for increased 
conversion of VII to alpha VIIa in hyperlipidaemia, with possible implications 
for ischaemic heart disease. British Journal of Haematology 59: 249–58.
Mitchell J R A. (1984) What constitutes evidence on the dietary prevention of 
coronary heart disease? Cosy beliefs or harsh facts? International Journal of 
Cardiology 5: 287–98.
Mitchell J R A. (1985) Diet and arterial disease: the myths and the realities. 
Proceedings of the Nutrition Society 44: 363–70.
Mitchell J R A, for GRAND (Glaxo Receptor Antagonist against Nottingham 
DVT) Study Group. (1987) Trial of Thromboxane Receptor Antagonist as 
Prophylaxis Against Deep Vein Thrombosis in Suspected Acute Myocardial 
Infarction. Uxbridge, Middlesex: Glaxo [Glaxo internal report].
Mitchell J R A, Schwartz C J. (1965) Arterial Disease. Oxford: Blackwell 
Scientifi c Publications.
Morgagni G B. (1762) De sedibus, et causis morborum per anatomen indagatis, 
libri quinque. Naples: Simoni [vols. II-III, Raymundi for D. Terres].
Morris J N. (1951) Recent history of coronary disease. Lancet i: 1–7; 69–73.
Morris J N. (1957) Uses of Epidemiology. Edinburgh; London: E & S 
Livingstone.
Morris J N. (1960) Occupation and coronary heart disease. In Medical Research 
Council, Current Medical Research. London: HMSO, 1–4.
Morris J N, Crawford M D. (1958) Coronary heart disease and physical activity 
of work; evidence of a national necropsy survey. British Medical Journal 
ii: 1485–96.
Morris J N, Dale R A. (1955) Epidemiology of coronary atherosclerosis. 
Proceedings of the Royal Society of Medicine 48: 667–73.
Morris J N, Raffl e P A B. (1954) Coronary heart disease in transport workers: a 
progress report. British Journal of Industrial Medicine 11: 260–4. 
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
108
Morris J N, Heady J A, Barley R G. (1952) Coronary heart disease in medical 
practitioners. British Medical Journal i: 503–20.
Morris J N, Heady J A, Raffl e P A, Roberts C G, Parks J W. (1953) Coronary 
heart-disease and physical activity of work. Lancet 265: 1053–7; 1111–20.
Morris J N, Everitt M G, Pollard R, Chave S P, Semmence A M. (1980) Vigorous 
exercise in leisure-time: protection against coronary heart disease. Lancet 
ii: 1207–10.
Morris J N, Chave S P, Adam C, Sirey C, Epstein L, Sheehan D J. (1973) 
Vigorous exercise in leisure-time and the incidence of coronary heart disease. 
Lancet i: 333–9. 
Moschcowitz E. (1942) Vascular Sclerosis with special reference to arteriosclerosis. 
New York, NY: Oxford University Press. 
Müller C. (1939) Angina pectoris in hereditary xanthomatosis. Archives of 
Internal Medicine 64: 675–700.
Mullis K B. (1990) The unusual origin of the polymerase chain reaction. 
Scientifi c American 262: 56–65.
Mullis K B, Faloona F, Scharf S, Saiki R, Horn G, Erlich H. (1986) Specifi c 
enzymatic amplifi cation of DNA in vitro: the polymerase chain reaction. 
Cold Spring Harbor Symposia on Quantitative Biology 51: 263–73. 
Multicentre Anti-Atheroma Study (MAAS). (1994) Effect of simvastatin on 
coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 
344: 633–8. Erratum in Lancet 344: 762.
Multiple Risk Factor Intervention Trial (MRFIT). (1976) The multiple risk 
factor intervention trial (MRFIT). A national study of primary prevention 
of coronary heart disease. Journal of the American Medical Association 
235: 825–7.
Multiple Risk Factor Intervention Trial Research Group (1982) Multiple risk 
factor intervention trial. Risk factor changes and mortality results. Journal of 
the American Medical Association 248: 1465–77.
Myant N B. (1990a) Cholesterol Metabolism, LDL and the LDL Receptor. 
San Diego, CA; London: Academic Press.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
109
Myant N B. (1990b) Current approaches to the genetics of coronary heart disease 
(CHD) including an account of work done at Hammersmith Hospital. 
Bollettino della Societa Italiana di Biologia Sperimentale 66: 1015–41.
Myant N B. (1993) Familial defective apolipoprotein B-100: a review, including 
some comparisons with familial hypercholesterolaemia. Atherosclerosis 
104: 1–18.
Neroth P. (2005) Interview: Advice from the heart. New Scientist 185(2486): 
44–7. Freely available at www.newscientist.com/channel/opinion/
mg18524861.700.html (visited 21 November 2005).
Ness A R, Reynolds L A, Tansey E M. (eds) (2002) Population-based Research 
in South Wales: The MRC Pneumoconiosis Research Unit and the MRC 
Epidemiology Unit. Wellcome Witnesses to Twentieth Century Medicine, vol. 
13. London: The Wellcome Trust Centre for the History of Medicine at 
UCL. Freely available from www.ucl.ac.uk/histmed following links to 
Publications/Wellcome Witnesses.
Nevin N C, Slack J. (1968) Hyperlipidaemic xanthomatosis: II. Mode of 
inheritance in 55 families with essential hyperlipidaemia and xanthomatosis. 
Journal of Medical Genetics 5: 9–28.
New M I, Roberts T N, Bierman E L, Reader G G. (1963) The signifi cance of 
blood lipid alterations in diabetes mellitus. Diabetes 12: 208–12.
Nikkilä E A. (1953) Studies on the lipid-protein relationship in normal 
and pathological sera and the effect of heparin on serum lipoproteins. 
Scandinavian Journal of Clinical and Laboratory Investigation 5: 9–100.
Nikkilä E A, Hormila P. (1978) Serum lipids and lipoproteins in insulin-
treated diabetes. Demonstration of increased high-density lipoprotein 
concentrations. Diabetes 27: 1078–86.
Oliver M F. (1962a) Reduction of serum lipid and uric acid levels by an orally 
active androsterone. Lancet i: 1321–3. 
Oliver M F. (1962b) Further observations of the effects of Atromid and of 
ethylchlorophenoxyisobutyrate on serum lipid levels. Journal of Atherosclerosis 
Research 3: 427–44.
Oliver M F, Boyd G S. (1953a) Changes in the plasma lipids during the 
menstrual cycle. Clinical Science 12: 217–22. 
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
110
Oliver M F, Boyd G S. (1953b) The clearing by heparin of alimentary lipaemia 
in coronary artery disease. Clinical Science 12: 293–8.
Oliver M F, Boyd G S. (1953c) The plasma lipids in coronary artery disease. 
British Heart Journal 15: 387–92. The communication to the British 
Cardiac Society was published on page 466, the full article appears in the 
same volume.
Oliver M F, Boyd G S. (1955) Serum lipoprotein patterns in coronary sclerosis 
and associated conditions. British Heart Journal 17: 299–302.
Oliver M F, Boyd G S. (1961) Infl uence of reduction of serum lipids on 
prognosis of coronary artery disease – a fi ve-year study using oestrogen. 
Lancet ii: 499–505. 
Osler W. (1910) Lumleian Lecture: angina pectoris. Lancet i: 697–702.
Padley F B, Timms R E. (1978) Determination of cocoa butter equivalents in 
chocolate. Chemistry and industry (23): 918–19. 
Paneth N, Susser M. (1995) Editorial: Early origin of coronary heart disease 
(the ‘Barker hypothesis’). British Medical Journal 310: 411–12.
Patterson D, Slack J. (1972) Lipid abnormalities in male and female survivors 
of myocardial infarction and their fi rst-degree relatives. Lancet i: 393–9.
Pietinen P, Aro A, Tuomilehto J, Uusitalo U, Korhonen H. (1990) Consumption 
of boiled coffee is correlated with serum cholesterol in Finland. International 
Journal of Epidemiology 19: 586–90. 
Pitas R E, Innerarity T L, Arnold K S, Mahley R W. (1979) Rate and equilibrium 
constants for binding of apo-E HDLc (a cholesterol-induced lipoprotein) 
and low density lipoproteins to human fi broblasts: evidence for multiple 
receptor binding of apo-E HDLc. Proceedings of the National Academy of 
Sciences of the USA 76: 2311–15. 
Pooling Project Research Group. (1978) Relationship of blood pressure, 
serum cholesterol, smoking habit, relative weight and ECG abnormalities 
to incidence of major coronary events: fi nal report of the pooling project. 
Journal of Chronic Diseases 31: 201–306. 
Popják G. (1958) Biosynthesis of cholesterol. British Medicial Bulletin 14: 221–6.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
111
Powell L M, Wallis S C, Pease R J, Edwards Y H, Knott T J, Scott J. (1987) A 
novel form of tissue-specifi c RNA processing produces apolipoprotein-B48 
in intestine. Cell 50: 831–40.
Price F W. (1950) A Textbook of the Practice of Medicine. 8th edn. Oxford Medical 
Publications series. London: Oxford University Press.
Principal Investigators. (1978) A cooperative trial in the primary prevention 
of ischaemic heart disease using clofi brate. Report of the Committee of 
Principal Investigators. British Heart Journal 40: 1069–118.
Principal Investigators. (1984) WHO cooperative trial on primary prevention 
of ischaemic heart disease with clofi brate to lower serum cholesterol: fi nal 
mortality follow-up. Report of the Committee of Principal Investigators. 
Lancet ii: 600–4.
Prospective Pravastatin Pooling (PPP) project. (1995) Design, rational, and 
baseline characteristics of the Prospective Pravastatin Pooling (PPP) project 
– a combined analysis of three large-scale randomized trials: Long-term 
Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and 
Recurrent Events (CARE), and West of Scotland Coronary Prevention Study 
(WOSCOPS). American Journal of Cardiology 76: 899–905. 
Puska P, Tuomilehto J, Salonen J, Nissinen A, Koskela K, Vartiainen E, 
et al. (1981) Community Control of Cardiovascular Disease: Evaluation of 
a comprehensive community programme for control of cardiovascular diseases 
in North Karelia, Finland, 1972–77. Copenhagen: World Health 
Organization, Regional Offi ce for Europe, for the National Public Health 
Laboratory of Finland. 
Randle P J, Bell J, Scott J. (eds) (1990) Genetics and Human Nutrition: 
International symposium papers. London: John Libbey.
Raz I, Havivi Y, Yarom R. (1998) Reduced negative surface charge on arterial 
endothelium of diabetic rats. Diabetologia 31: 618–20.
Reaven G M. (1988) Banting Lecture 1988: Role of insulin resistance in human 
disease. Diabetes 37: 1595–607. 
Reckless J P, Galton D J. (1980) Peripheral resistance to the cellular action of 
insulin in obese diabetic subjects in vivo. Clinical Science 58: 59–63. 
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
112
Reckless J P, Betteridge D J, Wu P, Payne B, Galton D J. (1978) High-density 
and low-density lipoproteins and prevalence of vascular disease in diabetes 
mellitus. British Medical Journal i: 883–6.
Rees A, Shoulders C C, Stocks J, Galton D J, Baralle F E. (1983) DNA 
polymorphism adjacent to human apoprotein A-1 gene: relation to 
hypertriglyceridaemia. Lancet i: 444–6.
Rees A, Stocks J, Sharpe C R, Vella M A, Shoulders C C, Katz J, Jowett N 
I,Baralle F E, Galton D J. (1985) Deoxyribonucleic acid polymorphism in the 
apolipoprotein A-1-C-III gene cluster. Association with hypertriglyceridemia. 
Journal of Clinical Investigation 76: 1090–5. 
Reynolds L A, Tansey E M. (eds) (2000) Clinical Research in Britain, 
1950–80. Wellcome Witnesses to Twentieth Century Medicine, vol. 7. London: 
The Wellcome Trust. Freely available online at www.ucl.ac.uk/histmed 
following the links to Publications/Wellcome Witnesses.
Reynolds L A, Tansey E M. (eds) (2005) The Recent History of Platelets in 
Thrombosis and Other Disorders. Wellcome Witnesses to Twentieth Century 
Medicine, vol. 23. London: The Wellcome Trust Centre for the History 
of Medicine at UCL. Freely available online at www.ucl.ac.uk/histmed 
following the links to Publications/Wellcome Witnesses. 
Richardson P D, Davies M J, Born G V R. (1989) Infl uence of plaque 
confi guration and stress distribution on fi ssuring of coronary atherosclerotic 
plaques. Lancet ii: 941–4.
Richmond W. (1973) Preparation and properties of a cholesterol oxidase from 
Nocardia sp. and its application to the enzymatic assay of total cholesterol in 
serum. Clinical Chemistry 19: 1350–6.
Richmond W. (1974) Proceedings: The development of an enzymic technique 
for the assay of cholesterol in biological fl uids. Clinical Science and Molecular 
Medicine 46: 6P–7P.
Richmond W. (1976) Use of cholesterol oxidase for assay of total and free 
cholesterol in serum by continuous-fl ow analysis. Clinical Chemistry 
22: 1579–88.
Rifkind B M, Segal P. (1983) Lipid Research Clinics Program reference values 
for hyperlipidemia and hypolipidemia. Journal of the American Medical 
Association 250: 1869–72.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
113
Robertson F W, Cumming A M. (1985) Effects of apoprotein E polymorphism 
on serum lipoprotein concentration. Arteriosclerosis 5: 283–92. 
Robertson G, Cramp D G. (1970) An evaluation of cholesterol determinations 
in serum and serum lipoprotein fractions by a semi-automated fl uorimetric 
method. Journal of Clinical Pathology 23: 243–5.
Rose G A. (1964) Familial patterns in ischaemic heart disease. British Journal of 
Preventive and Social Medicine 18: 75–80.
Rose G A. (1981) Strategy of prevention: lessons from cardiovascular disease. 
British Medical Journal 282: 1847–51.
Rose G A, Heller R F, Pedoe H T, Christie D G. (1980) Heart disease prevention 
project: a randomized controlled trial in industry. British Medical Journal 
280: 747–51.
Rose G A, Blackburn H, Keys A, Taylor H L, Kannel W B, Paul O, Reid D D, 
Stamler J. (1974) Colon cancer and blood-cholesterol. Lancet i: 181–3.
Royal College of Physicians of London and the British Cardiac Society. (1976) 
Prevention of Coronary Heart Disease: Report of a Joint Working Party. 
London: Royal College of Physicians of London. Dr A G Shaper, Chairman. 
Originally published in the Journal of the Royal College of Physicians (1975) 
10: 213–75. 
Royal Pharmaceutical Society, practice division. (2004) Practice guidance: OTC 
simvastatin 10mg. Pharmaceutical Journal 273: 169–70.
Rubins H B, Robins S J, Collins D, Fye C L, Anderson J W, Elam M B, Faas 
F H, Linares E, Schaefer E J, Schectman G, Wilt T J, Wittes J, for the 
Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial 
Study Group. (1999) Gemfi brozil for the secondary prevention of coronary 
heart disease in men with low levels of high-density lipoprotein cholesterol. 
New England Journal of Medicine 341: 410–18.
Ryle J A, Russell W T. (1949) The natural history of coronary disease. British 
Heart Journal 11: 370–8.
Sacks F M, Pfeffer M A, Moye L A, Brown L E, Hamm P, Cole T G, Hawkins 
C M, Braunwald E. (1992) Rationale and design of a secondary prevention 
trial of lowering normal plasma cholesterol levels after acute myocardial 
infarction: the Cholesterol and Recurrent Events trial (CARE). American 
Journal of Cardiology 68: 1436–46. Erratum in American Journal of Cardiology 
69: 574. 
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
114
Sacks F M, Pfeffer M A, Moye L A, Rouleau J L, Rutherford J D, Cole T G, 
Brown L E, Warnica J W, Arnold J M, Wun C C, Davis B R, Braunwald E. 
(1996) The effect of pravastatin on coronary events after myocardial infarction 
in patients with average cholesterol levels. Cholesterol and Recurrent Events 
Trial investigators. New England Journal of Medicine 335: 1001–9.
Sanders T A B. (1987) Diet and coronary heart disease. Journal of the Royal 
Society of Health 107: 163–5. 
Sanders T A B. (1988) Dietary fat and coronary heart disease. In Dobbing J. 
(ed.) A Balanced Diet. Berlin, Heidelberg: Springer-Verlag, 993–1116.
Sanders T A B. (2001) A life of good taste. Nature 413: 360–1.
Sanders T A B, Ellis F R, Dickerson J W. (1978) Studies of vegans: the fatty acid 
composition of plasma choline phosphoglycerides, erythrocytes, adipose 
tissue, and breast milk, and some indicators of susceptibility to ischemic 
heart disease in vegans and omnivore controls. American Journal of Clinical 
Nutrition 31: 805–13.
Scandinavian Simvastatin Survival Study (4S). (1993) Design and baseline 
results of the Scandinavian Simvastatin Survival Study of patients with stable 
angina and/or previous myocardial infarction. American Journal of Cardiology 
71: 393–400. 
Scandinavian Simvastatin Survival Study (4S). (1994) Randomized trial of 
cholesterol lowering in 4444 patients with coronary heart disease. Lancet 
344: 1383–9.
Schaffner C P, Gordon H W. (1968) The hypocholesterolemic activity of orally-
administered polyene macrolides. Proceedings of the National Academy of 
Sciences of the USA 61: 36–41.
Segrest J P, Jackson R L, Morrisett J D, Gotto A M Jr. (1974) A molecular 
theory of lipid-protein interactions in the plasma lipoproteins. FEBS Letters 
38: 247–58.
Shaper A G. (1962) Cardiovascular studies in the Samburu tribe of Northern 
Kenya. American Heart Journal 63: 437–42.
Shaper A G. (1972) Diet in the epidemiology of coronary heart disease. 
Proceedings of the Nutrition Society 31: 297–302. 
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
115
Shaper A G, Jones K W, Jones M, Kyobe J. (1963) Serum lipids in three 
nomadic tribes of northern Kenya. American Journal of Clinical Nutrition 
13: 135–46.
Shaper A G, Jones K W, Kyobe J, Jones M. (1966) Fibrinolysis in relation to 
body fatness, serum lipids and coronary heart disease in African and Asian 
men in Uganda. Journal of Atherosclerosis Research 6: 313–27.
Shepherd J, Bicker S, Lorimer A R, Packard C J. (1979) Receptor-mediated 
low-density lipoprotein catabolism in man. Journal of Lipid Research 
20: 999–1006.
Shepherd J, Cobbe S M, Ford I, Isles C G, Lorimer A R, MacFarlane P W, 
McKillop J H, Packard C J. (1995) Prevention of coronary heart disease with 
pravastatin in men with hypercholesterolemia. West of Scotland Coronary 
Prevention Study Group. New England Journal of Medicine 333: 1301–7.
Shepherd J, Blauw G J, Murphy M B, Cobbe S M, Bollen E L, Buckley B M, 
Ford I, Jukema J W, Hyland M, Gaw A, Lagaay A M, Perry I J, Macfarlane 
P W, Meinders A E, Sweeney B J, Packard C J, Westendorp R G, Twomey 
C, Stott D J. (1999) The design of a prospective study of Pravastatin in the 
Elderly at Risk (PROSPER). PROSPER Study Group. American Journal of 
Cardiology 84: 1192–7.
Shoulders C C, Baralle F E. (1982) Isolation of the human HDL apoprotein A1 
gene. Nucleic Acids Research 10: 4873–82.
Simionescu M. (1980) Structural and functional differentiation of microvascular 
endothelium. Ciba Foundation Symposium 71: 39–60.
Simpson H C, Simpson R W, Lousley S, Carter R D, Geekie M, Hockaday 
T D, Mann J I. (1981) A high carbohydrate leguminous fi bre diet improves 
all aspects of diabetic control. Lancet i: 1–5.
Sinclair H M. (1956) Defi ciency of essential fatty acids and atherosclerosis 
etcetera. Lancet i: 381–3.
Sing C F, Davignon J. (1985) Role of the apolipoprotein E polymorphism in 
determining normal plasma lipid and lipoprotein variation. American Journal 
of Human Genetics 37: 268–85.
Siperstein M D, Fagan V M. (1964) Studies on the feedback regulation of 
cholesterol synthesis. Advances in Enzyme Regulation 2: 249–64.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
116
Slack J. (1969) Risks of ischaemic heart disease in familial hyperlipoproteinaemic 
states. Lancet ii: 1380–2.
Slack J, Evans K A. (1966) The increased risk of death from ischaemic heart 
disease in fi rst degree relatives of 121 men and 96 women with ischaemic 
heart disease. Journal of Medical Genetics 3: 239–57. 
Slack J, Nevin N C. (1968) Hyperlipidaemic xanthomatosis: I. Increased risk of 
death from ischaemic heart disease in fi rst degree relatives of 53 patients with 
essential hyperlipidaemia and xanthomatosis. Journal of Medical Genetics 
5: 4–8. 
Smith E B. (1965) The infl uence of age and atherosclerosis on the chemistry of 
aortic intima. 1. The lipids. Journal of Atherosclerosis Research 5: 224–40.
Smith E B, Ashall C. (1983) Low-density lipoprotein concentration in 
interstitial fl uid from human atherosclerotic lesions. Relation to theories of 
endothelial damage and lipoprotein binding. Biochimica et Biophysica Acta 
754: 249–57. 
Smith E B, Slater R S. (1972) Relationship between low-density lipoprotein in 
aortic intima and serum-lipid levels. Lancet i: 463–9. 
Smith E B, Staples E M. (1980) Distribution of plasma proteins across the 
human aortic wall – barrier functions of endothelium and internal elastic 
lamina. Atherosclerosis  37: 579–90.
Smith E B, Staples E M. (1982) Plasma protein concentrations in interstitial 
fl uid from human aortas. Proceedings of the Royal Society of London, Series B, 
Biological Sciences 217: 59–75. 
Smith E B, Evans P H, Downham M D. (1967) Lipid in the aortic intima. 
The correlation of morphological and chemical characteristics. Journal of 
Atherosclerosis Research 7: 171–86.
Smith L C, Pownall H J, Gotto AM Jr. (1978) The plasma lipoproteins: structure 
and metabolism. Annual Review of Biochemistry 47: 751–7.
Soutar A K, Myant N B, Thompson G R. (1977) Simultaneous measurement 
of apolipoprotein B turnover in very-low-and low-density lipoproteins in 
familial hypercholesterolaemia. Atherosclerosis 28: 247–56. 
Southern E M. (1975) Detection of specifi c sequences among DNA fragments 
separated by gel electrophoresis. Journal of Molecular Biology 98: 503–17. 
Reprinted in Biotechnology (1992) 24: 122–39.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
117
Steel F. (2005) A source of our wealth, yet adverse to our health? Butter and the 
diet–heart link in New Zealand. Social History of Medicine 18: 475–93.
Stein O, Stein Y, Eisenberg S. (1973) A radioautograph study of the transport 
of 125I-labelled serum glycoproteins in rat aorta. Zeitschrift fur Zellforschung 
und mikroskopische Anatomie 138: 223–37.
Steinberg D. (2004) Thematic review series: the pathogenesis of atherosclerosis. 
An interpretive history of the cholesterol controversy, part I. Journal of Lipid 
Research 45: 1583–93. 
Steinberg D. (2005a) The pathogenesis of atherosclerosis, part II: the early 
evidence linking hypercholesterolemia to coronary disease in humans. 
Journal of Lipid Research 46: 179–90. 
Steinberg D. (2005b) The pathogenesis of atherosclerosis, part III: mechanistically 
defi ning the role of hyperlipidemia. Journal of Lipid Research 46: 2037–51. 
Steinberg D. (2006) The pathogenesis of atherosclerosis, part IV: the 1984 
coronary primary prevention trial ends it – almost. Journal of Lipid Research 
47: 1–14.
Strandberg T E, Pyörälä K, Cook T J, Wilhelmsen L, Faergeman O, Thorgeirsson 
G, Pedersen T R, Kjekshus J (4S Group). (2004) Mortality and incidence 
of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival 
Study (4S). Lancet 364: 771–7. 
van Stuyvenberg J H. (1969) Margarine: An economic, social and scientifi c history, 
1869–1969. Liverpool: Liverpool University Press.
Swales J D. (ed.) (1985) Platt versus Pickering: An episode in recent medical history. 
London: Keynes Press for the British Medical Association.
Tang J L, Armitage J M, Lancaster T, Silagy C A, Fowler G H, Neil H A. 
(1998) Systematic review of dietary intervention trials to lower blood total 
cholesterol in free-living subjects. British Medical Journal 316: 1213–20.
Tansey E M, Catterall P P. (1997) Technology Transfer in Britain: The case of 
Monoclonal Antibodies. In Tansey E M, Catterall P P, Christie D A, Willhoft 
S V, Reynolds L A. (eds) (1997) Wellcome Witnesses to Twentieth Century 
Medicine, vol. 1. London: The Wellcome Trust, 1–34. Freely available online 
at www.ucl.ac.uk/histmed following the links to Publications/Wellcome 
Witnesses.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
118
Tansey E M, Christie D A. (eds) (1999) Haemophilia: Recent history of 
clinical management. Wellcome Witnesses to Twentieth Century Medicine, vol. 
4. London: The Wellcome Trust. Freely available online at www.ucl.ac.uk/
histmed following the links to Publications/Wellcome Witnesses.
Tansey E M, Reynolds L A. (1997) The Committee on Safety of Drugs. In 
Tansey E M, Catterall P P, Christie D A, Willhoft S V, Reynolds L A. (eds) 
(1997) Wellcome Witnesses to Twentieth Century Medicine, vol. 1. London: 
The Wellcome Trust, 103–35. Freely available online at www.ucl.ac.uk/
histmed following the links to Publications/Wellcome Witnesses.
Thannhauser S J. (1940) Lipoidoses. New York, NY: Oxford University Press.
Thannhauser S J. (1950) Lipoidoses: Diseases of the cellular lipid metabolism. 2nd 
edn. New York, NY: Oxford University Press.
Thompson G R. (1974) Beware sweet reason in the search for causes of heart 
disease. The Times (31 July): 16.
Thompson G R. (1983) Plasma exchange and affi nity chromatographic therapy 
for hyperlipidaemia: a review. Apheresis Bulletin 1: 26–31.
Thompson G R. (1999) Hammersmith Marathon. London: Royal Society of 
Medicine Press.
Thompson G R, Lewis B, Booth C C. (1966) Absorption of vitamin D3-3H 
in control subjects and patients with intestinal malabsorption. Journal of 
Clinical Investigation 45: 94–102.
Thompson G R, Lowenthal R, Myant N B. (1975) Plasma exchange in the 
management of homozygous familial hypercholesterolaemia. Lancet 
i: 1208–11.
Thompson G R, Miller J P, Breslow J L. (1985) Improved survival of patients 
with homozygous familial hypercholesterolaemia treated with plasma 
exchange. British Medical Journal 291: 1671–3.
Thompson G R, Ford J, Jenkinson M, Trayner I. (1986) Effi cacy of mevinolin 
as adjuvant therapy for refractory familial hypercholesterolaemia. Quarterly 
Journal of Medicine 60: 803–11.
Thompson G R, Myant N B, Kilpatrick D, Oakley C M, Raphael M J, 
Steiner R E. (1980) Assessment of long-term plasma exchange for familial 
hypercholesterolaemia. British Heart Journal 43: 680–8.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
119
Thomson A L. (1975, 1987) Half a Century of Medical Research: vol. 2. The 
programme of the Medical Research Council (UK). London: Medical Research 
Council.
Thorp J M, Waring W S. (1962) Modifi cation of metabolism and distribution 
of lipids by ethyl chlorophenoxyisobutyrate. Nature 194: 948–9.
Tobert J A. (1987) New developments in lipid-lowering therapy: the role of 
inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 
76: 534–8.
Tobert J A. (2003) Lovastatin and beyond: the history of the HMG-CoA 
reductase inhibitors. Nature Reviews-Drug Discovery 2: 517–26.
Tobert J A, Hitzenberger G, Kukovetz W R, Holmes I B, Jones K H. (1982a) 
Rapid and substantial lowering of human serum cholesterol by mevinolin 
(MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. 
Atherosclerosis 41: 61–5.
Tobert J A, Bell G D, Birtwell J, James I, Kukovetz W R, Pryor J S, Buntinx A, 
Holmes I B, Chao Y S, Bolognese J A. (1982b) Cholesterol-lowering effect of 
mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, 
in healthy volunteers. Journal of Clinical Investigation 69: 913–19.
Truswell A S. (1984) Editorial: end of static decade for coronary disease? British 
Medical Journal 289: 509–10.
Tunstall-Pedoe H. (1975) Proceedings: Myocardial infarction in east London. 
British Heart Journal 37: 550–1. 
Tunstall-Pedoe H. (1978) Uses of coronary heart attack registers. British Heart 
Journal 40: 510–15. 
Tunstall-Pedoe H. (1980) Decline in mortality from coronary heart disease in 
America. Lancet i: 831.
Tunstall-Pedoe H, Clayton D, Morris J N, Brigden W, McDonald L. (1975) 
Coronary heart attacks in east London. Lancet ii: 833–8.
Tunstall-Pedoe H. (ed.) (2003) MONICA [MONItoring of trends and 
determinants in CArdiovascular disease] Monograph and Multimedia 
Sourcebook. World’s Largest Study of Heart Disease, Stroke, Risk Factors and 
Population Trends 1979–2003. Geneva: World Health Organization.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
120
Turnberg L A, Mahoney M P, Gleeson M H, Freeman C B, Gowenlock A 
H. (1972) Plasmaphoresis and plasma exchange in the treatment of 
hyperlipaemia and xanthomatous neuropathy in patients with primary 
biliary cirrhosis. Gut 13: 976–81.
Turnbull H M. (1915) Alterations in arterial structure and their relation to 
syphilis. Quarterly Journal of Medicine 8: 201–54.
Turnbull H M. (1920) Report to the Salvarsan Committee. I. Results of the 
examination of tissues from eight cases of death following injections of 
salvarsan. Special report series no. 55. London: HMSO.
UK Prospective Diabetes Study (UKPDS). (1991) VIII. Study design, progress 
and performance. Diabetologia 34: 877–90. 
Upritchard J E, Zeelenberg M J, Huizinga H, Verschuren P M, Trautwein 
E A. (2005) Modern fat technology: what is the potential for heart health? 
Proceedings of the Nutrition Society 64: 379–86.
Utermann G, Jaeschke M, Menzel J. (1975) Familial hyperlipoproteinemia type 
III: defi ciency of a specifi c apolipoprotein (apoEIII) in the very-low-density 
lipoproteins. FEBS Letters 56: 352–5.
Vagelos R, Galambos L. (2004) Medicine, Science and Merck. Cambridge; 
New York, NY: Cambridge University Press.
Vasile E, Simionescu M, Simionescu N. (1983) Visualization of the binding, 
endocytosis, and transcytosis of low-density lipoprotein in the arterial 
endothelium in situ. Journal of Cell Biology 96: 1677–89.
Venn B J, Mann J I. (2004) Cereal grains, legumes and diabetes. European 
Journal of Clinical Nutrition 58: 1443–61.
Walker J F, Tobert J A. (1987) The clinical effi cacy and safety of lovastatin and 
MK-733: an overview. European Heart Journal 8 Suppl E: 93–6.
Walton K W, Scott P J. (1964) Estimation of the low-density (beta) lipoproteins 
of serum in health and disease using large molecular weight dextran sulphate. 
Journal of Clinical Pathology 17: 627–43. 
Watts G F, Lewis B, Brunt J N, Lewis E S, Coltart D J, Smith L D, Mann J I, 
Swan A V. (1992) Effects on coronary artery disease of lipid-lowering diet, 
or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression 
Study (STARS). Lancet 339: 563–9.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
121
Weisgraber K H, Innerarity T L, Mahley R W. (1978) Role of lysine residues 
of plasma lipoproteins in high affi nity binding to cell surface receptors on 
human fi broblasts. Journal of Biological Chemistry 253: 9053–62.
West of Scotland Coronary Prevention Study Group (WOSCOPS). (1995) 
Screening experience and baseline characteristics in the West of Scotland 
Coronary Prevention Study. The West of Scotland Coronary Prevention 
Study. American Journal of Cardiology 76: 485–91.
West of Scotland Coronary Prevention Study Group (WOSCOPS). (1997) 
Baseline risk factors and their association with outcome in the West of 
Scotland Coronary Prevention Study. American Journal of Cardiology 
79: 756–62.
Westlund K, Nicolaysen R. (1966) Serum cholesterol and risk of mortality and 
morbidity. A 3-year follow-up of 6886 men. Scandinavian Journal of Clinical 
and Laboratory Investigation, Supplementum 87: 1–19. 
White P D. (1947) Heart Disease. 3rd edn. New York, NY: Macmillan.
Wilkes H C, Meade T W, Barzegar S, Foley A J, Hughes L O, Bauer K A, 
Rosenberg R D, Miller G J. (1992) Gemfi brozil reduces plasma prothrombin 
fragment F1 + 2 concentration, a marker of coagulability, in patients with 
coronary heart disease. Thrombosis and Haemostasis 67: 503–6.
Wood P H. (1950) Diseases of the Heart and Circulation. The Practitioner series. 
London: Eyre and Spottiswoode.
Woolf N, Pilkington T R. (1965) The immunohistochemical demonstration of 
lipoproteins in vessel walls. Journal of Pathology and Bacteriology 90: 459–63. 
Wright H P. (1941) Adhesiveness of blood platelets in normal subjects with 
varying concentration of anticoagulants. Journal of Pathology and Bacteriology 
53: 255–62.
Wright L D, Cresson E L, Skeggs H R, MacRae G D E, Hoffman C H, Wolf 
D E, Folkers K. (1956) Isolation of a new acetate-replacing factor. Journal of 
the American Chemical Society 78: 5273–5.
Writing Group for the Women’s Health Initiative Investigators. (2002) Risks 
and benefi ts of estrogen plus progestin in healthy postmenopausal women: 
Principal results from the Women’s Health Initiative Randomized Controlled 
Trial. Journal of the American Medical Association 288: 321–33.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – References
122
Yudkin J. (1958) This Slimming Business. London: MacGibbon and Kee. 
Yudkin J. (1964) Dietary fat and dietary sugar in relation to ischaemic heart 
disease and diabetes. Lancet 41: 4–5.
Yudkin J. (1972) Pure, White and Deadly: The problem of sugar. London: 
Davis-Poynter.
Yudkin J. (1974) Why suspicion falls on sugar as a major cause of heart disease. 
The Times (11 July): 16.
Yudkin J. (1985) The Penguin Encyclopedia of Nutrition. Harmondsworth: 
Viking.
Yudkin J S. (1993) Circulating proinsulin-like molecules. Journal of Diabetes 
and its Complications 7: 113–23.
Yudkin J S. (2000) Relationship of serum C3 complement with insulin resistance 
and coronary heart disease – cause, consequence or common antecedent? 
European Heart Journal 21: 1036–9.
Yudkin J S, May M, Elwood P, Yarnell J W, Greenwood R, Davey Smith G 
(Caerphilly Study). (2002) Concentrations of proinsulin like molecules 
predict coronary heart disease risk independently of insulin: prospective data 
from the Caerphilly Study. Diabetologia 45: 327–36.
Zannis V I, Just P W, Breslow J L. (1981) Human apolipoprotein E isoprotein 
subclasses are genetically determined. American Journal of Human Genetics 
33: 11–24.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – Biographical notes
123
 
Professor David Barker
CBE MD PhD FRCP FRS 
(b. 1938) has been Professor 
of Clinical Epidemiology at 
the University of Southampton 
since 1972, and Professor in 
the Department of Medicine of 
the Oregon Health in Science 
University, USA, since 2003. From 
1982–2003 he was Director of the 
MRC Environmental 
Epidemiology Unit at the 
University of Southampton.
Professor John Betteridge
MD PhD FRCP (b. 1948) is 
Professor of Endocrinology and 
Metabolism at the Royal Free 
and University College School 
of Medicine, London. He was 
appointed honorary physician 
to University College Hospital 
in 1981. He is a past chairman 
of the British Hyperlipidaemia 
Association (now HEART UK) 
and a past president of the Royal 
Society of Medicine’s section on 
lipids in clinical medicine. He was 
R D Lawrence Fellow of the British 
Diabetic Association (now 
Diabetes UK).
Sir Christopher Booth
Kt FRCP (b. 1924) trained as 
a gastroenterologist and was 
Professor of Medicine at the 
Royal Postgraduate Medical 
School, Hammersmith Hospital, 
London, from 1966 to 1977 and 
Director of the Medical Research 
Council’s Clinical Research Centre, 
Northwick Park Hospital, Harrow, 
from 1978 to 1988. He was the 
fi rst Convenor of the Wellcome 
Trust’s History of Twentieth 
Century Medicine Group, from 
1990 to 1996, and Harveian 
Librarian at the Royal College of 
Physicians from 1989 to 1997.
Professor Gustav Born
FRCP HonFRCS FRS (b. 1921) 
was Vandervell Professor of 
Pharmacology at the Royal College 
of Surgeons from 1960 to 1973; 
Sheild Professor of Pharmacology 
at the University of Cambridge, 
and Fellow of Gonville and 
Caius College, Cambridge, from 
1973 to 1978 and Professor of 
Pharmacology at King’s College, 
London, from 1978 to 1986, later 
Emeritus. He is currently Research 
Professor at the William Harvey 
Research Institute, Bart’s and the 
Biographical notes*
* Contributors are asked to supply details; other entries are compiled from conventional 
biographical sources. 
124
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – Biographical notes
Royal London School 
of Medicine and Dentistry, 
University of London. He was 
the Founding President of the 
British Society of Haemostasis 
and Thrombosis from 1979 to 
1981. One of the handmade 
aggregometers is in the Düsseldorf 
Academy of Science Museum. For 
further details of his work with the 
optical aggregometer, see Reynolds 
and Tansey (eds) (2005).
Professor George Boyd
PhD FRSE (1924–83) educated 
at Heriot-Watt and Edinburgh 
University, he obtained his PhD 
in 1951 and became a lecturer 
in biochemistry with Professor 
Guy Marrian FRS. He worked 
on cholesterol metabolism with 
Michael Oliver until 1960, when 
he became a senior lecturer in 
biochemistry, receiving a personal 
chair in 1970 and in 1976 became 
Chairman of the University 
of Edinburgh Department of 
Biochemistry until his death in 
1983. From 1969, he was Director 
of the MRC Group on Sterol 
Metabolism, a member of the 
MRC Physiological Systems Board, 
1980–83, and Vice-President of the 
Royal Society of Edinburgh from 
1980–83.
Professor Sydney Brenner
CH FRCP Hon FRCPath FRS 
(b. 1927) shared the 2002 Nobel 
Prize in Physiology or Medicine 
equally with H Robert Horvitz 
and John E Sulston ‘for their 
discoveries concerning genetic 
regulation of organ development 
and programmed cell death’. He 
qualifi ed at the University of 
Witwatersrand and Oxford, was 
a member of the scientifi c staff 
of the Medical Research Council 
from 1957 to 1992, and a Fellow 
of King’s College, Cambridge, 
since 1959. He directed the MRC 
Laboratory of Molecular Biology, 
Cambridge from 1979 to 1986 
and the MRC Molecular Genetics 
Unit, Cambridge, 1986 to 1992, 
when he moved to the Scripps 
Research Institute in La Jolla, 
California, in 1992, becoming 
President and Director of Research 
at the Molecular Sciences Institute, 
Berkeley, from 1996 to 2001. He 
has been Distinguished Research 
Professor at the Salk Institute, La 
Jolla, since 2001. In 2000 he was 
awarded the Albert Lasker Award 
for Special Achievement. See 
Brenner (2001). 
Professor Brian Bronte-Stewart
MD MRCP (1923–65) qualifi ed in 
medicine in 1944 at the University 
of Cape Town, South Africa, and 
trained at Groote Schuur Hospital, 
Cape Town. He started research 
into the role of cholesterol in 
the causation of atheroma while 
at St Mary’s Hospital, London 
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – Biographical notes
125
under Sir George Pickering and 
later with Ancel Keys on dietary 
infl uences on cholesterol. In 1961, 
Sir Harold Himsworth persuaded 
him to become Director of the 
newly established Medical Research 
Council Atheroma Research Unit 
in the Western Infi rmary, Glasgow, 
for four years until his death from 
cancer at the age of 42 in 1965. 
Professor Michael Brown 
MD (b. 1941) graduated in 
chemistry from the University 
of Pennsylvania and in 1966 
met Joseph L Goldstein, a fellow 
intern in Internal Medicine 
at the Massachusetts General 
Hospital in Boston. He was at the 
National Institutes of Health, from 
1968, moving to the division of 
gastroenterology in the Department 
of Internal Medicine, University 
of Texas Southwestern Medical 
School, Dallas, in 1971. There 
he succeeded in solubilizing and 
partially purifying an enzyme 
that catalyses the rate-controlling 
enzyme in cholesterol biosynthesis. 
He and Goldstein developed the 
hypothesis that abnormalities 
in the regulation of this enzyme 
were the cause of familial 
hypercholesterolaemia, and began 
collaborating in 1972 in Dallas, 
although their separate laboratories 
did not join until 1974. Brown 
was appointed Professor of Internal 
Medicine in 1976 and a year 
later as Paul Thomas Professor 
of Medicine and Genetics and 
Director of the Center for Genetic 
Disease, and he became Regental 
Professor of the University of Texas 
in 1985. Brown and Goldstein 
shared the Nobel Prize for 
Physiology or Medicine in 1985, 
as well as numerous other awards. 
See http://nobelprize.org/medicine/
laureates/1985/brown-bio.html 
(visited 2 November 2005). See 
Figure 2.
Professor Richard Bruckdorfer
PhD DSc (b. 1942) was educated 
at the University of Liverpool 
and held postdoctoral positions 
at the Universities of Utrecht 
and Munich, and then at Queen 
Elizabeth College, London. He was 
appointed lecturer in biochemistry 
at the Royal Free Hospital School 
of Medicine, and Professor of 
Biochemistry in 1995, and remains 
in that post at UCL. His original 
work was on the role of cholesterol 
in cell membranes, but increasingly 
became interested in oxidation of 
lipids and lipoproteins related to 
atherosclerosis and, in particular, its 
effects on nitric oxide biology.
Professor George Davey Smith
MSc MD DSc FFPHM FRCP 
(b. 1959) has been Professor of 
Clinical Epidemiology in the 
Department of Social Medicine at 
the University of Bristol 
since 1994. 
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Professor Michael Davies
MD FRCPath (1937–2003) 
qualifi ed at Middlesex Hospital 
Medical School, London, was 
appointed registrar in pathology 
in 1963 at St George’s Hospital 
and Medical School, London, later 
senior lecturer in pathology, reader 
in cardiac pathology, was appointed 
to a personal chair in cardiac 
pathology in 1977 and was the fi rst 
British Heart Foundation Professor 
of Cardiovascular Pathology from 
1981 until his retirement in 2001. 
He was editor of Heart (formerly 
the British Heart Journal), 1991–99, 
and a founder member of the 
European School for Cardiovascular 
Pathology (now the Association 
for European Cardiovascular 
Pathologists) from 1994.
Professor Paul Durrington
MD FRCP FRCPath FMedSci 
(b. 1947) is a physician, who has 
been Professor of Medicine at the 
University of Manchester since 
1995. His interest in lipoprotein 
metabolism began in 1974 with 
his MD studies on apolipoprotein 
B in Bristol. In 1979–80 he was 
a Travelling Fellow of the British 
Heart Foundation at the University 
of California, San Diego, 
investigating insulin and hepatic 
lipoprotein secretion. He was 
elected to the Fellowship of the 
Academy of Medical Sciences in 
2001 for his work on dyslipidaemia 
and HDL metabolism.
Lord Howard Florey
Bt OM FRS (1898–1968), 
Australian-born experimental 
pathologist and the main creator 
of penicillin therapy, studied blood 
fl ow in brain capillaries under Sir 
Charles Sherrington at Oxford, 
at the pathology department 
in Cambridge, and in the US. 
He was appointed Huddersfi eld 
lecturer in pathology, Cambridge, 
in 1927; Joseph Hunter Professor 
of Pathology, Sheffi eld, in 1932; 
and succeeded Georges Dreyer as 
Professor of Pathology, Oxford, 
from 1935 to 1962, later Emeritus. 
He carried out research with (Sir) 
Ernst Chain on penicillin, and 
its effectiveness was proved on 
patients at the Radcliffe Infi rmary, 
Oxford, 1941–42, and on war 
wounds in North Africa with (Sir) 
Hugh Cairns in 1943. He shared 
the Nobel Prize for Physiology or 
Medicine in 1945 for the discovery 
and development of penicillin with 
Sir Alexander Fleming Kt FRCP 
FRS (1881–1955), and Sir Ernst 
Chain Kt FRS (1906–1979). See 
Florey (ed.) (1970).
Dr John E French
DPhil, collaborated with Lord 
Florey and was University 
Demonstrator in Pathology at Sir 
William Dunn School of Pathology, 
University of Oxford.
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Dr W F M (Bill) Fulton
BSc MD FRCP (b. 1919), 
responsible for unique and 
pioneering studies on coronary 
arteries using stereoarteriography, 
serially-mounted 2mm transverse 
sections, selective histopathology 
and their relation to clinical 
events. He was Research Assistant 
in Cardiology at the University 
of Edinburgh from 1952–53, 
Consultant Physician, Stobhill 
General Hospital, Glasgow, and 
Reader, Department of Materia 
Medica, University of Glasgow 
from 1958 to 1984. Other 
appointments include Senior 
Fellow in Cardiology, the Johns 
Hopkins Hospital, Baltimore, 
Maryland, 1963–64, and 
Foundation Professor of Medicine, 
University of Nairobi, Kenya, 
1967–72. See Figure 4.
Professor David Galton
FRCP (b. 1937) was Professor 
and head of the Department of 
Human Metabolism and Molecular 
Genetics at St Bartholomew’s 
Hospital, London, from 1971 to 
2002, later Emeritus. He has been 
Professor Emeritus at the Wolfson 
Institute of Preventive Medicine, 
London, since 2003. See Galton 
(2003).
Professor Joseph Goldstein
MD (b. 1940) trained at 
Washington and Lee University 
in Lexington, Virginia, and 
Southwestern Medical School of 
the University of Texas Health 
Science Center, Dallas. Before 
returning to Dallas he worked with 
Arno Motulsky at the University 
of Washington in Seattle, where 
he and his colleagues discovered 
that 20 per cent of all heart attack 
survivors have one of three single-
gene determined types of hereditary 
hyperlipidaemia, including 
heterozygous FH. In 1972 he 
persuaded Brown to join him in 
Dallas when he was appointed 
Assistant Professor and head of the 
medical schools’ fi rst Division of 
Medical Genetics, later Associate 
Professor of Internal Medicine 
in 1974, Professor in 1976, and 
Chairman of the Department 
of Molecular Genetics at the 
University of Texas Health Science 
Center at Dallas and Paul J Thomas 
Professor of Medicine and Genetics 
a year later. Brown and Goldstein 
shared the Nobel Prize for 
Physiology or Medicine in 1985. 
See http://nobelprize.org/medicine/
laureates/1985/goldstein-bio.html 
(visited 2 November 2005). See 
Figure 2.
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Professor Antonio (Tony) 
Gotto, Jr
MD DPhil, researcher in the 
fi eld of lipid chemistry and the 
role of lipoproteins in cholesterol 
metabolism, has been Dean and 
Provost for Medical Affairs at 
Cornell University and Weill 
Medical College, New York, NY, 
since 1997. He was a Rhodes 
Scholar at Oxford University, 
trained in internal medicine at 
Massachusetts General Hospital, 
Boston, Massachusetts. He served 
in the US Public Health Service at 
the National Institutes of Health, 
1967–69, and then as a Research 
Associate of the National Heart, 
Lung and Blood Institute. From 
1971 to 1996, he was Professor 
of Medicine and Biochemistry 
at Baylor College of Medicine in 
Houston, Texas, and Chairman of 
Internal Medicine there from 1977 
to 1996. See Figure 2.
Sir Harold Himsworth
KCB FRCP FRS (1905–93), a 
distinguished clinical scientist, was 
appointed Professor of Medicine 
and Director of the Medical Unit 
at University College Hospital 
(UCH), London, in 1939, a post 
he held until appointed Secretary 
of the Medical Research Council 
(MRC) from 1949 to 1968. 
Although MRC Secretary, he was 
not a member of the Medical 
Research Council until 1957. His 
major project, the Clinical Research 
Centre at Northwick Park, Harrow, 
was inspired by Sir Thomas Lewis 
[Gray and Booth (1994): 240.].
Dr Arthur Hollman
MD FRCP FLS (b. 1923) was 
Consultant Cardiologist at 
University College Hospital, 
London, from 1962 until his 
retirement in 1988. He has been 
Honorary Consultant Cardiologist 
at the Conquest Hospital, Hastings, 
East Sussex, since 2001, and the 
Archivist to the British Cardiac 
Society since 1992. 
Professor Steve Humphries
PhD FRCPath MRCP (b. 1950) 
was educated at the Universities 
of Sussex and Glasgow, and 
held postdoctoral positions in 
Glasgow, Utah and at St Mary’s 
Hospital Medical School, London, 
before moving in 1985 to the 
British Heart Foundation-funded 
research team at the Charing 
Cross Sunley Research Centre 
as Senior Lecturer, later Reader 
and Professor in the University of 
London. He has been Professor 
of Cardiovascular Genetics at 
the Royal Free and University 
College Hospital Medical School, 
London, since 1991. He was 
one of the fi rst to recognize that 
pathophysiological insights could 
be gained through identifying 
functional candidate gene variants, 
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and determining their effect in 
healthy subjects, focusing on gene-
environment interactions, the key 
to understanding the multifactorial 
nature of heart disease.
Professor Ancel Keys
PhD PhD (1904–2004), an 
American scientist who studied 
the infl uence of different kinds of 
dietary fat on health, also called 
‘Mr Cholesterol’, was educated 
at the University of California, 
Berkeley, in economics and political 
science and biology, with PhDs in 
oceanography and biology (1930) 
and physiology (1938) from the 
University of Cambridge, UK. 
He was appointed Professor at the 
University of Minnesota in 1936, 
where he established the Laboratory 
of Physiological Hygiene, and was 
its Director from 1939 until his 
retirement in 1972. He designed 
the K-ration, investigated the 
physiological effects of starvation 
on humans [Keys et al. (1950)], 
was on the cover of Time magazine 
(31 January 1961), undertook 
the fi rst prospective study of 
cardiovascular disease, among 
Minnesota businessmen [Keys 
et al. (1963)], and later the Seven 
Countries study [Keys (1980)]. 
For a discussion of his work, see 
www.asph.org/movies/keys.pdf 
(visited 16 February 2006).
Sir Thomas Lewis
CBE FRCP FRS (1881–1945), 
cardiologist and clinical scientist, 
directed the fi rst of the MRC’s 
research units, the Clinical 
Research Department, established 
at University College Hospital 
Medical School, London, from 
1919 until his retirement in 1945. 
He was awarded the fi rst Beit 
Fellowships in 1910. See Lewis 
(1932, 1946); for further details 
of his appointment to UCL, see 
Himsworth (1982); and Drury 
and Grant (1945–48). A collection 
of his papers, CMAC/PP/LEW, is 
held in Archives and Manuscripts, 
Wellcome Library, London.
Dame June Lloyd
DBE MD FRCP FRCPE 
FRCGP DPH (b. 1928) trained 
at the Universities of Bristol and 
Durham, with posts in medicine 
and paediatrics at Bristol, Oxford, 
Newcastle and Birmingham from 
1951–65. She was appointed senior 
lecturer at the Institute of Child 
Health, London, in 1969, followed 
by reader in 1969 and professor 
in 1974. She was Professor at St 
George’s Medical School, London, 
from 1975–85 and Nuffi eld 
Professor of Child Health in the 
University of London from 1985 
until her retirement in 1992. 
She was scientifi c adviser to the 
Association of Medical Research 
Charities; Chairman of the Gene 
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Therapy Advisory Committee, and 
past paediatric vice-president of 
the Royal College of Physicians of 
London.
Professor Gordon Lowe
MD FRCP (b. 1949) trained in 
general medicine, haemostasis 
and thrombosis in Nottingham 
and Glasgow. He was appointed 
Senior Lecturer in Medicine at 
the University of Glasgow and 
Honorary Consultant Physician 
at the Glasgow Royal Infi rmary 
in 1985 and has been Professor of 
Vascular Medicine there since 1993.
Professor Jim Mann
PhD DM FFPHM FRACP 
(b. 1944) has been Professor of 
Human Nutrition and Medicine, 
University of Otago, Dunedin, New 
Zealand, since 1988. A physician, 
he trained in Cape Town, South 
Africa and Oxford, and worked in 
Oxford as University Lecturer in 
Social and Community Medicine, 
Honorary Consultant Physician and 
Fellow of Wolfson College from 
1972 to 1988.
Professor Vincent Marks
MA DM FRCP FRCPath (b. 1930) 
trained at St Thomas’ Hospital 
Medical School, was Senior 
Lecturer in Chemical Pathology 
at the Institute of Neurology, 
London, from 1958 to 1962. 
He was Consultant Chemical 
Pathologist at the Epsom Group of 
Hospitals from 1962 to 1970. He 
was appointed Professor of Clinical 
Biochemistry at the University 
of Surrey from 1970 until his 
retirement in 1995, later Emeritus.
Professor Sir Michael Marmot
Kt PhD MPH FRCP MPH 
FMedSci (b. 1945), an 
international authority on social 
inequalities in health, has been 
Professor of Epidemiology and 
Public Health at the Royal Free 
and University College Medical 
School, London, since 1985 and 
Director of the International 
Centre for Health and Society, 
UCL, since 1994. He was the co-
architect of the Whitehall Civil 
Servants Studies and Chairman 
of the third Report of the DHSS 
COMA Panel on Diet in relation to 
Cardiovascular Disease. 
Dr Archer (John Porter) Martin
FRS (1910–2002) was educated 
at Cambridge University and the 
Physical Chemistry Laboratory, 
moving to the Dunn Nutritional 
Laboratory, and in 1938 to 
the Wool Industries Research 
Association at Leeds, and later Head 
of the Biochemistry Division of the 
Research Department of Boots Pure 
Drug Company at Nottingham, 
1946–48. He joined the staff of the 
Medical Research Council in 1948, 
fi rst at the Lister Institute and in 
1950 at the National Institute for 
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Medical Research. He headed the 
Division of Physical Chemistry in 
1952 and was Chemical Consultant 
from 1956 to 1959, when he 
became Director of Abbotsbury 
Laboratories Ltd. At the Wool 
Industries Research Association he 
worked on the felting of wool and 
on amino-acid analysis. It was here 
that he developed his method of 
partition chromatography; later, 
with A T James, he developed 
the method of gas–liquid 
chromatography. See note 224.
Professor Sir John McMichael
FRS (1904–93) was Professor 
and Director of the Department 
of Medicine at the Postgraduate 
Medical School at Hammersmith 
between 1946 and 1966, then 
directed the British Postgraduate 
Medical Federation from 1966 
to 1971. His research interests 
were predominantly in the fi eld of 
cardiology and he was the fi rst in 
Britain to apply the technique of 
cardiac catheterization. See Dollery 
(1995).
Dr Clarence Merskey
FRCP (1914–82) worked with 
Rosemary Biggs and Gwyn 
Macfarlane from 1949 to 1951 
at the Radcliffe Infi rmary, 
Oxford, where he developed his 
coagulation expertise and made 
valuable contributions to the 
study of haemophilia. In New 
York he collaborated closely with 
Alan Johnson devising tests for 
measuring fi brin degradation 
products. For further aspects of his 
work, see Tansey and Christie (eds) 
(1999): 5, 9–10, 44–45.
Dr Norman Miller
MB PhD FRCP along with 
George Miller, he published the 
HDL hypothesis in 1975. He 
later participated in the Tromso 
Heart Study in Norway, and spent 
two years at the Baker Heart 
Research Institute, Melbourne, 
Australia. He was appointed 
Reader in Metabolic Disease at St 
Thomas’ Hospital Medical School, 
London, from 1978 to 1987; 
Professor of Medicine and Head of 
Endocrinology and Metabolism at 
Bowman Gray School of Medicine 
at Wake Forest University, 
Winston-Salem, North Carolina, 
for four years; and from 1992 to 
2002 was British Heart Foundation 
Professor of Cardiovascular 
Biochemistry at St Bartholomew’s 
Hospital Medical School, London. 
He is Adjunct Professor of Internal 
Medicine and Visiting Professor in 
Cardiovascular Genetics, University 
of Utah School of Medicine, Salt 
Lake City, Utah.
Dr Paul Miller 
MSc DPhil FRCP (b. 1940) is 
Consultant Gastroenterologist to 
the South Manchester University 
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Hospitals, where he started the 
Lipid Clinic in 1975. As an MRC 
Travelling Fellow he spent a period 
in lipoprotein research at Baylor 
College of Medicine, Houston, 
Texas, and was a founder member 
of the Committee of the British 
Hyperlipidaemia Society (now 
HEART UK). He was until 
recently Chairman of the Council 
of the Medical Protection Society.  
Professor J R A (Tony) Mitchell
(1928–91) was Foundation 
Professor of Medicine at the 
University of Nottingham, from 
1968 to 1990. See H(ampton) J R 
(1991); Mitchell (1987).
Professor Jerry Morris
CBE DSc DPH Hon MD FRCP 
(b. 1910) was Director of the MRC 
Social Medicine Research Unit 
from 1948 to 1975, initially as a 
member of staff of the Medical 
Research Council from 1948 to 
1966 and then also as Professor 
of Public Health, University of 
London, at the London Hospital 
and the London School of Hygiene 
and Tropical Medicine from 1966 
to 1978, later Emeritus. See a 
video recording of Jerry Morris 
in interview with Max Blythe, 
[Oxford Brookes University, 1986] 
held as 1856V, in the Moving 
Image and Sound Collection of the 
Wellcome Library, London. See 
also Davey Smith (2004).
Dr Nicolas (Nick) Myant
DM FRCP (b. 1917) qualifi ed at 
Oxford and University College 
Hospital, London, and was Sir 
Thomas Lewis’s House Physician 
in 1943. He was Director of the 
MRC Lipid Metabolism Unit at the 
Hammersmith Hospital, London, 
from 1969 to 1983. The British 
Hyperlipidaemia Association has 
supported an annual Myant Lecture 
since 1989 in recognition of his 
infl uential role in lipid research in 
Britain during the 1960s and 1970s 
at the Hammersmith Hospital, 
supported by the Medical Research 
Council. See, for example, Myant 
(1990a and b, 1993). See also 
Introduction and Figure 2.
Professor Michael Oliver
CBE MD MDhc (Karolinska 
and Bologna) FRCP FRSE 
(b. 1925) was the Duke of 
Edinburgh Professor of Cardiology 
at the University of Edinburgh 
from 1976 to 1989, later Emeritus. 
He was President of the British 
Cardiac Society from 1980 to 1984; 
of the Royal College of Physicians 
of Edinburgh from 1986 to 1988; 
and Director of the Wynn Institute 
for Metabolic Research from 1990 
to 1994. He served on the COMA 
and MAFF Committees; and 
was the UK representative on the 
Cardiovascular Division of WHO, 
1955–2000.
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Professor Chris Packard
PhD DSc FRCPath FRCP(Gla) 
FRSE (b. 1953) has been 
honorary professor in the Faculty 
of Medicine at University of 
Glasgow since 1995 and also 
works part of the time as a clinical 
scientist investigating the causes 
and treatment of heart disease, 
as well as the R&D Director for 
the North Glasgow University 
Hospitals Division of the Greater 
Glasgow Health Board. He was 
study director of the West of 
Scotland Coronary Prevention 
Study [Shepherd et al. (1995)] and 
the Prospective Study of Pravastatin 
in the Elderly at Risk [Shepherd 
et al. (1999)], trials that established 
statins as primary prevention and 
in the elderly. He is also founding 
chairman of Nexxus, the West 
of Scotland Bioscience Network, 
which promotes community 
building and knowledge exchange 
between the life sciences industry, 
academia and the NHS.
Professor Stuart Pocock
is Professor of Medical Statistics 
at the London School of Hygiene 
and Tropical Medicine, London, 
and Director of the Clinical Trials 
Research Group.
Professor Kalevi Pyörälä
FRCP (b. 1930) was Associate 
Professor of Medicine at the 
University of Helsinki from 1969 
to 1975, Research Professor at the 
Academy of Finland from 1973 to 
1975 and Professor of Medicine 
at the University of Kuopio from 
1975 to 1993, later Emeritus.
Professor Gerald Reaven
MD, Emeritus Professor of 
Medicine at Stanford University, 
fi rst described Syndrome X at the 
1988 Banting Lecture of the annual 
meeting of the American Diabetes 
Association. He served as Director 
of the Division of Endocrinology 
and Metabolism, the Division of 
Gerontology, and the combined 
Divisions of Endocrinology–
Metabolism–Gerontology at 
Stanford’s School of Medicine, 
California. See Reaven (1988).
Professor Geoffrey Rose
CBE DM FRCP FRCGP FFPHM 
(1926–93) was Professor of 
Epidemiology at St Mary’s Hospital 
Medical School from 1970 to 1977; 
at the London School of Hygiene 
and Tropical Medicine from 1977 
until his retirement in 1991, 
later Emeritus; and Honorary 
Consultant Physician, St Mary’s 
Hospital, 1964–91. He had been 
Chairman of the WHO Expert 
Committees on Heart Disease 
Prevention, 1982 and 1984; and of 
the Council on Epidemiology and 
Prevention, International Society 
and Federation of Cardiology, 
1982–86. See Barker and Rose 
(1976, 1979, 1984, 1990). 
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Professor William Rutter
(b. 1928), biochemist and 
biotechnologist, joined the 
Department of Biochemistry 
and Biophysics, University of 
California, San Francisco (UCSF) 
as Professor and chairman of the 
department from 1968 to 1982 and 
Director of the Hormone Research 
Institute, UCSF from 1983 to 
1994. For further details of his 
work, see a 1992 interview, freely 
available at http://content.cdlib.
org/xtf/view?docId=kt7q2nb2hm&
doc.view=entire_text&brand=oac 
(visited 27 February 2006).
Professor Tom Sanders
DSc (b. 1949), educated at 
the University of London, was 
appointed Professor of Nutrition 
and Dietetics at King’s College 
London in 1994 and is now 
Head of the Research Division of 
Nutritional Sciences there.
Professor James Scott
FRCP FIBiol FMedSci FRS 
(b. 1946), trained at the London 
Hospital and in Birmingham, 
was appointed to the Academic 
Department of Medicine at the 
Royal Free Hospital, London, in 
1975; an MRC Research Fellow 
and Honorary Senior Registrar at 
the Royal Postgraduate Medical 
School, Hammersmith Hospital, 
London, 1975–80; European 
Molecular Biology Fellow at the 
Department of Biochemistry, 
University of California, San 
Francisco, 1980–83 and MRC 
Clinical Scientist and Honorary 
Consultant Physician at the 
MRC Clinical Research Centre, 
Northwick Park Hospital, from 
1983 to 1991. He has been 
Honorary Consultant Physician 
at the Hammersmith Hospital 
since 1992; Professor and 
Chairman of Medicine at the Royal 
Postgraduate Medical School, 
Hammersmith Hospital, from 
1992 to 1998; and Director of the 
Genetics and Genomics Institute, 
Imperial College, and Professor 
of Cardiovascular Medicine 
National Heart and Lung Institute, 
Medicine, London, since 1998.
Sir Ernest Henry Shackleton 
Kt (1874–1922), explorer, went 
to the South Pole with Scott’s 
National Antarctic Expedition 
on the Discovery expedition 
in 1901. He commanded the 
Nimrod Expedition (1907–9), 
and the 1914–16 voyage on 
HMS Endurance. He died while 
attempting to circumnavigate 
the Antarctic continent on South 
Georgia Island where his wife 
insisted he be buried.
Professor A G (Gerry) Shaper
FRCP FRCPath (b. 1927) 
qualifi ed in Cape Town, joining 
the Department of Medicine at 
Makerere University Medical 
School, Kampala, Uganda, in 
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1957, moving to the MRC Social 
Medicine Unit at the London 
School of Hygiene and Tropical 
Medicine in 1970 and in 1975 to 
the Department of Epidemiology 
and Public Health as Professor of 
Clinical Epidemiology at the Royal 
Free Hospital School of Medicine, 
London, until his retirement in 
1992, later Emeritus.
Dr Hugh Sinclair
DM DSc FRCP (1910–90), 
an eccentric nutritionist, was 
educated at Winchester College 
and Magdalen College, Oxford. He 
pioneered work on vitamins and 
essential fatty acids and was Vice-
President of Magdalen College. He 
established the Chair of Human 
Nutrition at the University of 
Reading. See Ewin (2001). 
Dr Joan Slack
DM DCH FRCP (b. 1925) 
educated at St Hilda’s College, 
Oxford, followed by an NIH 
Foreign Fellowship in biochemical 
genetics at the Children’s Memorial 
Hospital, Chicago, Illinois, 1959–
60. She was a member of the MRC 
Clinical Genetics Research Unit 
at the Institute of Child Health, 
London, from 1960–72 and 
Consultant in Clinical Genetics 
at St Mark’s and the Royal Free 
Hospitals, London, 1975–90. Her 
early studies included lipoprotein 
lipase activity in children with 
cystic fi brosis and CHD in familial 
hypercholesterolaemia. See 
Figure 2.
Dr Elspeth Bruce Smith
PhD DSc FRS(E) (b. 1923)[née 
Dunkerley], was educated at 
Cambridge, London and Aberdeen. 
She worked in the Ministry of 
Aircraft Production during the 
war, was a research assistant at 
Cambridge and St Bartholomew’s 
Hospital, London, until appointed 
Senior Lecturer at the Middlesex 
Hospital, London, in 1955, moving 
to the University of Aberdeen in 
1968 as Lecturer and later Reader.
Professor Anne Soutar
PhD (b. 1945) educated as a 
biochemist and enzymologist, she 
has been a research programme 
leader in the Medical Research 
Council’s Clinical Sciences 
Centre, Imperial College at 
the Hammersmith Hospital, 
London, since 1993. Her career in 
lipoprotein research started in the 
early 1970s with a postdoctoral 
fellowship with Tony Gotto, 
at Baylor College of Medicine, 
Houston, Texas. 
Professor Siegfried Thannhauser
MD PhD (1885–1962) trained 
in medicine and biochemistry 
in Munich and was appointed 
assistant physician at the Hospital 
of the Ludwig-Maximilans-
University in 1912. After 
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military service, he directed 
the Departments of Medicine 
at Heidelberg, Dusseldorf and 
Freiburg from 1924 to 1934, 
before being dismissed by the 
Nazi government. He practised 
privately in Freiburg until the 
Rockefeller Foundation arranged 
an offer of the post of Associate 
Clinical Professor, later Clinical 
Professor, at Tufts University, 
Boston, and Senior Physician at 
the New England Medical Centre, 
Boston, Massachusetts, from 1937 
until his death in 1962. He was 
also Director of the Thannhauser 
Research Laboratory at the Boston 
Dispensary. 
Professor Gilbert Thompson
MD FRCP (b. 1932) qualifi ed at St 
Thomas’ Hospital Medical School, 
London, in 1956. Following 
military service he joined the Royal 
Postgraduate Medical School, 
Hammersmith Hospital, London, 
in 1963, where he remained 
until1998, with periods of research 
spent at the Massachusetts General 
Hospital, Boston, Massachusetts; 
the Methodist Hospital, Houston, 
Texas; and the Royal Victoria 
Hospital, Montreal, Quebec, 
Canada, where he was the recipient 
of the Lucien Award in 1982. He 
led the MRC Lipoprotein team 
at the Hammersmith Hospital, 
London and was Honorary 
Consultant Physician in charge of 
the lipid clinic from 1993–98; was 
a past Chairman of both the British 
Hyperlipidaemia Association and 
the British Atherosclerosis Society, 
and has been Emeritus Professor 
in Clinical Lipidology at Imperial 
College, London, since 1998. See 
Figure 2.
Dr Jonathan Tobert
MB BChir PhD (b. 1945) was 
a member of Merck Research 
Laboratories in Rahway, New 
Jersey, from 1976 until his 
retirement in 2004 as Executive 
Director, Department of Clinical 
Endocrinology and Metabolism. 
He is an honorary consultant to 
the Clinical Trials Service Unit, 
Nuffi eld Department of Medicine, 
University of Oxford.
Professor Hugh Tunstall-Pedoe
MD FRCP FRCPE FFPH FESC 
(b. 1939) trained in cardiology 
and general medicine before taking 
up cardiovascular epidemiology 
in 1969, working with Professor 
Jerry Morris in the MRC Social 
Medicine Unit and then with 
Professor Geoffrey Rose at St 
Mary’s Hospital Medical School, 
London, in 1974. He was Professor 
and Director of the Cardiovascular 
Epidemiology Unit at the 
University of Dundee from 1981 to 
2005, later Emeritus. See Tunstall-
Pedoe (ed.) (2003).
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Professor Hubert Maitland 
Turnbull
FRCP FRS (1875–1955) 
qualifi ed and trained at the 
London Hospital; was a Radcliffe 
Travelling Fellow in Copenhagen 
and Dresden, where his work 
as a voluntary assistant with 
Professor Georg Schmorl in 
Dresden determined his interest in 
pathology. He directed the Institute 
of Pathology, London Hospital, 
from 1906 to 1946, becoming 
Reader in Morbid Anatomy in the 
University of London in 1915 and 
Professor in 1919, later Emeritus. 
His meticulous care in the 
observation and recording of details 
at post mortem gave pathology a 
scientifi c basis. Much of his work 
appeared under his students’ names 
and his reputation ensured that 
the Institute of Pathology had a 
full quota of voluntary assistants. 
Anonymous (1968); Turnbull 
(1920).
Professor Paul Dudley White
MD FRCP (1886–1973), 
American cardiac physician, 
qualifi ed at Harvard and trained 
at the Massachusetts General 
Hospital, Boston, and University 
College Hospital Medical School, 
London. He taught at Harvard 
Medical School from 1914–20; 
was Professor of Medicine and 
physician in charge of the cardiac 
clinics and laboratory, from 
1919 to 1949. A founder of the 
American Heart Association, he 
served as President, 1940–42; and 
received the Albert Lasker award in 
1953. See White (1947, 1950).
Dr Paul Hamilton Wood
OBE MD FRCP (1907–62) 
trained at Melbourne University, 
did house jobs at Christchurch 
Hospital, New Zealand; Brompton 
Hospital, London; the National 
Heart Hospital, London, and 
the British Postgraduate Medical 
School, London, where he was 
First Assistant from 1935–40 and 
senior lecturer, 1946–48, after 
war service. He was Dean of the 
Institute of Cardiology, 1947–50, 
Cardiologist at the Rheumatic 
Fever Unit, Canadian Red Cross 
Memorial Hospital, Taplow, 1947–
53, and Director of the Institute 
of Cardiology, London; Physician, 
National Heart Hospital, London; 
Physician, Cardiac Department, 
Brompton Hospital, London, from 
1953–62. See Wood (1950).
Professor Neville Woolf
FRCPath (b. 1930), born and 
educated in Cape Town, South 
Africa, he came to Britain in 
1959, was appointed Reader in 
Experimental Pathology at St 
George’s Hospital Medical School, 
London, before moving to the 
Middlesex Hospital Medical School 
as Bland-Sutton Professor of 
138
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000 – Biographical notes
Histopathology in 1975. Following 
the merger of the Middlesex 
and University College Hospital 
Medical Schools, London, in 
1982, he became head of the joint 
department of histopathology 
until 1987. He retired from his 
chair in 1995, and was Vice-Dean 
and Faculty Tutor in the Faculty 
of Clinical Sciences at UCL until 
2004, at which time he became 
Emeritus.
Professor John Yudkin
(1910–92), Professor of Nutrition 
at Queen Elizabeth College, 
London, from 1954 until his 
retirement in 1971, later Emeritus, 
trained at Cambridge and the 
London Hospital. He worked 
at the Biochemical Laboratory, 
Cambridge, 1931–36; the 
Nutritional Laboratory, Cambridge, 
1938–43; and was Professor of 
Physiology, Queen Elizabeth 
College, London, 1945–54. In 
1953 Yudkin was responsible for 
the fi rst comprehensive university 
courses leading to Bachelor’s and 
Master’s degrees in nutrition. He 
was Chairman of the Food Group, 
Society of Chemical Industry. 
See, for example, Yudkin (1958, 
1972, 1985).
Professor John S Yudkin
MD FRCP (b. 1943) has been 
Professor of Medicine at UCL 
since 1992 and Director of 
the International Health and 
Medical Education Centre in 
the Diabetes and Cardiovascular 
Disease Academic Unit at the 
Royal Free and University College 
Medical School since 2000. He is 
interested in novel risk factors for 
cardiovascular disease, including 
insulin resistance and low-grade 
infl ammation.
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aldehyde
An organic compound with a 
double bond between a carbon 
atom and an oxygen stem, 
containing the aldehydric group, 
with at least one hydrogen 
attached to it. Lipoperoxidation-
derived aldehydes, for example 
malondialdehyde (MDA), can 
damage proteins.
antioxidants
Substances that reduce oxidative 
damage caused by free radicals.
apolipoprotein (A, B, C, E, etc.)
A protein found integrally 
associated with plasma lipoproteins.
arteriosclerosis
A term used in the past to describe 
generalized hardening of the 
arteries.
atherosclerosis
The term commonly used to 
describe the partially occlusive 
lesions that occur in the inner 
lining of arteries when there is 
cholesterol deposit and thrombosis.
atorvastatin
(Lipitor®, Parke, Davis and Co.) 
A statin. Licensed in the UK 
in 1996 as a prescription-only 
medicine.
autosomal recessive disorder
Caused by an error or mutation in 
a single unit of genetic information, 
a recessive disorder will be 
expressed in a person only if both 
copies of the gene are mutated.
carrier
An unaffected person who harbours 
a disease gene.
chlorophenoxyisobutyrate (CPIB)
The active principle of clofi brate.
cholesterol nomenclature, 
types I–V
Described by Fredrickson in 1966 
and now rarely used (Fredrickson 
et al. (1966): 429–88).
cholesterol readings
Normal values [in early 2006] for 
cholesterol, depending upon age 
and gender, are: 140–220mg/dl 
(US, which measures the mass in 
milligrammes); 3.6–5.7mmol/l 
(SI [Système Internationale] units 
measures concentrations in terms 
of the number of particles or moles 
present). To convert one to the 
other, multiply mg/dl by 0.0259 
to obtain mmol/l units. [Lewis 
et al. (1992): Table B-1, 1818.] For 
population readings, see Section 
9.3.2, Health Survey of England 
Glossary*
* We are grateful to Professors Michael Oliver and Chris Packard for assistance in compiling 
this glossary. 
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2003, following links at www.
dh.gov.uk/assetRoot/04/09/89/1
1/04098911.pdf (visited 9 March 
2006).
cholestyramine
A resin taken by mouth which is 
not itself absorbed but which acts 
to interfere with the reabsorption of 
bile acids in the gut. For example, 
Questran® (Bristol-Myers Squibb).
clofi brate (Atromid-S ®, ICI)
A broad-spectrum, lipid-lowering 
drug that decreases serum 
triglycerides and cholesterol, 
thereby altering the progression 
of coronary atherosclerosis. See 
Principal Investigators (1978, 
1984).
confounding factors
The association of a disease and a 
study factor with a third variable 
causing a spurious difference 
between cases and controls. Where 
an observed association between a 
factor and a disease is mediated by 
something else which has not been 
allowed for.
continuous fl ow blood cell 
separator
A system described in 1960 by 
Dr Jay Freireich. It permits the 
separation of cells and can be used 
for plasma exchange, the collection 
of platelets, and large numbers of 
lymphocytes for insertion and study 
of genes. See an interview with Dr 
Harvey Klein, Chief, Department 
of Transfusion Medicine at the 
National Institutes of Health, 
Bethesda, Maryland, 29 January 
1993. Freely available to download 
at http://aidshistory.nih.gov/
transcripts/transcripts/Klein93.pdf 
(visited 6 December 2005). See also 
Christie and Tansey (eds) (2003): 
60, note 171.
CPIB 
See chlorophenoxyisobutyrate. 
C-reactive protein
A protein produced by liver cells in 
response to infl ammation and used 
as a marker of an infl ammatory 
state.
Coons fl uorescent antibody 
method
A technique used for the 
microscopic identifi cation of native 
and foreign antigens in tissue 
sections examined in ultraviolet 
light and depends on the fact 
that coupling an antibody with a 
fl uorescent dye does not impair 
immunological specifi city.
deletion
The loss of a piece of DNA from 
a chromosome that may lead to a 
disease or abnormality.
delipidation pathway
The metabolic sequence where 
VLDL is converted to LDL by 
progressive removal of triglyceride 
by lipases from the particle. 
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The process by which fat is 
removed from lipoproteins during 
circulation.
diabetes, type 2
An acquired insulin resistance or 
undersecretion in adult life, usually 
associated with obesity.
diet–cholesterol–heart hypothesis
Proposes that an excess of 
saturated fat and cholesterol in 
food is a major cause of coronary 
heart disease.
diet–heart hypothesis
Proposes that an excess of 
saturated fat and cholesterol in 
food is an essential cause of 
coronary heart disease.
dyslipidaemia
Blood fat disorders that favour 
plaque formation in artery walls, 
including high triglycerides, low 
HDL cholesterol and high LDL 
cholesterol.
edge-irregularity index
A technique applied in quantitative 
image analysis of coronary 
angiograms to measure the severity 
of disease. See Brunt et al. (1995).
electrophoresis
A technique using an electrical fi eld 
to separate a mixture of molecules 
by their differential migration 
through a gel or on specially 
prepared paper. 
enzyme assay
A laboratory method to test the 
activity of an ‘enzyme’, a protein 
which has catalytic properties to 
convert substrate into a product.
factor VII
An essential component of blood 
clotting (coagulation). A defi ciency 
of factor VII can be congenital, or 
acquired as a result of liver disease, 
vitamin K defi ciency or other 
malabsorption conditions.
factorial trial
A randomized controlled trial of 
two drugs at the same time, which 
requires four groups: one receives 
both drugs; the second is given one 
drug; the third, the other drug; and 
the fourth receives neither drug 
(placebo).
familial hypercholesterolaemia 
(FH)
A genetic disease in which excess 
cholesterol accumulates in blood 
and tissues. Plasma cholesterol 
concentrations may exceed 
300mg/dl and even reach 2g/dl.
foam cells 
Macrophages loaded with lipid.
free radicals
Molecules with unpaired electrons 
in the outer orbital resulting in 
oxidation of other molecules.
Friedewald formula
A method of calculating LDL 
concentrations when triglycerides 
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are normal: total cholesterol 
minus HDL cholesterol minus 
VLDL cholesterol (estimated as 
a triglyceride divided by 5). See 
Friedewald et al. (1972).
gas chromatography
A means of separating, identifying 
and measuring volatile compounds 
according to how well they move 
with the fl ow of a carrier gas, using 
a fi xed solid phase and a moving 
gaseous phase. Fatty acids separate 
on columns (celite) containing 
absorptive material. An inert gas 
(Argon) is passed through and 
the fatty acids are detected by 
ionization.
gemfi brozil
(Lopid®, Parke-Davis) A broad-
spectrum lipid-modulating agent 
that decreases serum triglycerides 
and also lowers LDL-cholesterol 
and raises HDL-cholesterol.
gene
A fundamental unit of heredity. A 
locus defi nes the position of a gene.
gynaecomastia
The enlargement of the male 
breast.
HDL 
See high-density lipoproteins 
Hardy–Weinberg equation of 
population genetics
This equation permits the net 
effects of evolutionary mechanisms 
to be analysed and applied to 
particular populations. It was 
named for the independent work of 
the English mathematician Godfrey 
Hardy and the German physician 
Wilhelm Weinberg in 1908. 
Genotype frequencies are given by 
the equation:
p2 (AA) + 2pq (Aa) + q2 (aa) = 1
where A and a are two alleles at a 
gene; p is the frequency of the A 
allele; q is the frequency of the a 
allele; 1 = p + q; p = 1 - q.
heterozygous
Possessing two different forms 
(alleles) of a particular gene, one 
from each parent.
HMG-CoA reductase [3-hydroxy-
3-methylglutaryl coenzyme A]
A fundamental enzyme in the 
conversion of acetate to cholesterol.
high-density lipoproteins (HDL)
Cholesterol-carrying lipoproteins 
which may have a protective effect 
against arterial atheroma.
homozygotes
People who inherit two copies of a 
defective gene.
homozygous
Possessing identical alleles at a given 
locus on a chromosome pair.
hypertension
Raised blood pressure. 
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hypertriglyceridaemia
Raised plasma triglyceride or VLDL 
concentrations.
intima 
The inner membrane of an 
artery, or a vein. Cholesterol is 
carried into the intima by plasma 
low-density lipoprotein (LDL) 
particles, and plasma high density 
lipoproteins (HDL) clear it back 
to the circulation. See www.wri.
fi /atherosclerosis.html (visited 
8 December 2005).
Lieberman–Burchard reagent
A combination of sulphuric acid 
and acetic acid that reacts to 
produce a green colour in the 
presence of cholesterol. The colour’s 
intensity indicates the amount of 
cholesterol in solution.
LP receptor
Lipoprotein receptors. 
lipoproteins; ß-lipoproteins
Lipid-carrying globulins.
LDL; ß-LDL 
See low-density lipoproteins 
linoleic acid
An unsaturated fatty acid with 
18 carbon atoms and two double 
bonds (18:2).
lipase
An enzyme normally present in 
blood and tissues, particularly 
adipose tissue.
lovastatin
(Meracor®, Merck) A statin 
or an inhibitor of HMG-CoA 
reductase that reduces cholesterol 
biosynthesis. Never licensed in the 
UK. See Appendix 2.
low-density lipoproteins 
(LDL, ß-LDL)
Cholesterol-rich lipoproteins 
which, when increased in 
concentration, may lead to 
cholesterol deposit in the 
arterial wall.
meta-analysis
A systematic review of a number 
of different, but similar, studies 
using quantitative methods to 
summarize the results. The meta-
analysis pools information to give 
a large enough sample of suffi cient 
quality and validity to illustrate the 
results clearly, lessening the effect 
of random chance. Small, poorly 
constructed trials with few events 
are likely to mislead.
Metabolic Syndrome (also known 
as insulin-resistance syndrome)
People with the Metabolic 
Syndrome have a cluster of 
metabolic features, including 
abdominal obesity; atherogenic 
dyslipidaemia; elevated blood 
pressure; insulin resistance 
or glucose intolerance; a 
prothrombotic state (having 
high fi brinogen or plasminogen 
activator inhibitor-1 in the blood); 
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a proinfl ammatory state (having 
elevated C-reactive protein in the 
blood). They are at increased risk of 
coronary heart disease and type 2 
diabetes.
microalbuminuria
The appearance of microquantities 
of albumin in the urine.
myocardial infarction (MI, also 
heart attack)
The death of cardiac tissue 
following interruption of the blood, 
usually caused by obstruction of 
circulation due to thrombosis in 
a coronary artery. Infarction can 
result in permanent damage to an 
area of the heart.
oestradiol
One of the naturally occurring 
oestrogens.
oleic acid
A mono-unsaturated fatty acid with 
18 carbon atoms and one double 
bond (18:1). It has a neutral effect 
on plasma lipoproteins and forms 
the basis of olive oil.
oxidized LDL
Low-density lipoprotein that has 
been oxidized. When this occurs in 
the arterial wall, it accumulates in 
macrophages.
PAI-1 [plasminogen activator 
inhibitor type 1]
A prothrombotic enzyme 
that inhibits the activation of 
plasminogen by tissue plasminogen 
inhibitor and thus decreases 
fi brinolytic activity.
paper chromatography
A technique that separates and 
identifi es pigments and other 
molecules from extracts that 
contain a complex mixture 
of molecules. It relies on the 
differential affi nities of substances 
for a gas or mobile liquid medium 
and for a stationary medium 
through which they pass, such as 
paper, gelatin or magnesia. Also 
called absorption chromatography. 
In paper chromatography the 
solvent moves up the paper by 
capillary action carrying along any 
substance dissolved in it. Once 
the paper has dried, the individual 
components can be identifi ed by 
physical (such as ultraviolet light) 
or chemical (such as a chemical 
spray) methods.
phenotype
The observable features of an 
organism that results from the 
interaction of genes and the 
environment.
pleiotropic
Effects that are not anticipated. For 
example, the pleotropic effects of 
statins are effects on metabolism 
that are not directly related to its 
cholesterol-lowering properties.
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polymerase chain reaction
A fast, inexpensive technique for 
making an unlimited number of 
copies of any piece of DNA. For 
the background to this discovery, 
for which Kary Mullis shared the 
1993 Nobel Prize for Chemistry, 
see http://nobelprize.org/
chemistry/laureates/1993/mullis-
lecture.html (visited 14 
December 2005).
pravastatin
(Lipostat®, pravastatin sodium, 
E R Squibb and Sons Ltd) A 
lipid-lowering compound and a 
statin which was licensed in the 
UK in 1990 as a prescription-only 
medicine. 
prothrombotic change
An abnormality in clotting 
elements in the blood (such as 
PAI-1 or fi brinogen) that increases 
the tendency of blood to clot.
remnant particle accumulation
An elevated concentration in the 
blood of lipoproteins that were 
triglyceride rich (chylomicrons, 
VLDL), now partially delipidated, 
but are resistant to further lipase 
action. They are remnants of 
chylomicron or VLDL metabolism 
that fail to be cleared effi ciently, 
or, in the case of VLDL, fail to 
be converted to LDL; can cause 
foam cells and contribution to 
atherosclerosis as in type III 
hyperlipoproteinaemia.
scavenger receptor
Receptors on macrophages which 
take up modifi ed cholesterol.
serum cholesterol
A sterol normally circulating in 
the blood in the form of LDL 
(bad cholesterol), HDL (good 
cholesterol) and to a lesser extent 
in VLDL.
simvastatin
(Zocor®, Merck Sharp and Dohme 
Ltd) A statin licensed in the UK 
in 1989 as a prescription-only 
medicine, and sold over the counter 
as Zocor Heart Pro without a 
doctor’s prescription since 2004.
Southern blotting method
Named after Dr Ed Southern 
whose invention this was in 
1975. A method for detecting the 
presence of DNA or RNA that 
permitted the detection, using a 
radio-labelled probe, of a single 
copy of a human gene in a sample 
of DNA fragments separated by size 
by gel electrophoresis. This involves 
transfer from a gel to retentive 
paper (blotting with paper towels 
facilitates the physical transfer of 
the nucleic acids).
statins
Inhibitors of HMG-CoA 
reductase which reduce cholesterol 
biosynthesis. See also atorvastatin, 
lovastatin, pravastatin and 
simvastatin.
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stop codon
Any of three mRNA sequences 
(UGA, UAG, UAA) that do not 
code for an amino acid and thus 
signal the end of protein synthesis.
streptozotocin
A nitrosamine compound 
(specifi c β-cell cyototoxin) used 
experimentally in rodents to 
produce diabetes by destroying 
pancreatic β islet cells that secrete 
insulin. It is used clinically 
for treatment of malignant 
insulinomas.
Sudan Black
A fat-soluble dye used to stain 
phospholipids, neutral fats 
and sterols.
superoxide dismutase
An antioxidant enzyme that 
converts the free radical superoxide 
anion, a potentially toxic molecule 
generated by cells in the body, into 
hydrogen peroxide.
Svedberg fl otation unit (S
f
)
A fl otation coeffi cient that 
describes the gravitation force 
needed to separate compounds by 
ultracentrifugation, named after 
Theodor Svedberg, the inventor 
of the analytical ultracentrifuge. 
The fl otation rate for a particular 
lipoprotein species is a physical 
constant characteristic, after 
adjustment for concentration 
effects [1 S
f
 unit = fl otation rate 
of 1x10-13cm/s/dyne/gm at 26°C 
(French (1958): 367)]. See Kyle 
and Shampo (1997). For human 
and rabbit ultracentrifugal fl otation 
patterns, see Gofman et al. 
(1952): 121.
triparanol
A cholesterol-lowering agent 
marketed in the US from 1959. In 
1962 the US FDA inspected the 
manufacturer and discovered that 
the company had provided falsifi ed 
laboratory data, suppressing the 
cataracts that had appeared in rats 
and dogs receiving the drug, and it 
was withdrawn from the market 
in 1962.
tritiate
To label a cell or compound 
with tritium.
very low-density lipoprotein 
(VLDL) 
A lipid–globulin complex 
composed mostly of triglyceride 
and with some cholesterol.
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academic medicine, 48, 55–6, 59
acetyl-CoA, xxii
acute coronary events/syndromes, 
18–19, 24, 42
adrenaline, 23
Africa, 16, 54, 64, 69–70, 82
aldehydes, 37, 139
American Heart Association, 47, 81
androgens, 65
angina pectoris, xxiv, 14, 39, 80
angiography, 27, 47–8
animal feeding studies, xxi, 13, 15–16, 
20, 21, 60
antibodies, 16–17
antioxidants, 36–7, 139
antiplasmin, 26
apheresis, 34–6
apolipoproteins, 8, 31–4, 139
 AI (apoAI), 33–4
 B (apoB), 31–2
 B48 (apoB48), 32–3
 CIII (apoCIII) gene, 33, 34
 E (apoE) gene, 29–30
Archives of Internal Medicine, 14
arterial wall, lipid infi ltration, 20–3, 
52–3
arteriography, 27
arteriosclerosis, 3–4, 15, 139
Asians, British, 57, 61, 62
Aspergillus terreus, xxv, 85
aspirin, 24, 25
assay, cholesterol, 50
Atheroma Research Unit, MRC, 16
atherosclerosis, 15–23, 139
 animal feeding studies, xxi, 13, 
15–16, 20, 21
 causation, 4, 15–16
 as cause of CHD, 4
 in diabetes, 49, 51
 essential fatty acids and, 66
 fi rst international symposium 
(1955), 6
 as multifactorial disease, 81
 paradigm shift, 74
 post mortem study, 40
 regression, 26–7, 35, 47–8
 role of cholesterol, xxi, 16, 19, 62
Atherosclerosis Discussion Group (now 
British Atherosclerosis Society), 
12, 70
atherosclerotic plaques
 fragility/stability, 74, 75
 injury/disruption, 18–19, 22
 lipids in, 20
 role of thrombi in growth, 16–17
atorvastatin (Lipitor®), 139
Atromid see clofi brate
autoradiography, 22
Banting Lecture (1988), 51
BCS see British Cardiac Society
Becel margarine, 68
Beechams (now a subsidiary of 
GlaxoSmithKline, Brentford, 
Middx), 78–9
birth weight, low, 44
blood
 clot lysis time, 25–6
 coagulation, 24–5, 26, 82
blood cell separator, continuous fl ow, 
35, 140
blood pressure, 23, 49, 57, 79, 82
 high see hypertension
BMJ see British Medical Journal
Boston, Massachusetts, 3, 8, 13
brain cancer, 45
BRHS (British Regional Heart 
Study), 84
Index: Subject 
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Bristol-Myers Squibb, Princeton, NJ, 
74–5, 77
British Atherosclerosis Society 
(BAS) (formerly Atherosclerosis 
Discussion Group), 12, 70
British Cardiac Society (BCS), 6–7, 
59, 83–4
British Medical Journal (BMJ), 11, 
50, 59
British Regional Heart Study 
(BRHS), 84
Budapest, Hungary, 73
butter, 9, 13, 66–7, 68
Butter Information Council 
pamphlet, 59
Caerphilly heart disease study, 69
Cambridge, 12, 33
cancer, 31, 45–7, 62, 77
candicidin, 15
cardiac catheterization, 48
cardiologists, attitudes of, 47–9, 63
 cholesterol/risk factors, 11, 58, 
59, 60
 epidemiological studies, 6–7, 42, 
47, 55
Cardiology (Evans, 1948), 4
cardiovascular disease, regional 
variations, 82, 84
CARE study, 74, 76
carrier, 139
case–control studies, xxi
cataracts, 80
catecholamines, 23
Cell, 33
cell membranes, 14–15
Central Middlesex Hospital, London, 
73
CHD see coronary heart disease
cheese, 13, 51, 66–7
children, postnatal growth, 44
China, 53
chlorophenoxyisobutyrate (CPIB), 
72–3, 139
 see also clofi brate
cholesterol
 animal feeding studies, xxi, 13, 20, 
21, 60
 assay, 50
 biosynthesis, xxii–xxiii, 7
 in clinical biochemistry, 15
 dietary, 67, 68
 LDL see low-density lipoprotein 
(LDL) cholesterol
 in lipoprotein fractions, 5–6
 low, adverse effects, 45–7, 60, 73, 
83–4
 measurement, 56–8, 59, 60
 membrane, 14–15
 metabolism, 12
 nomenclature, 8, 12, 139 
 oxidation state, 21
 plasma/serum/blood, xxi, 145
  benefi ts of reducing, xxi–xxii, 27
  in diabetes, 50, 51
  diet and, 16, 66–72, 81
  early studies, 6–7
  high see hypercholesterolaemia
  international variations, 53, 
 69–70
  menstrual cycle changes, 7
  normal values, 48, 57, 139–40
  population levels, 60–1, 64,   
 69–70, 71, 79–80
 readings, 57–8, 139–40
 role in atherosclerosis, xxi, 16, 
19, 62
Cholesterol: Chemistry, biochemistry and 
pathology (Cook, 1958), xxiii, 7, 
59–60
cholesterol–coronary heart disease 
hypothesis, xxi–xxv, 3–14
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 attitudes of cardiologists, 47–9
 controversy, xxi–xxii, 8–10, 58–9, 
83–4
 early history (up to 1950s), 3–7, 
13–14
 epidemiological studies, 45–6, 60–1
 importance of FH, 38–9
 public awareness, 44–5, 68
 vs diet–heart hypothesis, 51–2
cholesterol ester fatty acids, 20
Cholesterol Wars, The (Steinberg, 
forthcoming), xxii
cholesterol-lowering therapy see diet, 
cholesterol-lowering; drugs, 
cholesterol-lowering
cholestyramine, xxiv, 27, 74, 76, 
86, 140
chromatography
 gas, 20, 142
 gas–liquid, 65
civil servants, 41–2, 46, 61, 82
clinical biochemistry, 15
Clinical Research Centre, MRC, 32
clinical trials, 72–80
 pre-statin, xxi–xxii, 73–4
 risks of low cholesterol, 46–7, 
60, 73
 statins, xxii, 47, 74–8, 86
clofi brate (Atromid), xxiv, 27, 140
 development, 72–3
 WHO trial, 9, 49, 73, 76, 78
clotting times, 25
coagulation, blood, 24–5, 26, 82
cocoabutter substitutes, 65
coffee, boiled, 71
colon cancer, 46, 47
COMA see Committee on Medical 
Aspects of Food Policy
Committee on Medical Aspects of 
Food Policy (COMA) report 
(1984), 62
compactin, xxiv–xxv, 79, 85
confounding factors, 46, 47, 140
Coons fl uorescent antibody method, 
16–17, 140
corn oil, xxiv
coronary angiography, 27, 47–8
coronary arteries, post mortem 
examination, 40–1, 80
coronary artery disease see coronary 
heart disease
coronary heart disease (CHD)
 aging as cause, 3–4
 cholesterol as cause see cholesterol–
coronary heart disease 
(CHD) hypothesis
 early plasma lipid studies, 5–7
 epidemiology, 39–48, 53, 55–61
 gender differences, 7, 61–5
 genetic susceptibility, 28–31
 international variations, 16, 53–4
 mortality, xxi, 39, 71
 as multifactorial disease, 81
 pathology, 15–26, 40–1
 prenatal infl uences, 43–4
 prevention see prevention, coronary 
heart disease
 risk factors see risk factors, coronary
 sugar as cause, 8–9, 67
 treatment-induced regression, 27
coronary thrombosis
 early research, 17, 18, 22, 27–8
 post mortem study, 40, 41
cortisol, 23
CPIB see chlorophenoxyisobutyrate
C-reactive protein, 52, 140 
dairy products, 65, 66–7
 see also butter; cheese; milk
DART (diet and reinfarction trial) 
study, 76
data monitoring committee, 77
death rates see mortality
delipidation pathway, 11–12, 140–1
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Denmark, 26
deprivation, economic, 43, 63
development, pre- and postnatal, 43–4
diabetes, 4, 49–51, 81
 experimental, in rats, 54
 insulin resistant, 51
 type 2 (maturity onset), 49, 52, 141
diet, 49, 53, 65–72
 blood cholesterol and, 16, 81
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